[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"R82 A\u002FS\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":386},{"warningLetters":4,"total":385},[5,31,51,73,91,106,126,144,163,185,203,222,239,260,277,295,312,333,350,367],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1482,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-05-07T13:20:00Z\">05\u002F07\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-21T04:00:00Z\">03\u002F21\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjolca-sa-677664-03212024\">Jolca, S.A.\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Carlos Mejias\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Jolca, S.A.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Post Office No. 13 Apartado No. 13\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Huevar Del Aljarafe\u003C\u002Fspan> \u003Cspan>Sevilla\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Spain\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 21, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nReference # 677664\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Mejias:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted a Foreign Regulatory Assessment (FRRA) of your seafood processing facility, located at Autovia Sevilla - Huelva Km 22.5, Huevar De Aljarafe, Sevilla, Spain on October 2 through October 11, 2023. During that assessment, we found that you have serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123 (21 CFR 123). At the conclusion of the assessment, the FDA investigator issued you a listing of the observations made during the assessment. You provided responses to the observations, describing corrective actions taken by your firm. After reviewing the remote regulatory assessment findings and the responses that your firm provided, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility. We also address your responses below.\u003C\u002Fp>\n\n\u003Cp>In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Furthermore, Accordingly, your ready-to-eat (RTE) cold smoked salmon products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and FDA’s 4th Edition of the Fish and Fisheries Products Hazards &amp; Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov. The 4th Edition of the Hazards Guide can be found on our web site at: https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidanceregulation\u002Fguidancedocumentsregulatoryinformation\u002Fseafood\u002Fucm2018426.htm\u003C\u002Fp>\n\n\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You must conduct a hazard analysis to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the food safety hazards that are reasonably likely to occur to comply with 21 CFR 123.6(a) and (c). A food safety hazard is defined in 21 CFR 123.3 (f) as “any biological, chemical, or physical property that may cause a food to be unsafe for human consumption.” However, your firm’s HACCP plan for green olives stuffed with anchovy or tuna does not list the food safety hazard of scombrotoxin (histamine) formation, \u003Cem>Staphylococcus aureus (S. aureus)\u003C\u002Fem> growth and toxin formation, and allergens associated with the tuna and anchovies; and the food safety hazard of \u003Cem>S. aureus\u003C\u002Fem> growth and toxin formation associated with the olives cooked and fermented at your facility.\u003C\u002Fp>\n\n\u003Cp>a. Your HACCP plan does not list the hazards of histamine formation and \u003Cem>S. aureus\u003C\u002Fem> growth and toxin formation associated with the salted anchovies, tuna in oil and natural tuna. Your firm introduces these hazards when you make your filling pastes with the addition of water. The addition of water to the anchovies may affect the water activity of the fermented anchovies allowing histamine formation and \u003Cem>S. aureus\u003C\u002Fem> growth and toxin formation in the absence of time\u002Ftemperature controls. The manipulation of the shelf stable tuna products can have a similar effect in that the hazard of histamine formation is reintroduced by the grinding and mixing of the tuna and the manipulation also allows the re-introduction of \u003Cem>S. aureus\u003C\u002Fem> into the paste. Neither hazard is eliminated by the subsequent thermal process. Time and temperature controls, including refrigeration, must be in place to prevent the formation of scombrotoxin and \u003Cem>S. aureus\u003C\u002Fem> toxin when the products have not achieved a pH, water activity, or water phase salt level sufficient to prevent toxin formation in the absence of refrigeration or time\u002Ftemperature controls.\u003C\u002Fp>\n\n\u003Cp>In addition, we note that your product specifications allow for a histamine content of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm and that your internal histamine specification allows histamine levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong> &lt; m:\u003Cstrong>(b)(4)\u003C\u002Fstrong>, M:\u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm. Please be aware that when histamine levels meet or exceed 50 ppm but are below 500 ppm, the fishery products are considered adulterated by FDA under Sec. 402(a)(3) of the Food, Drug, and Cosmetic Act in that they are decomposed. FDA considers scombrotoxin species products decomposed when histamine meets or exceeds 50 ppm and that scombrotoxin species products where histamine content meets or exceeds 500 ppm to contain a “poisonous or deleterious substance.”\u003C\u002Fp>\n\n\u003Cp>b. Your hazard analysis and HACCP plan fail to identify \u003Cem>S. aureus\u003C\u002Fem> growth and toxin formation at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step. Pre-formed \u003Cem>S. aureus\u003C\u002Fem> toxin will not be eliminated by the subsequent thermal process. Your firm has \u003Cstrong>(b)(4)\u003C\u002Fstrong> underground \u003Cstrong>(b)(4)\u003C\u002Fstrong> tanks on site. After olives are cooked, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> tanks are buried because the temperature is cooler in the ground than atmospheric temperature. In the absence of controls (temperature, pH, salinity, water activity), \u003Cem>S. aureus\u003C\u002Fem> toxin formation appears reasonably likely. The controls should be listed in the HACCP plan and critical control point(s) identified.\u003C\u002Fp>\n\n\u003Cp>Subsequent processing steps may require time\u002Ftemperature controls until the thermal process occurs, if a pH or water activity sufficient to prevent \u003Cem>S. aureus\u003C\u002Fem> toxin formation has not been achieved during \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, when temperatures remain between 10°C (50°F) and 21.1°C (70°F), FDA recommends that a pH of &lt;4.0 or water activity of &lt;0.85 be achieved within 12 hrs. to prevent \u003Cem>S. aureus\u003C\u002Fem> toxin formation during the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process and subsequent processing steps until the thermal process.\u003C\u002Fp>\n\n\u003Cp>c. Although your hazard analysis considers allergens as a hazard, your HACCP plan does not identify undeclared major food allergens as a food safety hazard that is reasonably likely to occur. Anchovies and tuna are finfish identified by FDA as a major allergen and food safety hazard which requires inclusion of controls for the hazard in the HACCP plan. Your HACCP plan should include a critical control point the ensures the accurate declaration of all food allergens on the finished product labels.\u003C\u002Fp>\n\n\u003Cp>Furthermore, the HACCP plan you provided does not meet the requirements of 21 CFR 123.6(c) in that it does not list critical limits; monitoring procedures; monitoring records; or verification procedures for any of the critical control points identified.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated you re-evaluated your hazard analysis to include the hazards of histamine and \u003Cem>S. aureus\u003C\u002Fem> toxin during \u003Cstrong>(b)(4)\u003C\u002Fstrong> which are carried out at room temperature. You also stated you included labeling as a critical control point in your HACCP plan that includes a critical limit, monitoring procedures, verification procedures, and corrective actions procedures to control allergens. You also stated you would include critical control points that include critical limits, monitoring procedures, verification and corrective actions for histamine and allergens. However, you did not provide supporting documentation, (e.g., revised hazard analysis, revised HACCP plan and monitoring records) to demonstrate the adequacy and implementation of these corrective actions. You should at a minimum have a product flow chart, hazard analysis and HACCP plan specific to your seafood (e.g., tuna and anchovy) stuffed olives. You must also ensure your seafood HACCP plans specifically address the seafood products you process and clearly identify the reasonably likely to occur hazards associated with the seafood products as required by 21 CFR 123.6(a) and (b) and meets the requirements of 123.6(c). To assist you with complying with 21 CFR 123.6, we suggest that you use FDA’s Fish and Fishery Products Hazards and Controls Guidance to create your new seafood HACCP plans. As part of your response, you should provide your revised seafood HACCP plans including supporting documentation (e.g., product flow chart and hazard analysis) for all seafood products processed at your facility. In addition, the individual responsible for developing your HACCP plan must complete training under a standardized HACCP curriculum recognized as adequate by the U.S. FDA or have job experience which demonstrates equivalent knowledge to the standardized HACCP curriculum.\u003C\u002Fp>\n\n\u003Cp>Failure to adequately address these violations may lead to regulatory action. For instance, we may, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. You may view this alert at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to correct or implement corrections to the violations cited in this letter.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>In addition to the violations described above, we offer the following comments:\u003C\u002Fstrong>\u003Cbr>\nWe acknowledge you filed new scheduled processes for your green olive products, including the seafood stuffed green olives, with an updated equilibrium pH of 4.3 in November 2023. You must also process each food in conformity with at least the scheduled processes filed, as required by 21 CFR 108.25(c)(3).\u003C\u002Fp>\n\n\u003Cp>In addition, you must also maintain processing and production records showing adherence to scheduled processes, including records of pH measurements and other critical factors (e.g., initial temperature, processing time, temperature, and conveyor speed) intended to ensure a safe product, as required by 21 CFR 114.100(b). Specifically, with respect to the pH measurement, we recommend you follow the procedures outlined in 21 CFR 114.90, including determining pH on samples (21 CFR 114.90(a)(5)), preparation of samples (21 CFR 114.90(a)(6)), and process pH determination (21 CFR 114.90(a)(7).\u003C\u002Fp>\n\n\u003Cp>Please respond in writing within fifteen (15) working days from your receipt of this letter. Your response to this letter should outline the specific steps you are taking or have taken to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan or plans, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>You should direct your written response to Victoria Wagoner, Compliance Officer, Food Adulteration Assessment Branch (HFS-607), Division of Enforcement, Office of Compliance, 5001 Campus Drive, College Park, MD 20740 U.S.A. You may submit documentation accompanying your request to Victoria Wagoner via email at: Victoria.Wagoner@fda.hhs.gov. Please include reference # 677664 on any submissions and within the subject line of any emails to us. If you have any questions regarding this letter, you may contact Victoria Wagoner via email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and\u003Cbr>\n&nbsp; &nbsp;Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nCarlos Mejias\n\nRecipient Title\n\nPresident\n\nJolca, S.A.\n\nPost Office No. 13 Apartado No. 13\n\nHuevar Del Aljarafe Sevilla\n\nSpain\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nMarch 21, 2024\n\nWARNING LETTER\n\nReference # 677664\n\nDear Mr. Mejias:\n\nThe United States Food and Drug Administration (FDA) conducted a Foreign Regulatory Assessment (FRRA) of your seafood processing facility, located at Autovia Sevilla - Huelva Km 22.5, Huevar De Aljarafe, Sevilla, Spain on October 2 through October 11, 2023. During that assessment, we found that you have serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123 (21 CFR 123). At the conclusion of the assessment, the FDA investigator issued you a listing of the observations made during the assessment. You provided responses to the observations, describing corrective actions taken by your firm. After reviewing the remote regulatory assessment findings and the responses that your firm provided, we are issuing this letter to advise you of FDA’s concerns and to provide detailed information describing the findings at your facility. We also address your responses below.\n\nIn accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Furthermore, Accordingly, your ready-to-eat (RTE) cold smoked salmon products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and FDA’s 4th Edition of the Fish and Fisheries Products Hazards & Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov. The 4th Edition of the Hazards Guide can be found on our web site at: https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Fguidanceregulation\u002Fguidancedocumentsregulatoryinformation\u002Fseafood\u002Fucm2018426.htm\n\nYour significant violations are as follows:\n\n1. You must conduct a hazard analysis to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the food safety hazards that are reasonably likely to occur to comply with 21 CFR 123.6(a) and (c). A food safety hazard is defined in 21 CFR 123.3 (f) as “any biological, chemical, or physical property that may cause a food to be unsafe for human consumption.” However, your firm’s HACCP plan for green olives stuffed with anchovy or tuna does not list the food safety hazard of scombrotoxin (histamine) formation, Staphylococcus aureus (S. aureus) growth and toxin formation, and allergens associated with the tuna and anchovies; and the food safety hazard of S. aureus growth and toxin formation associated with the olives cooked and fermented at your facility.\n\na. Your HACCP plan does not list the hazards of histamine formation and S. aureus growth and toxin formation associated with the salted anchovies, tuna in oil and natural tuna. Your firm introduces these hazards when you make your filling pastes with the addition of water. The addition of water to the anchovies may affect the water activity of the fermented anchovies allowing histamine formation and S. aureus growth and toxin formation in the absence of time\u002Ftemperature controls. The manipulation of the shelf stable tuna products can have a similar effect in that the hazard of histamine formation is reintroduced by the grinding and mixing of the tuna and the manipulation also allows the re-introduction of S. aureus into the paste. Neither hazard is eliminated by the subsequent thermal process. Time and temperature controls, including refrigeration, must be in place to prevent the formation of scombrotoxin and S. aureus toxin when the products have not achieved a pH, water activity, or water phase salt level sufficient to prevent toxin formation in the absence of refrigeration or time\u002Ftemperature controls.\n\nIn addition, we note that your product specifications allow for a histamine content of (b)(4) ppm and that your internal histamine specification allows histamine levels of (b)(4) \u003C m:(b)(4), M:(b)(4) ppm. Please be aware that when histamine levels meet or exceed 50 ppm but are below 500 ppm, the fishery products are considered adulterated by FDA under Sec. 402(a)(3) of the Food, Drug, and Cosmetic Act in that they are decomposed. FDA considers scombrotoxin species products decomposed when histamine meets or exceeds 50 ppm and that scombrotoxin species products where histamine content meets or exceeds 500 ppm to contain a “poisonous or deleterious substance.”\n\nb. Your hazard analysis and HACCP plan fail to identify S. aureus growth and toxin formation at the “(b)(4)” step. Pre-formed S. aureus toxin will not be eliminated by the subsequent thermal process. Your firm has (b)(4) underground (b)(4) tanks on site. After olives are cooked, (b)(4). The (b)(4) tanks are buried because the temperature is cooler in the ground than atmospheric temperature. In the absence of controls (temperature, pH, salinity, water activity), S. aureus toxin formation appears reasonably likely. The controls should be listed in the HACCP plan and critical control point(s) identified.\n\nSubsequent processing steps may require time\u002Ftemperature controls until the thermal process occurs, if a pH or water activity sufficient to prevent S. aureus toxin formation has not been achieved during (b)(4). For example, when temperatures remain between 10°C (50°F) and 21.1°C (70°F), FDA recommends that a pH of \u003C4.0 or water activity of \u003C0.85 be achieved within 12 hrs. to prevent S. aureus toxin formation during the (b)(4) process and subsequent processing steps until the thermal process.\n\nc. Although your hazard analysis considers allergens as a hazard, your HACCP plan does not identify undeclared major food allergens as a food safety hazard that is reasonably likely to occur. Anchovies and tuna are finfish identified by FDA as a major allergen and food safety hazard which requires inclusion of controls for the hazard in the HACCP plan. Your HACCP plan should include a critical control point the ensures the accurate declaration of all food allergens on the finished product labels.\n\nFurthermore, the HACCP plan you provided does not meet the requirements of 21 CFR 123.6(c) in that it does not list critical limits; monitoring procedures; monitoring records; or verification procedures for any of the critical control points identified.\n\nIn your response, you stated you re-evaluated your hazard analysis to include the hazards of histamine and S. aureus toxin during (b)(4) which are carried out at room temperature. You also stated you included labeling as a critical control point in your HACCP plan that includes a critical limit, monitoring procedures, verification procedures, and corrective actions procedures to control allergens. You also stated you would include critical control points that include critical limits, monitoring procedures, verification and corrective actions for histamine and allergens. However, you did not provide supporting documentation, (e.g., revised hazard analysis, revised HACCP plan and monitoring records) to demonstrate the adequacy and implementation of these corrective actions. You should at a minimum have a product flow chart, hazard analysis and HACCP plan specific to your seafood (e.g., tuna and anchovy) stuffed olives. You must also ensure your seafood HACCP plans specifically address the seafood products you process and clearly identify the reasonably likely to occur hazards associated with the seafood products as required by 21 CFR 123.6(a) and (b) and meets the requirements of 123.6(c). To assist you with complying with 21 CFR 123.6, we suggest that you use FDA’s Fish and Fishery Products Hazards and Controls Guidance to create your new seafood HACCP plans. As part of your response, you should provide your revised seafood HACCP plans including supporting documentation (e.g., product flow chart and hazard analysis) for all seafood products processed at your facility. In addition, the individual responsible for developing your HACCP plan must complete training under a standardized HACCP curriculum recognized as adequate by the U.S. FDA or have job experience which demonstrates equivalent knowledge to the standardized HACCP curriculum.\n\nFailure to adequately address these violations may lead to regulatory action. For instance, we may, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. You may view this alert at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. You should take prompt action to correct or implement corrections to the violations cited in this letter.\n\nIn addition to the violations described above, we offer the following comments:\n\nWe acknowledge you filed new scheduled processes for your green olive products, including the seafood stuffed green olives, with an updated equilibrium pH of 4.3 in November 2023. You must also process each food in conformity with at least the scheduled processes filed, as required by 21 CFR 108.25(c)(3).\n\nIn addition, you must also maintain processing and production records showing adherence to scheduled processes, including records of pH measurements and other critical factors (e.g., initial temperature, processing time, temperature, and conveyor speed) intended to ensure a safe product, as required by 21 CFR 114.100(b). Specifically, with respect to the pH measurement, we recommend you follow the procedures outlined in 21 CFR 114.90, including determining pH on samples (21 CFR 114.90(a)(5)), preparation of samples (21 CFR 114.90(a)(6)), and process pH determination (21 CFR 114.90(a)(7).\n\nPlease respond in writing within fifteen (15) working days from your receipt of this letter. Your response to this letter should outline the specific steps you are taking or have taken to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan or plans, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYou should direct your written response to Victoria Wagoner, Compliance Officer, Food Adulteration Assessment Branch (HFS-607), Division of Enforcement, Office of Compliance, 5001 Campus Drive, College Park, MD 20740 U.S.A. You may submit documentation accompanying your request to Victoria Wagoner via email at: Victoria.Wagoner@fda.hhs.gov. Please include reference # 677664 on any submissions and within the subject line of any emails to us. If you have any questions regarding this letter, you may contact Victoria Wagoner via email.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and\n\nApplied Nutrition","Jolca, S.A.","jolca-sa-677664-03212024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjolca-sa-677664-03212024","2026-10-26T08:09:05.192631+00:00","Warning Letter","Issued","2024-05-07","677664","Food & Beverages","Carlos Mejias","2026-08-20T00:07:20.781+00:00","Via Express Delivery","2024-03-21",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":48,"body_fetched_at":49,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},1754,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-11-14T05:00:00Z\">11\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-05T04:00:00Z\">09\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgondi-sa-658698-09052023\">Gondi S.A.\u003C\u002Fa>","Center for Food Safety and Applied Nutrition","Low Acid Canned Food Regulation\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Carlos Villacis Guzman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Gondi S.A.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Edificio Pireos Calle 17 Entre Calle 19 Y 20\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Barrio Cordoba, Manta\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Manabi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ecuador\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:cvillacis@gondi.com.ec\"> cvillacis@gondi.com.ec\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 5, 2023\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Reference No. CMS 658698\u003C\u002Fp>\u003Cp>Dear Mr. Villacis:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your low-acid canned food (LACF) product facility located at Km 5 1\u002F2 Via Manta -Portoviejo, Conservas Ideal Plant (Industria De Enlatados Alimenticios Cia Ltda Ideal), Portoviejo, Manabi, Ecuador 130216 on April 10 through April 24, 2023. The inspection was initiated in response to FDA laboratory analysis of samples of your LACF seafood products which indicated the products may have been under processed, which could lead to the presence of spoilage organisms or pathogens.\u003C\u002Fp>\u003Cp>During the inspection, we found that your firm had serious violations of the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation (21 CFR Part 113). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations that lists the serious violations found at your firm. We received your response to the FDA-483 via email on May 12, 2023. Based on our review of the inspectional findings and the responses that your firm provided, we are issuing this Warning Letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\u003C\u002Fp>\u003Cp>As a manufacturer of LACF products intended for export to the United States, you are required to comply with the Federal Food, Drug and Cosmetic Act (the Act) and applicable Federal regulations. Regulations specific to the processing of LACF products are codified in 21 CFR Parts 108 and 113. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.35, including registration and filing of process information, and the mandatory requirements in 21 CFR Parts 113. For imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States (see 21 CFR 108.35(k)). Violation of the mandatory requirements set forth in 21 CFR 108.35 and 21 CFR 113 renders your LACF products adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4). You can find the Act and LACF regulations through links in FDA’s home page at www.fda.gov.\u003C\u002Fp>\u003Cp>Furthermore, this letter is to inform you that FDA has placed your firm’s LACF products on Import Alert #99-38, “Detention Without Physical Examination of Low-Acid Canned Foods or Acidified Foods Due to Inadequate Process Control.” As a result, when your LACF products are offered for import into the United States, FDA may take steps to refuse admission, called Detention Without Physical Examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. The procedure is generally based on past history or other information, such as an establishment inspection, that indicates a product or products appear not to be in compliance with FDA’s laws and regulations.\u003C\u002Fp>\u003Cp>This letter describes the reasons for FDA’s action and steps you can take to address our findings and be considered for removal from the Import Alert.\u003C\u002Fp>\u003Cp>\u003Cstrong>Potentially Under Processed Low-acid Canned Foods\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On February 15, 2023, the Utah Department of Agriculture &amp; Food (UDAF) collected sample 1217315 of Geisha brand medium shrimp 4 oz. (Geisha medium shrimp) lot LGC12W12E22; BEST BY: MAY\u002F12\u002F2026 after receiving reports of swelling, leaking, and bursting cans. In addition, after additional reports of swelling, leaking, and bursting cans, UDAF collected sample 1219196 of Geisha medium shrimp, lot LGC12W04E22; BEST BY MAY\u002F04\u002F2026. Both lots were manufactured at your facility and distributed in the US by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA laboratory analysis of samples 1217315 and 1219196 found microbiological contamination in both lots and found anaerobic, mesophilic, gram positive rods with terminal spores in sample 1219196. Based on these findings, FDA determined that these products may have been under processed and could be contaminated with spoilage organisms or pathogens. On February 27, 2023, \u003Cstrong>(b)(4)\u003C\u002Fstrong> recalled lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> and on April 21, 2023, \u003Cstrong>(b)(4)\u003C\u002Fstrong> recalled all lots of Geisha medium shrimp for which you were the supplier. On March 14, 2023, FDA collected sample 1218618 of Alberto brand sardines in tomato sauce lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>; EXP: 01-FEB-2026 manufactured in your facility and presented for entry into the United States. FDA laboratory analysis of sample 1218618 found facultative anaerobic gram-positive rods, again supporting that the products may have been under processed; therefore, this product was refused.\u003C\u002Fp>\u003Cp>\u003Cstrong>Emergency Permit Control (21 CFR 108) and Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers (21 CFR 113)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. You must process each low-acid canned food in conformity with at least the scheduled process, as required by 21 CFR 108.35(c)(3)(i). However, during our inspection, our investigators reviewed processing records for your canned shrimp in brine and your filed scheduled process for canned shrimp in brine in size \u003Cstrong>(b)(4)\u003C\u002Fstrong> metal cans (SID: \u003Cstrong>(b)(4)\u003C\u002Fstrong>), and observed the following deviations from the filed scheduled process:\u003C\u002Fp>\u003Cp>a. Your scheduled process for shrimp in brine in size \u003Cstrong>(b)(4)\u003C\u002Fstrong> metal cans identifies the minimum initial temperature as \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C (\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F). You did not meet the minimum initial temperature during the processing of “Camaron al natural” (shrimp in brine) on the following dates: May 4, 10, 12, 13, 16, 18, and 20, 2022 and July 13, 15, 19, 20, 22, 28, 2022. Your processing records show that the minimum initial temperature was between \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C and \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C on these dates.\u003C\u002Fp>\u003Cp>We also note that your filed process identifies the processing time and temperature as \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F for \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes. However, according to your processing records, your processing time was less than \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes (\u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes at \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F) on these dates. Your heat penetration study from 2018, which was filed with your scheduled process, indicates that when the minimum initial temperature is \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F, the processing time and temperature to reach commercial sterility is \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F for \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes; however, you did not have your process authority evaluate the under processed product for safety.\u003C\u002Fp>\u003Cp>b. Your scheduled process for shrimp in brine size \u003Cstrong>(b)(4)\u003C\u002Fstrong> metal cans identifies the maximum net fill weight as \u003Cstrong>(b)(4)\u003C\u002Fstrong> oz. (\u003Cstrong>(b)(4)\u003C\u002Fstrong>g), and your heat penetration study from 2018 identifies the fill weight as \u003Cstrong>(b)(4)\u003C\u002Fstrong> oz. However, you exceeded the net fill weight on the following dates: May 4, 10, 12, 13, 16, 18, and 20, 2022 and July 13, 15, 19, 20, 22, 28, 2022. According to your net fill weight monitoring records, the maximum net fill weight was greater than approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>g for all the cans produced on those dates. In addition, you approved a minimum net fill weight product specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong>g for this product on January 28, 2019, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> months after submitting the filed scheduled process to the FDA with a maximum net fill weight of \u003Cstrong>(b)(4)\u003C\u002Fstrong>g.\u003C\u002Fp>\u003Cp>c. Your scheduled process provides for the use of a can size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for canned shrimp in brine. However, you used a can size of \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the following 13 dates: May 4, 10, 12, 13, 16, 18, and 20, 2022 and July 13, 15, 19, 20, 22, 28, 2022. In addition, you approved the can specifications for the size \u003Cstrong>(b)(4)\u003C\u002Fstrong> metal cans on January 28, 2019, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> months after you were using the larger cans.\u003C\u002Fp>\u003Cp>d. Your scheduled process for shrimp in brine size \u003Cstrong>(b)(4)\u003C\u002Fstrong> metal cans identifies the type of retorts as \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your retort operator told our investigators that your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> retorts. Your retort operator stated that they monitor the water level for the retorts, but they could not identify how the water level is monitored, and the water level was not documented on the processing records. Furthermore, our investigators did not observe a water level sight glass or any other type of water level near the retort door. The lack of a sight glass on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> retort can lead to low water levels not being detected. Moreover, on April 10, 2023, our investigators observed that retort \u003Cstrong>(b)(4)\u003C\u002Fstrong> was leaking from the bottom of the retort door, which could also result in low water levels. Low water levels may cause temperature drops in the retort and lead to under processing.\u003C\u002Fp>\u003Cp>On April 12, 2023, you provided our investigators with a heat penetration study and temperature distribution study for retort “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” dated April 4, 2023, which identifies the retort as a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These studies were completed after the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of canned shrimp in brine were manufactured in 2022, and your filed scheduled process in place in 2022 identified a \u003Cstrong>(b)(4)\u003C\u002Fstrong> retort. Furthermore, all your filed scheduled processes for canned shrimp identify a \u003Cstrong>(b)(4)\u003C\u002Fstrong> retort.\u003C\u002Fp>\u003Cp>Your May 12, 2023, response stated that you filed a new scheduled process in 2023 to support the product manufactured in 2022. However, you did not provide any documentation that the process had been reviewed by your process authority prior to the processing of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots manufactured in 2022, as required by 21 CFR 108.35(c)(2)(ii). Further, you have not evaluated all products manufactured prior to the heat penetration study dated January 18, 2023, and the temperature distribution study dated April 4, 2023, nor have you provided an evaluation by your process authority of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of canned shrimp manufactured in 2022, as required by 21 CFR 113.89. Furthermore, pursuant to 21 CFR 108.35(c)(3)(ii) and as explained in FDA’s notifications dated January 27, 2023 and April 21, 2023, FDA cancelled the new scheduled process because of your failure to respond to an FDA inquiry regarding the process. As part of your response to this Warning Letter, you should have all the products and processes evaluated by your process authority and file new scheduled processes that are reflective of the actual operations and equipment in your facility.\u003C\u002Fp>\u003Cp>In addition, we note that you have a second Food Canning Establishment number under the firm name, “Godi S:A Company” that appears to be the same facility registered as a food canning establishment under the name Gondi, S.A.; however, it does not have a valid food facility registration under section 415 of the FD&amp;C Act (21 U.S.C. § 350(d)). You cancelled both Food Canning Establishment registrations on June 8, 2023, stating your firm is out of business, however, you have not cancelled your food facility registration. If you intend to ship LACF products to the United States, you should promptly take action to rectify these discrepancies with your required registrations as required by 21 CFR Part 1, Subpart H and 21 CFR 108.35(c)(1).\u003C\u002Fp>\u003Cp>2. You must record all processing and production information at the time it was observed by the retort or processing system operator, or other designated person, as required by 21 CFR 113.100(a). You must also determine and record with sufficient frequency the initial temperature of the contents of the containers, as required by 21 CFR 113.87(c). Your operators record processing and production information on a retort operator log. On April 12, 2023, our investigators observed part of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle of tuna in can size \u003Cstrong>(b)(4)\u003C\u002Fstrong> in \u003Cstrong>(b)(4)\u003C\u002Fstrong> (retort) “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Venting time must be observed and recorded during this process. Your retort operator did not record the venting time, and the operator log was not in the retort area. The retort operator log was later identified on a table outside of the production room and had multiple empty data fields, including date, product name, code, lot code, and time and temperature for the sterilization program. Furthermore, information was missing from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle, including the initial temperature, total venting time and temperature, start of sterilization, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> temperature. Your retort operator stated they complete the log after the end of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle by reviewing the temperature charts to determine the time and temperature for each event and stated that the retort is left unattended during employee breaks. You are not adequately monitoring and recording the processing and production information so that process deviations can be identified when they occur.\u003C\u002Fp>\u003Cp>Your response stated that the retort operator considered the electronic data provided by the driver software and temperature charts to be sufficient to complete the manual record at the end of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle. This response is not adequate to address the violation. You must ensure all important processing information is recorded and monitored in real time to achieve commercial sterility and to identify process deviations in a timely manner.\u003C\u002Fp>\u003Cp>3. You must mark each \u003Cstrong>(b)(4)\u003C\u002Fstrong> sealed container of low-acid processed food with an identifying code that identifies in code the establishment where packed, the product contained therein, the year packed, the day packed, and the period during which packed, as required by 21 CFR 113.60(c). The packing period code shall be changed with sufficient frequency to enable ready identification of lots during their sale and distribution. Codes may be changed on the basis of one of the following: intervals of \u003Cstrong>(b)(4)\u003C\u002Fstrong> hours; personnel shift changes; or batches, as long as the containers that constitute the batch do not extend over a period of more than one personnel shift. However, your operations manager indicated that your commercial lot code that is printed on a can may contain more than one production lot code, (i.e., it may represent several days of production).\u003C\u002Fp>\u003Cp>Your response indicated you would make a change, but you did not provide any supporting documentation for the changes to the identifying code, nor did you provide a timeframe for which the corrective action will be implemented.\u003C\u002Fp>\u003Cp>4. You must have plant personnel involved in thermal processing systems or other critical factors of the operation under the operating supervision of a person who has attended a school approved by FDA, as required by 21 CFR 108.35(g) and 21 CFR 113.10. During the inspection, our investigators requested records to show that one or more of your plant personnel have attended such a school, but you did not provide any such records.\u003C\u002Fp>\u003Cp>Your response did not provide documentation demonstrating that any of your plant personnel have attended such a school or plan to attend such a school.\u003C\u002Fp>\u003Cp>\u003Cstrong>Products currently on the market in the U.S.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On May 11, 2023, we shared our concerns, based on the sample and inspectional findings, that all products processed in your facility for the US market may be under processed. We asked you to provide a list of your US customers and the LACF products you process for them. Further, we asked you to evaluate all LACF products that may still be available to US consumers and to take appropriate corrective actions, including a voluntary recall. You have not responded to our requests.\u003C\u002Fp>\u003Cp>This letter may not list all the violations at your facility. You are responsible for ensuring that your facility operates in compliance with the Act and all applicable regulations, including the LACF regulations (21 CFR 108 and 113). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations. If you do not believe your products are in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>In addition to the above listed violations, we provide the following comment:\u003C\u002Fp>\u003Cp>As your firm is a low-acid canned food processor for seafood products, including shrimp, tuna, and sardines, you must be in compliance the seafood Hazard Analysis and Critical Control Point (HACCP) regulation (21 CFR Part 123), among other requirements. Our investigators observed inadequate measures to protect food from contamination, inadequate sanitary facilities, and inadequate pest control related to the processing of your canned seafood products. Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified to advise you regarding compliance with 21 CFR Parts 108, 113, 117, and 123. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm's compliance status with FDA.\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these violations. More specifically, your response should include documentation and information that would assist us in evaluating your corrections, including processing records for five lots of product produced over at least five days. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. Responding in English will help to assist us in our review of your documentation.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Victoria Wagoner, Compliance Officer, Office of Compliance, Division of Enforcement, Food Assessment and Adulteration Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Victoria Wagoner via email at Victoria.Wagoner@fda.hhs.gov. Please reference 658698 on any submissions and within the subject line of any emails to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Ann Oxenham, J.D.\u003Cbr>Director\u003Cbr>Office of Compliance\u003Cbr>Center for Food Safety\u003Cbr>&nbsp; &nbsp;and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Carlos Villacis Guzman\n\nRecipient Title\n\nPresident and Owner\n\nGondi S.A.\n\nEdificio Pireos Calle 17 Entre Calle 19 Y 20\n\nBarrio Cordoba, Manta\n\nManabi\n\nEcuador\n\ncvillacis@gondi.com.ec\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nSeptember 5, 2023\nWARNING LETTER\nReference No. CMS 658698\nDear Mr. Villacis:\nThe U.S. Food and Drug Administration (FDA) inspected your low-acid canned food (LACF) product facility located at Km 5 1\u002F2 Via Manta -Portoviejo, Conservas Ideal Plant (Industria De Enlatados Alimenticios Cia Ltda Ideal), Portoviejo, Manabi, Ecuador 130216 on April 10 through April 24, 2023. The inspection was initiated in response to FDA laboratory analysis of samples of your LACF seafood products which indicated the products may have been under processed, which could lead to the presence of spoilage organisms or pathogens.\nDuring the inspection, we found that your firm had serious violations of the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation (21 CFR Part 113). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations that lists the serious violations found at your firm. We received your response to the FDA-483 via email on May 12, 2023. Based on our review of the inspectional findings and the responses that your firm provided, we are issuing this Warning Letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\nAs a manufacturer of LACF products intended for export to the United States, you are required to comply with the Federal Food, Drug and Cosmetic Act (the Act) and applicable Federal regulations. Regulations specific to the processing of LACF products are codified in 21 CFR Parts 108 and 113. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.35, including registration and filing of process information, and the mandatory requirements in 21 CFR Parts 113. For imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States (see 21 CFR 108.35(k)). Violation of the mandatory requirements set forth in 21 CFR 108.35 and 21 CFR 113 renders your LACF products adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4). You can find the Act and LACF regulations through links in FDA’s home page at www.fda.gov.\nFurthermore, this letter is to inform you that FDA has placed your firm’s LACF products on Import Alert #99-38, “Detention Without Physical Examination of Low-Acid Canned Foods or Acidified Foods Due to Inadequate Process Control.” As a result, when your LACF products are offered for import into the United States, FDA may take steps to refuse admission, called Detention Without Physical Examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. The procedure is generally based on past history or other information, such as an establishment inspection, that indicates a product or products appear not to be in compliance with FDA’s laws and regulations.\nThis letter describes the reasons for FDA’s action and steps you can take to address our findings and be considered for removal from the Import Alert.\nPotentially Under Processed Low-acid Canned Foods\nOn February 15, 2023, the Utah Department of Agriculture & Food (UDAF) collected sample 1217315 of Geisha brand medium shrimp 4 oz. (Geisha medium shrimp) lot LGC12W12E22; BEST BY: MAY\u002F12\u002F2026 after receiving reports of swelling, leaking, and bursting cans. In addition, after additional reports of swelling, leaking, and bursting cans, UDAF collected sample 1219196 of Geisha medium shrimp, lot LGC12W04E22; BEST BY MAY\u002F04\u002F2026. Both lots were manufactured at your facility and distributed in the US by (b)(4). FDA laboratory analysis of samples 1217315 and 1219196 found microbiological contamination in both lots and found anaerobic, mesophilic, gram positive rods with terminal spores in sample 1219196. Based on these findings, FDA determined that these products may have been under processed and could be contaminated with spoilage organisms or pathogens. On February 27, 2023, (b)(4) recalled lot (b)(4) and on April 21, 2023, (b)(4) recalled all lots of Geisha medium shrimp for which you were the supplier. On March 14, 2023, FDA collected sample 1218618 of Alberto brand sardines in tomato sauce lot (b)(4); EXP: 01-FEB-2026 manufactured in your facility and presented for entry into the United States. FDA laboratory analysis of sample 1218618 found facultative anaerobic gram-positive rods, again supporting that the products may have been under processed; therefore, this product was refused.\nEmergency Permit Control (21 CFR 108) and Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers (21 CFR 113)\n1. You must process each low-acid canned food in conformity with at least the scheduled process, as required by 21 CFR 108.35(c)(3)(i). However, during our inspection, our investigators reviewed processing records for your canned shrimp in brine and your filed scheduled process for canned shrimp in brine in size (b)(4) metal cans (SID: (b)(4)), and observed the following deviations from the filed scheduled process:\na. Your scheduled process for shrimp in brine in size (b)(4) metal cans identifies the minimum initial temperature as (b)(4)°C ((b)(4)°F). You did not meet the minimum initial temperature during the processing of “Camaron al natural” (shrimp in brine) on the following dates: May 4, 10, 12, 13, 16, 18, and 20, 2022 and July 13, 15, 19, 20, 22, 28, 2022. Your processing records show that the minimum initial temperature was between (b)(4)°C and (b)(4)°C on these dates.\nWe also note that your filed process identifies the processing time and temperature as (b)(4)°F for (b)(4) minutes. However, according to your processing records, your processing time was less than (b)(4) minutes ((b)(4) minutes at (b)(4)°F) on these dates. Your heat penetration study from 2018, which was filed with your scheduled process, indicates that when the minimum initial temperature is (b)(4)°F, the processing time and temperature to reach commercial sterility is (b)(4)°F for (b)(4) minutes; however, you did not have your process authority evaluate the under processed product for safety.\nb. Your scheduled process for shrimp in brine size (b)(4) metal cans identifies the maximum net fill weight as (b)(4) oz. ((b)(4)g), and your heat penetration study from 2018 identifies the fill weight as (b)(4) oz. However, you exceeded the net fill weight on the following dates: May 4, 10, 12, 13, 16, 18, and 20, 2022 and July 13, 15, 19, 20, 22, 28, 2022. According to your net fill weight monitoring records, the maximum net fill weight was greater than approximately (b)(4)g for all the cans produced on those dates. In addition, you approved a minimum net fill weight product specification of (b)(4)g for this product on January 28, 2019, approximately (b)(4) months after submitting the filed scheduled process to the FDA with a maximum net fill weight of (b)(4)g.\nc. Your scheduled process provides for the use of a can size of (b)(4) for canned shrimp in brine. However, you used a can size of (b)(4) on the following 13 dates: May 4, 10, 12, 13, 16, 18, and 20, 2022 and July 13, 15, 19, 20, 22, 28, 2022. In addition, you approved the can specifications for the size (b)(4) metal cans on January 28, 2019, approximately (b)(4) months after you were using the larger cans.\nd. Your scheduled process for shrimp in brine size (b)(4) metal cans identifies the type of retorts as (b)(4). However, your retort operator told our investigators that your firm uses (b)(4) retorts. Your retort operator stated that they monitor the water level for the retorts, but they could not identify how the water level is monitored, and the water level was not documented on the processing records. Furthermore, our investigators did not observe a water level sight glass or any other type of water level near the retort door. The lack of a sight glass on a (b)(4) retort can lead to low water levels not being detected. Moreover, on April 10, 2023, our investigators observed that retort (b)(4) was leaking from the bottom of the retort door, which could also result in low water levels. Low water levels may cause temperature drops in the retort and lead to under processing.\nOn April 12, 2023, you provided our investigators with a heat penetration study and temperature distribution study for retort “(b)(4)” dated April 4, 2023, which identifies the retort as a (b)(4). These studies were completed after the (b)(4) lots of canned shrimp in brine were manufactured in 2022, and your filed scheduled process in place in 2022 identified a (b)(4) retort. Furthermore, all your filed scheduled processes for canned shrimp identify a (b)(4) retort.\nYour May 12, 2023, response stated that you filed a new scheduled process in 2023 to support the product manufactured in 2022. However, you did not provide any documentation that the process had been reviewed by your process authority prior to the processing of the (b)(4) lots manufactured in 2022, as required by 21 CFR 108.35(c)(2)(ii). Further, you have not evaluated all products manufactured prior to the heat penetration study dated January 18, 2023, and the temperature distribution study dated April 4, 2023, nor have you provided an evaluation by your process authority of the (b)(4) lots of canned shrimp manufactured in 2022, as required by 21 CFR 113.89. Furthermore, pursuant to 21 CFR 108.35(c)(3)(ii) and as explained in FDA’s notifications dated January 27, 2023 and April 21, 2023, FDA cancelled the new scheduled process because of your failure to respond to an FDA inquiry regarding the process. As part of your response to this Warning Letter, you should have all the products and processes evaluated by your process authority and file new scheduled processes that are reflective of the actual operations and equipment in your facility.\nIn addition, we note that you have a second Food Canning Establishment number under the firm name, “Godi S:A Company” that appears to be the same facility registered as a food canning establishment under the name Gondi, S.A.; however, it does not have a valid food facility registration under section 415 of the FD&C Act (21 U.S.C. § 350(d)). You cancelled both Food Canning Establishment registrations on June 8, 2023, stating your firm is out of business, however, you have not cancelled your food facility registration. If you intend to ship LACF products to the United States, you should promptly take action to rectify these discrepancies with your required registrations as required by 21 CFR Part 1, Subpart H and 21 CFR 108.35(c)(1).\n2. You must record all processing and production information at the time it was observed by the retort or processing system operator, or other designated person, as required by 21 CFR 113.100(a). You must also determine and record with sufficient frequency the initial temperature of the contents of the containers, as required by 21 CFR 113.87(c). Your operators record processing and production information on a retort operator log. On April 12, 2023, our investigators observed part of the (b)(4) cycle of tuna in can size (b)(4) in (b)(4) (retort) “(b)(4).” Venting time must be observed and recorded during this process. Your retort operator did not record the venting time, and the operator log was not in the retort area. The retort operator log was later identified on a table outside of the production room and had multiple empty data fields, including date, product name, code, lot code, and time and temperature for the sterilization program. Furthermore, information was missing from the (b)(4) cycle, including the initial temperature, total venting time and temperature, start of sterilization, and (b)(4) temperature. Your retort operator stated they complete the log after the end of the (b)(4) cycle by reviewing the temperature charts to determine the time and temperature for each event and stated that the retort is left unattended during employee breaks. You are not adequately monitoring and recording the processing and production information so that process deviations can be identified when they occur.\nYour response stated that the retort operator considered the electronic data provided by the driver software and temperature charts to be sufficient to complete the manual record at the end of the (b)(4) cycle. This response is not adequate to address the violation. You must ensure all important processing information is recorded and monitored in real time to achieve commercial sterility and to identify process deviations in a timely manner.\n3. You must mark each (b)(4) sealed container of low-acid processed food with an identifying code that identifies in code the establishment where packed, the product contained therein, the year packed, the day packed, and the period during which packed, as required by 21 CFR 113.60(c). The packing period code shall be changed with sufficient frequency to enable ready identification of lots during their sale and distribution. Codes may be changed on the basis of one of the following: intervals of (b)(4) hours; personnel shift changes; or batches, as long as the containers that constitute the batch do not extend over a period of more than one personnel shift. However, your operations manager indicated that your commercial lot code that is printed on a can may contain more than one production lot code, (i.e., it may represent several days of production).\nYour response indicated you would make a change, but you did not provide any supporting documentation for the changes to the identifying code, nor did you provide a timeframe for which the corrective action will be implemented.\n4. You must have plant personnel involved in thermal processing systems or other critical factors of the operation under the operating supervision of a person who has attended a school approved by FDA, as required by 21 CFR 108.35(g) and 21 CFR 113.10. During the inspection, our investigators requested records to show that one or more of your plant personnel have attended such a school, but you did not provide any such records.\nYour response did not provide documentation demonstrating that any of your plant personnel have attended such a school or plan to attend such a school.\nProducts currently on the market in the U.S.\nOn May 11, 2023, we shared our concerns, based on the sample and inspectional findings, that all products processed in your facility for the US market may be under processed. We asked you to provide a list of your US customers and the LACF products you process for them. Further, we asked you to evaluate all LACF products that may still be available to US consumers and to take appropriate corrective actions, including a voluntary recall. You have not responded to our requests.\nThis letter may not list all the violations at your facility. You are responsible for ensuring that your facility operates in compliance with the Act and all applicable regulations, including the LACF regulations (21 CFR 108 and 113). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations. If you do not believe your products are in violation of the Act, include your reasoning and any supporting information for our consideration.\nIn addition to the above listed violations, we provide the following comment:\nAs your firm is a low-acid canned food processor for seafood products, including shrimp, tuna, and sardines, you must be in compliance the seafood Hazard Analysis and Critical Control Point (HACCP) regulation (21 CFR Part 123), among other requirements. Our investigators observed inadequate measures to protect food from contamination, inadequate sanitary facilities, and inadequate pest control related to the processing of your canned seafood products. Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified to advise you regarding compliance with 21 CFR Parts 108, 113, 117, and 123. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm's compliance status with FDA.\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these violations. More specifically, your response should include documentation and information that would assist us in evaluating your corrections, including processing records for five lots of product produced over at least five days. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. Responding in English will help to assist us in our review of your documentation.\nPlease send your reply to the Food and Drug Administration, Attention: Victoria Wagoner, Compliance Officer, Office of Compliance, Division of Enforcement, Food Assessment and Adulteration Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Victoria Wagoner via email at Victoria.Wagoner@fda.hhs.gov. Please reference 658698 on any submissions and within the subject line of any emails to us.\nSincerely,\n\u002FS\u002F\nAnn Oxenham, J.D.\nDirector\nOffice of Compliance\nCenter for Food Safety\nand Applied Nutrition","Gondi S.A.","gondi-sa-658698-09052023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgondi-sa-658698-09052023","2026-10-26T08:08:48.029352+00:00","2023-11-14","658698","Mr. Carlos Villacis Guzman","2026-08-20T00:31:36.761+00:00","2023-09-05",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},871,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2025-05-27T04:00:00Z\">05\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-05T04:00:00Z\">05\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsedecal-sa-707156-05052025\">Sedecal S.A.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>S. Manuel Martinez García\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sedecal S.A.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>C\u002FPelaya, 9-13 Pol Industrial Rio De Janeiro\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>28110\u003C\u002Fspan> \u003Cspan>ALGETE\u003C\u002Fspan> \u003Cspan>Madrid\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Spain\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mmartinez@sedecal.com\"> mmartinez@sedecal.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mmartinezjr@sedecal.com\"> mmartinezjr@sedecal.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 5, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Martinez García:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Madrid, Spain on January 20, 2025, through January 24, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures DX-D 100, DX-D 600, and MobileDiagnost wDR systems. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received a response from Maria Luisa Gomez de Aguero, Director of Quality and Regulatory Affairs dated February 14, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish and maintain procedures for implementing corrective and preventative action (CAPA), as required by 21 CFR 820.100(a). Specifically, your firm initiated CAPA 20\u002F028 to address customer complaints reporting DXD100 mobile x-ray units self-propelling crashing into x-ray control panel in one case and almost running into the patient, in the other case. This issue affects all mobile x-ray unit models. However, your firm failed to document an assessment of the risk of the affected units in the field for this issue, when investigating the cause of nonconformities relating to the product.\u003C\u002Fp>\u003Cp>We reviewed your response and conclude that the adequacy of your firm’s response cannot be determined at this time. You stated that you will revise procedures PG-031 Customer complaint and PG-020 Risk management procedures to ensure that an investigation is documented properly. You also stated that you will revise procedure PG-019 Corrective and Preventive action and conduct training for the relevant personnel. Although your firm’s response states you will revise the relevant procedures, the revised procedures were not included in the response for evaluation. Your firm’s response does not include a retrospective review of related documentation to ensure compliance with the updated procedures and how these will be implemented moving forward. Documentation of corrective action, retrospective review as well as training is needed in order to adequately address this observation.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Design validation shall include risk analysis, where appropriate. Specifically, your firm conducted a recall to address unintended movement of MobileDiagnost wDR that could result in life threatening situations and cause the device to stop working as intended. However, the risk analysis for MobileDiagnost wDR (Document IH0532RA_Annex, dated April 26, 2022) fails to include this increased hazard severity (life threatening) to ensure that appropriate risk control measures are implemented.\u003C\u002Fp>\u003Cp>We reviewed your response and conclude that the adequacy of your firm’s response cannot be determined at this time. Your response states that you will re-evaluate and document the risk analysis for the recall. You also state that you will revise procedures PG-031 Customer complaint and PG-020 Risk management procedures to account for risk analysis. Although your firm’s response states you will revise the relevant procedures, the revised procedures were not included in the response for evaluation. Your firm’s response does not include a retrospective review of related documentation to ensure compliance with the updated procedures and how these will be implemented moving forward. Documentation of corrective action, retrospective review as well as training is needed in order to adequately address this observation.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s DX-D100 devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Device; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>3. Failure to submit a written report of a correction or removal of a device to FDA, initiated to reduce a risk to health or to remedy a violation which may present a risk to health, as required by 21 CFR 806.10. Specifically, your firm initiated CAPA 20\u002F028 to address customer complaints reporting DXD100 mobile x-ray units self-propelling crashing into x-ray control panel in one case and almost running into the patient, in the other case. This issue affects all mobile x-ray unit models. Your firm implemented two corrective actions to address this issue and issued a service note to be distributed to customers. However, your firm failed to submit a report of correction or removal to FDA for these actions.\u003C\u002Fp>\u003Cp>We reviewed your response to Observation 1 and conclude it is not adequate. Your investigation of the issue concluded that this issue does not pose a risk to safety due to the low speed of the movement and did not consider it as a reportable recall. However, your firm implemented two corrections to address this issue and issued a service note to be distributed to the customers. Our assessment concluded that the unintended movement presents a risk to health and your firm’s actions were initiated to reduce the risk to health.\u003C\u002Fp>\u003Cp>Your firm’s devices are also electronic products subject to compliance with Subchapter C of the Act, Electronic Product Radiation Control, the requirements at 21 CFR 1000-1005, and the performance standards at 21 CFR 1020.30 and 1020.31. Your firm failed to comply with the regulations regarding reporting and recordkeeping.\u003C\u002Fp>\u003Cp>4. Failure to conduct certification of an electronic product, based upon a testing program which is in accordance with good manufacturing practices, as required by 21 CFR 1002.30(a)(1). Specifically, a review of the design control records revealed that the wDR2.2 was approved and released for distribution in the US without documentation to show that the required performance standard checklist (Technical Report Subchapter J of 21 CFR MobileDiagnost wDR 2.2, Doc #R01005_21CKL) was completed to demonstrate compliance with the performance standard requirements prior to release of the product. The performance standard checklist was not completed until Jan. 14, 2025.\u003C\u002Fp>\u003Cp>We reviewed your response and conclude that the adequacy of your firm’s response cannot be determined at this time. You stated that you will review and revise procedures PE-062 Design Verification, PG-044 Organization of Project Teams among others. Although your firm’s response states you will revise the relevant procedures, the revised procedures were not included in the response for evaluation. Your firm’s response does not include a retrospective review of related documentation to ensure compliance with the updated procedures. Documentation of corrective action, retrospective review as well as training is needed in order to adequately address this observation.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case 707156 when replying. If you have any questions about the contents of this letter, please contact: Lu Jiang at +1(240)402-5779.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Robert Ochs, Ph.D.\u003Cbr>Director\u003Cbr>OHT8: Office of Radiological Health\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Devan Moser\u003Cbr>U.S. Agent\u003Cbr>Sedecal USA Inc.\u003Cbr>7555 N. Caldwell Avenue\u003Cbr>Niles, Illinois 60714\u003Cbr>dmoser@sedecalusa.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nS. Manuel Martinez García\n\nRecipient Title\n\nPresident and CEO\n\nSedecal S.A.\n\nC\u002FPelaya, 9-13 Pol Industrial Rio De Janeiro\n\n28110 ALGETE Madrid\n\nSpain\n\nmmartinez@sedecal.com\n\nmmartinezjr@sedecal.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nMay 5, 2025\nDear Mr. Martinez García:\nDuring an inspection of your firm located in Madrid, Spain on January 20, 2025, through January 24, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures DX-D 100, DX-D 600, and MobileDiagnost wDR systems. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Maria Luisa Gomez de Aguero, Director of Quality and Regulatory Affairs dated February 14, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish and maintain procedures for implementing corrective and preventative action (CAPA), as required by 21 CFR 820.100(a). Specifically, your firm initiated CAPA 20\u002F028 to address customer complaints reporting DXD100 mobile x-ray units self-propelling crashing into x-ray control panel in one case and almost running into the patient, in the other case. This issue affects all mobile x-ray unit models. However, your firm failed to document an assessment of the risk of the affected units in the field for this issue, when investigating the cause of nonconformities relating to the product.\nWe reviewed your response and conclude that the adequacy of your firm’s response cannot be determined at this time. You stated that you will revise procedures PG-031 Customer complaint and PG-020 Risk management procedures to ensure that an investigation is documented properly. You also stated that you will revise procedure PG-019 Corrective and Preventive action and conduct training for the relevant personnel. Although your firm’s response states you will revise the relevant procedures, the revised procedures were not included in the response for evaluation. Your firm’s response does not include a retrospective review of related documentation to ensure compliance with the updated procedures and how these will be implemented moving forward. Documentation of corrective action, retrospective review as well as training is needed in order to adequately address this observation.\n2. Failure to adequately establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Design validation shall include risk analysis, where appropriate. Specifically, your firm conducted a recall to address unintended movement of MobileDiagnost wDR that could result in life threatening situations and cause the device to stop working as intended. However, the risk analysis for MobileDiagnost wDR (Document IH0532RA_Annex, dated April 26, 2022) fails to include this increased hazard severity (life threatening) to ensure that appropriate risk control measures are implemented.\nWe reviewed your response and conclude that the adequacy of your firm’s response cannot be determined at this time. Your response states that you will re-evaluate and document the risk analysis for the recall. You also state that you will revise procedures PG-031 Customer complaint and PG-020 Risk management procedures to account for risk analysis. Although your firm’s response states you will revise the relevant procedures, the revised procedures were not included in the response for evaluation. Your firm’s response does not include a retrospective review of related documentation to ensure compliance with the updated procedures and how these will be implemented moving forward. Documentation of corrective action, retrospective review as well as training is needed in order to adequately address this observation.\nOur inspection also revealed that your firm’s DX-D100 devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Device; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\n3. Failure to submit a written report of a correction or removal of a device to FDA, initiated to reduce a risk to health or to remedy a violation which may present a risk to health, as required by 21 CFR 806.10. Specifically, your firm initiated CAPA 20\u002F028 to address customer complaints reporting DXD100 mobile x-ray units self-propelling crashing into x-ray control panel in one case and almost running into the patient, in the other case. This issue affects all mobile x-ray unit models. Your firm implemented two corrective actions to address this issue and issued a service note to be distributed to customers. However, your firm failed to submit a report of correction or removal to FDA for these actions.\nWe reviewed your response to Observation 1 and conclude it is not adequate. Your investigation of the issue concluded that this issue does not pose a risk to safety due to the low speed of the movement and did not consider it as a reportable recall. However, your firm implemented two corrections to address this issue and issued a service note to be distributed to the customers. Our assessment concluded that the unintended movement presents a risk to health and your firm’s actions were initiated to reduce the risk to health.\nYour firm’s devices are also electronic products subject to compliance with Subchapter C of the Act, Electronic Product Radiation Control, the requirements at 21 CFR 1000-1005, and the performance standards at 21 CFR 1020.30 and 1020.31. Your firm failed to comply with the regulations regarding reporting and recordkeeping.\n4. Failure to conduct certification of an electronic product, based upon a testing program which is in accordance with good manufacturing practices, as required by 21 CFR 1002.30(a)(1). Specifically, a review of the design control records revealed that the wDR2.2 was approved and released for distribution in the US without documentation to show that the required performance standard checklist (Technical Report Subchapter J of 21 CFR MobileDiagnost wDR 2.2, Doc #R01005_21CKL) was completed to demonstrate compliance with the performance standard requirements prior to release of the product. The performance standard checklist was not completed until Jan. 14, 2025.\nWe reviewed your response and conclude that the adequacy of your firm’s response cannot be determined at this time. You stated that you will review and revise procedures PE-062 Design Verification, PG-044 Organization of Project Teams among others. Although your firm’s response states you will revise the relevant procedures, the revised procedures were not included in the response for evaluation. Your firm’s response does not include a retrospective review of related documentation to ensure compliance with the updated procedures. Documentation of corrective action, retrospective review as well as training is needed in order to adequately address this observation.\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case 707156 when replying. If you have any questions about the contents of this letter, please contact: Lu Jiang at +1(240)402-5779.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nRobert Ochs, Ph.D.\nDirector\nOHT8: Office of Radiological Health\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nDevan Moser\nU.S. Agent\nSedecal USA Inc.\n7555 N. Caldwell Avenue\nNiles, Illinois 60714\ndmoser@sedecalusa.com","Sedecal S.A.","sedecal-sa-707156-05052025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsedecal-sa-707156-05052025","2026-10-26T08:09:55.130548+00:00","2025-05-27","707156","Medical Devices","S. Manuel Martinez García","2026-08-19T16:44:48.776+00:00","Via Email","2025-05-05",{"id":74,"raw":75,"subject":79,"body_html":80,"body_text":81,"firm_name":82,"letter_id":83,"created_at":18,"fei_number":19,"letter_url":84,"updated_at":85,"action_type":22,"case_status":23,"posted_date":86,"marcs_cms_no":87,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":88,"body_fetched_at":89,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":90,"medical_device_id":19,"response_letter_date":19},1313,[76,77,78,37,79,13,13,13],"\u003Ctime datetime=\"2024-08-20T04:00:00Z\">08\u002F20\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-08-13T04:00:00Z\">08\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagustson-687113-08132024\">Agustson A\u002FS\u003C\u002Fa>","Seafood HACCP\u002FCGMP for Foods\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Esben Anderson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Agustson A\u002FS\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Englandsvej 11 Vejle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>7100\u003C\u002Fspan> \u003Cspan>Syddanmark\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Denmark\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 13, 2024\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Reference # 687113\u003C\u002Fp>\u003Cp>Dear Mr. Anderson:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your seafood processing facility, Agustson A\u002FS, located at Englandsvej 11, Vejle, Syddanmark, Denmark 7100 on March 7 – 8, 2024. During the inspection, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123 (21 CFR Part 123). At the conclusion of the inspection, the FDA investigator issued an FDA 483, Inspectional Observations, listing the deviations found at your firm. We acknowledge receipt of your responses, received via email on March 31, April 5, May 8 and 13, and June 6, 2024, which included a written statement of corrective actions, letter from Acme Smoked Fish Corp, product information and data sheet for laminated film used for food packaging, HACCP Plan for frozen hot smoked trout fillets in reduced-oxygen packaging, and other supporting documents. However, our evaluation of your responses revealed that you continue to have serious concerns with your HACCP program, as further described in this letter.\u003C\u002Fp>\u003Cp>In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your frozen, reduced oxygen packed hot smoked trout fillets are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the June 2022 Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>Your significant deviations are as follows:\u003C\u002Fp>\u003Cp>1. You must conduct or have conducted for you a hazard analysis for each kind of fish and fishery product that you produce to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the food safety hazards that are reasonably likely to occur, to comply with 21 CFR 123.6(a) and (c)(1). A food safety hazard is defined in 21 CFR 123.3(f) as “any biological, chemical, or physical property that may cause a food to be unsafe for human consumption.” However, your firm’s HACCP plan for “Hot Smoked trout Fillets (farm-raised), Reduced-Oxygen Packed, Frozen”, dated June 6, 2024, does not identify the following food safety hazards:\u003C\u002Fp>\u003Cp>a. You do not identify agriculture drugs as a food safety hazard. Your hazard analysis states that you will control environmental chemicals by “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” through “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, the seafood HACCP regulation requires that food safety hazards that are reasonably likely to occur in the absence of controls be addressed in a HACCP plan.\u003C\u002Fp>\u003Cp>b. You do not identify \u003Cem>Staphylococcus aureus\u003C\u002Fem> growth and toxin formation as a food safety hazard. The hazard is introduced at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step where the fish are first salted and competing bacteria are significantly reduced. The hazard continues to be reasonably likely during the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” steps in the absence of time and temperature controls.\u003C\u002Fp>\u003Cp>2. You must conduct a hazard analysis to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the critical control points to comply with 21 CFR 123.6(a) and (c)(2). A “critical control point” is defined in 21 CFR 123.3(b) as a “point, step, or procedure in a food process at which control can be applied and a food safety hazard can as a result be prevented, eliminated, or reduced to acceptable levels.” However, your firm’s HACCP plan for “Hot Smoked trout Fillets (farm-raised), Reduced-Oxygen Packed, Frozen”, dated June 6, 2024, does not list a critical control point to control pathogenic bacteria growth and toxin formation during refrigerated storage. Pathogenic bacteria can be introduced during processing, even after cooking.\u003C\u002Fp>\u003Cp>3. You must have a HACCP plan that, at a minimum, lists the critical limits that must be met to comply with 21 CFR 123.6 (c)(3). A critical limit is defined in 21 CFR 123.3 (c) as “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard.” However, your firm’s HACCP plan for “Hot Smoked trout Fillets (farm-raised), Reduced-Oxygen Packed, Frozen”, dated June 6, 2024, list the critical limits of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “Log 5 reduction” at the “CCP 5: \u003Cstrong>(b)(4)\u003C\u002Fstrong>” critical control point that are not adequate to control pathogenic bacteria growth and survival. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> process should achieve at least a 6-log reduction of \u003Cem>Listeria\u003C\u002Fem> \u003Cem>monocytogenes\u003C\u002Fem>. For \u003Cstrong>(b)(4)\u003C\u002Fstrong> operations, FDA recommends that the internal temperature of the fish be maintained at or above 145°F (62.8°C) throughout the fish for at least 30 minutes.\u003C\u002Fp>\u003Cp>4. You must have a HACCP plan that, at a minimum, lists monitoring procedures and their frequencies for each critical control point to comply with 21 CFR 123.6(c)(4). However, your firm’s HACCP plan for “Hot Smoked trout Fillets (farm-raised), Reduced-Oxygen Packed, Frozen”, dated June 6, 2024, lists a critical limit of “Minimum brining time and brining strength as stated in the brining SOP and programmes in EQ section 4.8.4” to control \u003Cem>Clostridium botulinum\u003C\u002Fem> (\u003Cem>C. botulinum\u003C\u002Fem>) growth and toxin formation, however, you do not list monitoring procedures for the minimum brining time.\u003C\u002Fp>\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that all of your processing plants operate in compliance with the Act and all applicable regulations, including the seafood HACCP regulation, acidified foods regulations (21 CFR Parts 108 and 114), and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). FDA also conducted an inspection at your acidified food facility located at Lundahl Nielsens Vej 2, Vejle, Syddanmark, Denmark 7100 on March 4 through March 5, 2024. During the inspection, we found that your firm had serious violations of the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and the Acidified Foods regulation (21 CFR Part 114). Therefore, you were issued a Warning Letter on August 13, 2024 (Reference #684572). You have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. You may view this alert at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>Additionally, we offer the following comment:\u003C\u002Fp>\u003Cul>\u003Cli>Your critical limit at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> critical control points lists that that the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” are defined in the “\u003Cstrong>(b)(4)\u003C\u002Fstrong> SOP and programmes in \u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, you have not provided these documents that are considered part of the HACCP plan. You should provide the documents, or the critical limits should be included in the HACCP plan.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan(s), five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply to the U.S. Food and Drug Administration, Attention: Sheena Phillips, Compliance Officer, Office of Compliance, Division of Enforcement, Food Adulteration and Assessment Branch (HFS-607), 5001 Campus Drive, College Park, Maryland 20740 U.S.A. If you have any questions regarding this letter, you may contact Ms. Phillips via email at Sheena.Phillips@fda.hhs.gov. Please reference CMS # 687113 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Ann M. Oxenham, J.D.\u003Cbr>Director\u003Cbr>Office of Compliance\u003Cbr>Center for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Esben Anderson\n\nRecipient Title\n\nChief Executive Officer\n\nAgustson A\u002FS\n\nEnglandsvej 11 Vejle\n\n7100 Syddanmark\n\nDenmark\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nAugust 13, 2024\nWARNING LETTER\nReference # 687113\nDear Mr. Anderson:\nThe United States Food and Drug Administration (FDA) conducted an inspection of your seafood processing facility, Agustson A\u002FS, located at Englandsvej 11, Vejle, Syddanmark, Denmark 7100 on March 7 – 8, 2024. During the inspection, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123 (21 CFR Part 123). At the conclusion of the inspection, the FDA investigator issued an FDA 483, Inspectional Observations, listing the deviations found at your firm. We acknowledge receipt of your responses, received via email on March 31, April 5, May 8 and 13, and June 6, 2024, which included a written statement of corrective actions, letter from Acme Smoked Fish Corp, product information and data sheet for laminated film used for food packaging, HACCP Plan for frozen hot smoked trout fillets in reduced-oxygen packaging, and other supporting documents. However, our evaluation of your responses revealed that you continue to have serious concerns with your HACCP program, as further described in this letter.\nIn accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of Section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your frozen, reduced oxygen packed hot smoked trout fillets are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the June 2022 Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\nYour significant deviations are as follows:\n1. You must conduct or have conducted for you a hazard analysis for each kind of fish and fishery product that you produce to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the food safety hazards that are reasonably likely to occur, to comply with 21 CFR 123.6(a) and (c)(1). A food safety hazard is defined in 21 CFR 123.3(f) as “any biological, chemical, or physical property that may cause a food to be unsafe for human consumption.” However, your firm’s HACCP plan for “Hot Smoked trout Fillets (farm-raised), Reduced-Oxygen Packed, Frozen”, dated June 6, 2024, does not identify the following food safety hazards:\na. You do not identify agriculture drugs as a food safety hazard. Your hazard analysis states that you will control environmental chemicals by “(b)(4)” through “(b)(4).” However, the seafood HACCP regulation requires that food safety hazards that are reasonably likely to occur in the absence of controls be addressed in a HACCP plan.\nb. You do not identify Staphylococcus aureus growth and toxin formation as a food safety hazard. The hazard is introduced at the “(b)(4)” step where the fish are first salted and competing bacteria are significantly reduced. The hazard continues to be reasonably likely during the “(b)(4)”, “(b)(4)”, and “(b)(4)” steps in the absence of time and temperature controls.\n2. You must conduct a hazard analysis to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the critical control points to comply with 21 CFR 123.6(a) and (c)(2). A “critical control point” is defined in 21 CFR 123.3(b) as a “point, step, or procedure in a food process at which control can be applied and a food safety hazard can as a result be prevented, eliminated, or reduced to acceptable levels.” However, your firm’s HACCP plan for “Hot Smoked trout Fillets (farm-raised), Reduced-Oxygen Packed, Frozen”, dated June 6, 2024, does not list a critical control point to control pathogenic bacteria growth and toxin formation during refrigerated storage. Pathogenic bacteria can be introduced during processing, even after cooking.\n3. You must have a HACCP plan that, at a minimum, lists the critical limits that must be met to comply with 21 CFR 123.6 (c)(3). A critical limit is defined in 21 CFR 123.3 (c) as “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard.” However, your firm’s HACCP plan for “Hot Smoked trout Fillets (farm-raised), Reduced-Oxygen Packed, Frozen”, dated June 6, 2024, list the critical limits of “(b)(4)” and “Log 5 reduction” at the “CCP 5: (b)(4)” critical control point that are not adequate to control pathogenic bacteria growth and survival. Your (b)(4) process should achieve at least a 6-log reduction of Listeria monocytogenes. For (b)(4) operations, FDA recommends that the internal temperature of the fish be maintained at or above 145°F (62.8°C) throughout the fish for at least 30 minutes.\n4. You must have a HACCP plan that, at a minimum, lists monitoring procedures and their frequencies for each critical control point to comply with 21 CFR 123.6(c)(4). However, your firm’s HACCP plan for “Hot Smoked trout Fillets (farm-raised), Reduced-Oxygen Packed, Frozen”, dated June 6, 2024, lists a critical limit of “Minimum brining time and brining strength as stated in the brining SOP and programmes in EQ section 4.8.4” to control Clostridium botulinum (C. botulinum) growth and toxin formation, however, you do not list monitoring procedures for the minimum brining time.\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that all of your processing plants operate in compliance with the Act and all applicable regulations, including the seafood HACCP regulation, acidified foods regulations (21 CFR Parts 108 and 114), and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). FDA also conducted an inspection at your acidified food facility located at Lundahl Nielsens Vej 2, Vejle, Syddanmark, Denmark 7100 on March 4 through March 5, 2024. During the inspection, we found that your firm had serious violations of the Emergency Permit Control regulation, Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and the Acidified Foods regulation (21 CFR Part 114). Therefore, you were issued a Warning Letter on August 13, 2024 (Reference #684572). You have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. You may view this alert at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nAdditionally, we offer the following comment:\nYour critical limit at the (b)(4) critical control points lists that that the “(b)(4)” are defined in the “(b)(4) SOP and programmes in (b)(4)” and “(b)(4).” However, you have not provided these documents that are considered part of the HACCP plan. You should provide the documents, or the critical limits should be included in the HACCP plan.\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan(s), five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\nPlease send your reply to the U.S. Food and Drug Administration, Attention: Sheena Phillips, Compliance Officer, Office of Compliance, Division of Enforcement, Food Adulteration and Assessment Branch (HFS-607), 5001 Campus Drive, College Park, Maryland 20740 U.S.A. If you have any questions regarding this letter, you may contact Ms. Phillips via email at Sheena.Phillips@fda.hhs.gov. Please reference CMS # 687113 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nAnn M. Oxenham, J.D.\nDirector\nOffice of Compliance\nCenter for Food Safety and Applied Nutrition","Agustson A\u002FS","agustson-687113-08132024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagustson-687113-08132024","2026-10-26T08:07:51.380419+00:00","2024-08-20","687113","Mr. Esben Anderson","2026-08-19T23:52:47.629+00:00","2024-08-13",{"id":92,"raw":93,"subject":96,"body_html":97,"body_text":98,"firm_name":82,"letter_id":99,"created_at":18,"fei_number":19,"letter_url":100,"updated_at":101,"action_type":22,"case_status":23,"posted_date":102,"marcs_cms_no":103,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":104,"body_fetched_at":105,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":90,"medical_device_id":19,"response_letter_date":19},1155,[94,77,95,37,96,13,13,13],"\u003Ctime datetime=\"2024-11-26T14:20:00Z\">11\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagustson-684572-08132024\">Agustson A\u002FS\u003C\u002Fa>","Acidified Foods\u002FEmergency Permit Control\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Esben Anderson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Agustson A\u002FS\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Lundahl Nielsens Vej 2\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>7100\u003C\u002Fspan> \u003Cspan>Syddanmark\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Denmark\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 13, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nReference No. 684572\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Anderson:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your acidified food (AF) facility located at Lundahl Nielsens Vej 2, Vejle, Syddanmark, Denmark 7100 on March 4 through March 5, 2024. During that inspection we found that your firm had serious deviations from the Emergency Permit Control regulation (Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and the Acidified Foods regulation (21 CFR Part 114). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations that lists the serious deviations found at your firm. We received your written response dated March 25, 2024. Our evaluation found your response was not adequate, as further described in this letter.\u003C\u002Fp>\n\n\u003Cp>As a manufacturer of acidified foods intended for export to the United States, you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the Federal regulations relating to the processing of acidified food products packaged in hermetically sealed containers. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.25, including registration, and filing of process information, and the mandatory requirements in 21 CFR Parts 114. Regulations specific to the processing of acidified foods are described in 21 CFR 108 and 21 CFR 114.\u003C\u002Fp>\n\n\u003Cp>As outlined in these regulations, a commercial processor that does not adhere to all of the mandatory requirements of 21 CFR 108.25 and 21 CFR 114 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. 344). As stated in 21 CFR 108.25(j) for imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States. Violation of the mandatory requirements set forth in 21 CFR 108.25 and 21 CFR 114 renders your acidified food products adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4). You can find the Act and LACF regulations through links in FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\n\n\u003Cp>1. As a commercial processor engaged in the processing of acidified foods you must process each food in conformity with at least the filed scheduled process, as required by 21 CFR 108.25(c)(3)(i).\u003C\u002Fp>\n\n\u003Cp>Specifically, your filed scheduled processes for acidified Seaweed Cavi-art Black packed in \u003Cstrong>(b)(4)\u003C\u002Fstrong>g \u003Cstrong>(b)(4)\u003C\u002Fstrong> glass jars I and Seaweed Cavi-art Black packed in \u003Cstrong>(b)(4)\u003C\u002Fstrong>g \u003Cstrong>(b)(4)\u003C\u002Fstrong> glass jars on July 9, 2023, and July 10, 2023, respectively, identify the following critical factors: pH and cold processing parameters (initial temperature, process temperature, and process time). Since July 2023, you have exported Seaweed Cavi-art Black to the United States approximately three (3) times and at least one lot produced did not adhere to the filed scheduled processes. You told the FDA investigator that the Seaweed Cavi-art Black (Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>) exported to the United States was manufactured on August 29, 2022, prior to the filing the scheduled processes for Seaweed Cavi-art Black in July 2023. According to the batch record for Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you did not monitor pH nor the cold hold process parameters. Production records do not indicate pH values and the parameters of the cold fill process. Furthermore, as a commercial processor engaged in the processing of acidified foods, you must file scheduled processes before packing any new product including, as necessary, conditions for heat processing and control of pH, salt, sugar, and preservative levels and source and date of the establishment of the process, for each acidified food in each container size, as required by 21 CFR 108.25(c)(2).\u003C\u002Fp>\n\n\u003Cp>Your response stated that you do not manufacture the seaweed caviar black bulk product used for the packing of the Seaweed Cavi-art black 50g\u002F100g, as you purchase it “ready for repacking” from your supplier. You stated you receive the bulk product from your supplier with a Certificate of Analysis (COA) that certifies the pH level of the batch (less than 4.6) and TPC level as indicator for microbiological quality. You concluded that your supplier’s COA documenting pH of the received batch was reliable basis for establishing the safety of the incoming bulk material and thus was the control point for accepting bulk ingredient for (re)packing. However, you stated going forward you would verify the values of the pH on the COA internally prior to filling. You also reported you had previously tested microbiological quality of the bulk product regularly upon reception and based on consistent conformity in the result that you significantly reduced sampling frequency. You also stated the stabilization of the bulk product was the responsibility of your supplier. You concluded that any risk of post-contamination is controlled by observing your established SOP (for repacking) and SSOP, provided bulk product received is within specification. Although the health risk is minimal at the product pH, the product is exposed to air during the repacking at your facility. If the opened product were to become contaminated with airborne mold the product pH could shift and provide a suitable environment for \u003Cem>Clostridium botulinum\u003C\u002Fem> to grow underneath the pellicle. Therefore, an additional \u003Cstrong>(b)(4)\u003C\u002Fstrong> step is required. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> step could be in the form of an additional cold fill and hold or the application of a mild heat treatment to kill vegetative pathogens. In addition, as a processor (re-packer) of acidified foods, you are also required to assure that the finished product equilibrium pH of less than 4.6 is maintained in all finished foods, as required by 21 CFR 114.80(a)(1).\u003C\u002Fp>\n\n\u003Cp>Before processing product for export to the United States in the future, you must file your scheduled processes for Seaweed Cavi-art black 50g\u002F100g established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of acidified foods in accordance with 21 CFR 108.25(c)(2).\u003C\u002Fp>\n\n\u003Cp>2. You did not mark each container or product with an identifying code permanently visible to the naked eye to specify the establishment where the product was packed and the product contained within, as required by 21 CFR 114.80(b). Specifically, your identifying lot code on the metal lid of your Seaweed Cavi-art black 50g\u002F100g product only identifies the best by date and the date the product was repacked.\u003C\u002Fp>\n\n\u003Cp>Your response stated the lot code will be corrected and implemented at next production. We will verify the adequacy of your corrective action during a future inspection.\u003C\u002Fp>\n\n\u003Cp>3. You must have plant personnel involved in thermal processing systems or other critical factors of the operation under the operating supervision of a person who has attended a school approved by FDA to comply with 21 CFR 114.10. Specifically, our inspection revealed no one at your firm has received training in critical factors in the production of LACF products nor aseptic processing.\u003C\u002Fp>\n\n\u003Cp>Your response states your Quality Assurance Manager completed “the Better Process Control School, a course of instruction approved by the Commissioner of the U.S. Food and Drug Administration to meet the requirements of 21 CFR 108.25(f), 21 CFR 108.35(g), 21 CFR 113 and 21 CFR 114” on March 23, 2024, and you provided the certificate of completion.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. Responding in English will help to assist us in our review of your documentation.\u003C\u002Fp>\n\n\u003Cp>If you do not respond to this letter or if we find your response inadequate, we may take further action. For instance, we may take action to refuse admission of your imported acidified food products under section 801(a) of the Act (21 U.S.C. 381(a)) including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, examples of Import Alerts that convey information specific to foreign firms that are not in compliance with the acidified food regulations (21 CFR 108 and 114) are Import Alert 99-37, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods without Filed Scheduled Processes and Import Alert #99-38, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods due to Inadequate Process Control. These alerts can be found on FDA’s web site at: www.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\n\n\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that all processing plants you operate are in compliance with the Act and all applicable FDA regulations, including the seafood HACCP regulation (21 CFR Part 123), Acidified Foods regulation (21 CFR Part 114), and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). FDA also conducted an inspection at your seafood processing facility located at Englandsvej 11, Vejle, Syddanmark, 7100 Denmark on March 7 and 8, 2024. During the inspection, we found that you had serious violations of the seafood HACCP regulation. Therefore, you were also issued a Warning Letter on August 13, 2024 for violations of the seafood HACCP regulation at your seafood processing facility located at Englandsvej 11, Vejle, Syddanmark, 7100 Denmark. You have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations. You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Victoria Wagoner, Compliance Officer, Office of Compliance, Division of Enforcement, Food Assessment and Adulteration Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Victoria Wagoner via email at Victoria.Wagoner@fda.hhs.gov. Please reference 684572 on any submissions and within the subject line of any emails to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nEsben Anderson\n\nRecipient Title\n\nChief Executive Officer\n\nAgustson A\u002FS\n\nLundahl Nielsens Vej 2\n\n7100 Syddanmark\n\nDenmark\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nAugust 13, 2024\n\nWARNING LETTER\n\nReference No. 684572\n\nDear Mr. Anderson:\n\nThe United States Food and Drug Administration (FDA) inspected your acidified food (AF) facility located at Lundahl Nielsens Vej 2, Vejle, Syddanmark, Denmark 7100 on March 4 through March 5, 2024. During that inspection we found that your firm had serious deviations from the Emergency Permit Control regulation (Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and the Acidified Foods regulation (21 CFR Part 114). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations that lists the serious deviations found at your firm. We received your written response dated March 25, 2024. Our evaluation found your response was not adequate, as further described in this letter.\n\nAs a manufacturer of acidified foods intended for export to the United States, you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the Federal regulations relating to the processing of acidified food products packaged in hermetically sealed containers. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for thermally processed low-acid foods packaged in hermetically sealed containers whenever a processor has failed to fulfill the requirements of 21 CFR 108.25, including registration, and filing of process information, and the mandatory requirements in 21 CFR Parts 114. Regulations specific to the processing of acidified foods are described in 21 CFR 108 and 21 CFR 114.\n\nAs outlined in these regulations, a commercial processor that does not adhere to all of the mandatory requirements of 21 CFR 108.25 and 21 CFR 114 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. 344). As stated in 21 CFR 108.25(j) for imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States. Violation of the mandatory requirements set forth in 21 CFR 108.25 and 21 CFR 114 renders your acidified food products adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4). You can find the Act and LACF regulations through links in FDA’s home page at www.fda.gov.\n\nYour significant violations are as follows:\n\n1. As a commercial processor engaged in the processing of acidified foods you must process each food in conformity with at least the filed scheduled process, as required by 21 CFR 108.25(c)(3)(i).\n\nSpecifically, your filed scheduled processes for acidified Seaweed Cavi-art Black packed in (b)(4)g (b)(4) glass jars I and Seaweed Cavi-art Black packed in (b)(4)g (b)(4) glass jars on July 9, 2023, and July 10, 2023, respectively, identify the following critical factors: pH and cold processing parameters (initial temperature, process temperature, and process time). Since July 2023, you have exported Seaweed Cavi-art Black to the United States approximately three (3) times and at least one lot produced did not adhere to the filed scheduled processes. You told the FDA investigator that the Seaweed Cavi-art Black (Lot (b)(4)) exported to the United States was manufactured on August 29, 2022, prior to the filing the scheduled processes for Seaweed Cavi-art Black in July 2023. According to the batch record for Lot (b)(4), you did not monitor pH nor the cold hold process parameters. Production records do not indicate pH values and the parameters of the cold fill process. Furthermore, as a commercial processor engaged in the processing of acidified foods, you must file scheduled processes before packing any new product including, as necessary, conditions for heat processing and control of pH, salt, sugar, and preservative levels and source and date of the establishment of the process, for each acidified food in each container size, as required by 21 CFR 108.25(c)(2).\n\nYour response stated that you do not manufacture the seaweed caviar black bulk product used for the packing of the Seaweed Cavi-art black 50g\u002F100g, as you purchase it “ready for repacking” from your supplier. You stated you receive the bulk product from your supplier with a Certificate of Analysis (COA) that certifies the pH level of the batch (less than 4.6) and TPC level as indicator for microbiological quality. You concluded that your supplier’s COA documenting pH of the received batch was reliable basis for establishing the safety of the incoming bulk material and thus was the control point for accepting bulk ingredient for (re)packing. However, you stated going forward you would verify the values of the pH on the COA internally prior to filling. You also reported you had previously tested microbiological quality of the bulk product regularly upon reception and based on consistent conformity in the result that you significantly reduced sampling frequency. You also stated the stabilization of the bulk product was the responsibility of your supplier. You concluded that any risk of post-contamination is controlled by observing your established SOP (for repacking) and SSOP, provided bulk product received is within specification. Although the health risk is minimal at the product pH, the product is exposed to air during the repacking at your facility. If the opened product were to become contaminated with airborne mold the product pH could shift and provide a suitable environment for Clostridium botulinum to grow underneath the pellicle. Therefore, an additional (b)(4) step is required. The (b)(4) step could be in the form of an additional cold fill and hold or the application of a mild heat treatment to kill vegetative pathogens. In addition, as a processor (re-packer) of acidified foods, you are also required to assure that the finished product equilibrium pH of less than 4.6 is maintained in all finished foods, as required by 21 CFR 114.80(a)(1).\n\nBefore processing product for export to the United States in the future, you must file your scheduled processes for Seaweed Cavi-art black 50g\u002F100g established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of acidified foods in accordance with 21 CFR 108.25(c)(2).\n\n2. You did not mark each container or product with an identifying code permanently visible to the naked eye to specify the establishment where the product was packed and the product contained within, as required by 21 CFR 114.80(b). Specifically, your identifying lot code on the metal lid of your Seaweed Cavi-art black 50g\u002F100g product only identifies the best by date and the date the product was repacked.\n\nYour response stated the lot code will be corrected and implemented at next production. We will verify the adequacy of your corrective action during a future inspection.\n\n3. You must have plant personnel involved in thermal processing systems or other critical factors of the operation under the operating supervision of a person who has attended a school approved by FDA to comply with 21 CFR 114.10. Specifically, our inspection revealed no one at your firm has received training in critical factors in the production of LACF products nor aseptic processing.\n\nYour response states your Quality Assurance Manager completed “the Better Process Control School, a course of instruction approved by the Commissioner of the U.S. Food and Drug Administration to meet the requirements of 21 CFR 108.25(f), 21 CFR 108.35(g), 21 CFR 113 and 21 CFR 114” on March 23, 2024, and you provided the certificate of completion.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. Responding in English will help to assist us in our review of your documentation.\n\nIf you do not respond to this letter or if we find your response inadequate, we may take further action. For instance, we may take action to refuse admission of your imported acidified food products under section 801(a) of the Act (21 U.S.C. 381(a)) including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, examples of Import Alerts that convey information specific to foreign firms that are not in compliance with the acidified food regulations (21 CFR 108 and 114) are Import Alert 99-37, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods without Filed Scheduled Processes and Import Alert #99-38, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods due to Inadequate Process Control. These alerts can be found on FDA’s web site at: www.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\n\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that all processing plants you operate are in compliance with the Act and all applicable FDA regulations, including the seafood HACCP regulation (21 CFR Part 123), Acidified Foods regulation (21 CFR Part 114), and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). FDA also conducted an inspection at your seafood processing facility located at Englandsvej 11, Vejle, Syddanmark, 7100 Denmark on March 7 and 8, 2024. During the inspection, we found that you had serious violations of the seafood HACCP regulation. Therefore, you were also issued a Warning Letter on August 13, 2024 for violations of the seafood HACCP regulation at your seafood processing facility located at Englandsvej 11, Vejle, Syddanmark, 7100 Denmark. You have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations. You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\n\nPlease send your reply to the Food and Drug Administration, Attention: Victoria Wagoner, Compliance Officer, Office of Compliance, Division of Enforcement, Food Assessment and Adulteration Branch (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Victoria Wagoner via email at Victoria.Wagoner@fda.hhs.gov. Please reference 684572 on any submissions and within the subject line of any emails to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition","agustson-684572-08132024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagustson-684572-08132024","2026-10-26T08:07:51.329445+00:00","2024-11-26","684572","Esben Anderson","2026-08-19T17:57:59.029+00:00",{"id":107,"raw":108,"subject":58,"body_html":113,"body_text":114,"firm_name":115,"letter_id":116,"created_at":18,"fei_number":19,"letter_url":117,"updated_at":118,"action_type":22,"case_status":119,"posted_date":120,"marcs_cms_no":121,"product_type":68,"closeout_date":122,"issuing_office":57,"recipient_name":123,"body_fetched_at":124,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":125,"medical_device_id":19,"response_letter_date":19},1116,[109,110,111,57,58,13,112,13],"\u003Ctime datetime=\"2024-12-24T14:20:00Z\">12\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-28T04:00:00Z\">10\u002F28\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frontis-hellas-sa-695160-10282024\">Rontis Hellas S.A. \u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frontis-hellas-sa-695160-02262026\">\u003Ctime datetime=\"2026-03-12T04:00:00Z\">03\u002F12\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Efi Soultou\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Rontis Hellas S.A. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Industrial Area of Larissa\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Larissa\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>415 00\u003C\u002Fspan> \u003Cspan>Thessaloniki\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Greece\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS# 695160\u003C\u002Fp>\u003Cp>October 28, 2024\u003C\u002Fp>\u003Cp>Dear Ms. Efi Soultou,\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Larissa, Thessaloniki, 415 00 Greece on July 22, 2024 through July 25, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Cronus HP PTA OTW Balloon Catheter. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Irene Tsaliki, QA Manager &amp; RA Coordinator dated August 2, 2024, September 10, 2024, and September 30, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations.\u003C\u002Fp>\u003Cp>1. A process where results cannot be fully verified by subsequent inspection and test, the process has not been validated with a high degree of assurance and approved according to established procedures as required by 21 CFR 820.75(a).\u003C\u002Fp>\u003Cp>For example, in regard to sterilization validation conducted to meet ISO 11135-1:2007, Validation Infrastructure Utilities Ethylene Oxide (EtO) Sterilization Process, Protocol, Validation Code C1\u002F2013, 10\u002F1\u002F2013, Validation Infrastructure Utilities EtO Sterilization Process Annual Qualification of EtO Sterilization Process Protocol, C1\u002F2013-R\u002F2023, 15\u002F3\u002F2023, Validation of Infrastructure Utilities Annual Qualification of EtO Sterilization Process Report, and EtO Sterilization Report on 14\u002F3\u002F2013:\u003C\u002Fp>\u003Cp>&nbsp; a. The 2013 validation was performed on \u003Cstrong>(b)(4)\u003C\u002Fstrong> without EtO gas.\u003Cbr>&nbsp; b. The 2023 validation was performed with \u003Cstrong>(b)(4)\u003C\u002Fstrong> without EtO gas.\u003Cbr>&nbsp; c. The 2013 report of CC BE Iliac Stent sterilized with EtO on 14\u002F3\u002F2013 with \u003Cstrong>(b)(4)\u003C\u002Fstrong> noted a deviation yet a discussion and evaluation of the impact of the deviation and a justification for the use of the CC BE iliac stent for supporting the sterilization validation for the Cronus HP PTA Balloon Catheter was not provided.\u003Cbr>&nbsp; d. All of the above identified reports do not provide a justification for the product selected as required by ISO 11135-1:2007 and the more recent ISO 11135:2014, which is the current version of the FDA recognized standard. Further, the validation was not completed with EtO gas or with full sterilization cycles. Your 510(k)s (K151141 and K190037) and validation reports state that “the validation study has been performed in full compliance with the relevant validation protocol and in conformity with ISO 11135-1:2007”. However, Per ISO 11135:2007 and the more recent ISO 11135:2014, Section 9.4.3.2, the process performance qualification (PPQ) shall confirm the process such that gaseous EtO has been admitted to the sterilizer chamber, and the pressure rise and quantity of EtO used or the concentration of EtO in the sterilizer chamber have been established. Additionally, per ISO 11135-1:2007 and ISO 11135:2014, temperature and humidity in the chamber should be measured during the PPQ, as it is possible that temperature and humidity readings may be impacted by the presence and absence of EtO gas. Lastly, ISO 11135:2014 states, “Demonstration of the ability to maintain process parameters within defined limits during the proposed full cycle is necessary.”\u003Cbr>&nbsp; e. The product adoption of the Cronus HP PTA catheter into the existing EtO sterilization cycle was not documented in the 2023 revalidation report. If the product has not been adopted into the completed 2023 revalidation studies per AAMI TIR28:2016, “Product adoption and process equivalence for ethylene oxide sterilization”, then it is unclear if the completed adoption in 2023 demonstrates that the Cronus HP PTA catheter is adequately sterilized.\u003C\u002Fp>\u003Cp>The adequacy of your responses dated August 2, 2024, September 10, 2024, and September 30, 2024 cannot be determined at this time as the establishment and completion of the process performance qualification validation report has not been completed. Please perform all corrective actions and provide the associated documentation including, but not limited to, full test reports of a full sterilization cycle with EtO gas.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s Cronus HP PTA OTW Balloon Catheter devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\u003C\u002Fp>\u003Cp>For example, during the inspection, your firm presented the document titled “RC_SOP-10-003: Medical Device Reporting”, Edition 7, dated 3\u002F7\u002F2023 as its written MDR procedure. However, this procedure does not meet the requirements of 12 CFR 803.17. For example:\u003C\u002Fp>\u003Cp>1. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1).\u003Cbr>&nbsp; a. The procedure omits definitions of the terms ‘become aware’, ‘caused or contributed’, ‘malfunction’, and ‘serious injury’, from 21 CFR Part 803.3. The exclusion of the definitions for these term from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003Cbr>&nbsp; b. The procedure, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR Part 803 in a manner that will result in incomplete, inadequate, or even non-reporting of adverse events that meet the reportability requirements under 21 CFR Part 803.\u003C\u002Fp>\u003Cp>2. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example, although the procedure includes instructions for how your firm will evaluate information about an event to make a reportability decision, it fails to include instructions for making determinations in a timely manner.\u003C\u002Fp>\u003Cp>3. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include:\u003Cbr>&nbsp; a. Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>&nbsp; b. The circumstances under which your firm must submit supplemental or follow-up report and the requirements for such reports.\u003Cbr>&nbsp; c. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a); and\u003Cbr>&nbsp; d. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\u003C\u002Fp>\u003Cp>4. The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses dated August 2, 2024, September 10, 202, and September 30, 2024, and conclude that they are not adequate. In your September 30, 2024 response, you provided the revised procedure “RC_SOP-10-003: Medical Device Reporting”, Edition No. 8, dated 30\u002F09\u002F2024. Your revised procedure continues to not meet the requirements of 21 CFR 803.17. For example:\u003C\u002Fp>\u003Cp>1. The revision does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example,\u003Cbr>&nbsp; a. The procedure omits definitions of the terms ‘caused or contributed’ and ‘malfunction’ from 21 CFR Part 803.3. The exclusion of the definitions for these term from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003Cbr>&nbsp; b. The term ‘serious injury’ is incorrectly referred to as ‘serious adverse event’, which might not allow your firm to correctly identify complaints as reportable events.\u003Cbr>&nbsp; c. The revision, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR Part 803 in a manner that will result in incomplete, inadequate, or even non‐reporting of adverse events that meet the reportability requirements under 21 CFR Part 803. For example, terms including but not necessarily limited to, ‘serious incident’ and ‘serious adverse event’, which are intended for OUS vigilance reporting, are included in the procedure within the context of the US MDR reporting requirements.\u003C\u002Fp>\u003Cp>2. The revision does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include:\u003Cbr>&nbsp; a. Instructions for how to obtain and complete the FDA 3500A form.\u003Cbr>&nbsp; b. A process for submitting initial and supplement or follow‐up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a).\u003Cbr>&nbsp; c. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow‐up within your firm.\u003C\u002Fp>\u003Cp>Additionally, the FDA verified that, as of October 17, 2024, your firm still does not have an active ESG production account for the electronic submission of MDR reports. Information about the ESG and creating an account can be found at: How to Enroll in eMDR Program | FDA (https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femdr-electronic-medical-device-reporting\u002Fhow-enrollemdr-program).\u003C\u002Fp>\u003Cp>Please note that your firm’s response dated October 15, 2024 to the Form FDA 483 (FDA 483) was not reviewed because it was received too late in the review cycle after issuance of the FDA 483. Therefore, the October 15, 2024 response will be evaluated along with any other written material provided in response to the violations cited in this Warning Letter.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to \u003Ca href=\"mailto:CDRHWarningLetterResponses@fda.hhs.gov\">CDRHWarningLetterResponses@fda.hhs.gov\u003C\u002Fa> or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #695160 when replying. If you have any questions about the contents of this letter, please contact: Ariel Ash-Shakoor at ariel.ash-shakoor@fda.hhs.gov or 240-402-4912.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Bram Zuckerman, M.D.\u003Cbr>Director\u003Cbr>OHT 2: Office of Cardiovascular Devices\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Jessica Osward-McLeod\u003Cbr>Nipro Medical Corporation,\u003Cbr>3150 NW 107th Ave.\u003Cbr>Miami, Florida, 33172, USA\u003Cbr>Tel: 786-567-6343\u003Cbr>jessicao@nipromed.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMs. Efi Soultou\n\nRecipient Title\n\nCEO\n\nRontis Hellas S.A.\n\nIndustrial Area of Larissa\n\nLarissa\n\n415 00 Thessaloniki\n\nGreece\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS# 695160\nOctober 28, 2024\nDear Ms. Efi Soultou,\nDuring an inspection of your firm located in Larissa, Thessaloniki, 415 00 Greece on July 22, 2024 through July 25, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Cronus HP PTA OTW Balloon Catheter. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Irene Tsaliki, QA Manager & RA Coordinator dated August 2, 2024, September 10, 2024, and September 30, 2024 concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations.\n1. A process where results cannot be fully verified by subsequent inspection and test, the process has not been validated with a high degree of assurance and approved according to established procedures as required by 21 CFR 820.75(a).\nFor example, in regard to sterilization validation conducted to meet ISO 11135-1:2007, Validation Infrastructure Utilities Ethylene Oxide (EtO) Sterilization Process, Protocol, Validation Code C1\u002F2013, 10\u002F1\u002F2013, Validation Infrastructure Utilities EtO Sterilization Process Annual Qualification of EtO Sterilization Process Protocol, C1\u002F2013-R\u002F2023, 15\u002F3\u002F2023, Validation of Infrastructure Utilities Annual Qualification of EtO Sterilization Process Report, and EtO Sterilization Report on 14\u002F3\u002F2013:\na. The 2013 validation was performed on (b)(4) without EtO gas.\nb. The 2023 validation was performed with (b)(4) without EtO gas.\nc. The 2013 report of CC BE Iliac Stent sterilized with EtO on 14\u002F3\u002F2013 with (b)(4) noted a deviation yet a discussion and evaluation of the impact of the deviation and a justification for the use of the CC BE iliac stent for supporting the sterilization validation for the Cronus HP PTA Balloon Catheter was not provided.\nd. All of the above identified reports do not provide a justification for the product selected as required by ISO 11135-1:2007 and the more recent ISO 11135:2014, which is the current version of the FDA recognized standard. Further, the validation was not completed with EtO gas or with full sterilization cycles. Your 510(k)s (K151141 and K190037) and validation reports state that “the validation study has been performed in full compliance with the relevant validation protocol and in conformity with ISO 11135-1:2007”. However, Per ISO 11135:2007 and the more recent ISO 11135:2014, Section 9.4.3.2, the process performance qualification (PPQ) shall confirm the process such that gaseous EtO has been admitted to the sterilizer chamber, and the pressure rise and quantity of EtO used or the concentration of EtO in the sterilizer chamber have been established. Additionally, per ISO 11135-1:2007 and ISO 11135:2014, temperature and humidity in the chamber should be measured during the PPQ, as it is possible that temperature and humidity readings may be impacted by the presence and absence of EtO gas. Lastly, ISO 11135:2014 states, “Demonstration of the ability to maintain process parameters within defined limits during the proposed full cycle is necessary.”\ne. The product adoption of the Cronus HP PTA catheter into the existing EtO sterilization cycle was not documented in the 2023 revalidation report. If the product has not been adopted into the completed 2023 revalidation studies per AAMI TIR28:2016, “Product adoption and process equivalence for ethylene oxide sterilization”, then it is unclear if the completed adoption in 2023 demonstrates that the Cronus HP PTA catheter is adequately sterilized.\nThe adequacy of your responses dated August 2, 2024, September 10, 2024, and September 30, 2024 cannot be determined at this time as the establishment and completion of the process performance qualification validation report has not been completed. Please perform all corrective actions and provide the associated documentation including, but not limited to, full test reports of a full sterilization cycle with EtO gas.\nOur inspection also revealed that your firm’s Cronus HP PTA OTW Balloon Catheter devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\nFor example, during the inspection, your firm presented the document titled “RC_SOP-10-003: Medical Device Reporting”, Edition 7, dated 3\u002F7\u002F2023 as its written MDR procedure. However, this procedure does not meet the requirements of 12 CFR 803.17. For example:\n1. The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1).\na. The procedure omits definitions of the terms ‘become aware’, ‘caused or contributed’, ‘malfunction’, and ‘serious injury’, from 21 CFR Part 803.3. The exclusion of the definitions for these term from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nb. The procedure, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR Part 803 in a manner that will result in incomplete, inadequate, or even non-reporting of adverse events that meet the reportability requirements under 21 CFR Part 803.\n2. The procedure does not establish internal systems that provide for a standardized review process to determine when an event meets the criteria for reporting under this part, as required by 21 CFR 803.17(a)(2). For example, although the procedure includes instructions for how your firm will evaluate information about an event to make a reportability decision, it fails to include instructions for making determinations in a timely manner.\n3. The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include:\na. Instructions for how to obtain and complete the FDA 3500A form.\nb. The circumstances under which your firm must submit supplemental or follow-up report and the requirements for such reports.\nc. A process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a); and\nd. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\n4. The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\nWe reviewed your firm’s responses dated August 2, 2024, September 10, 202, and September 30, 2024, and conclude that they are not adequate. In your September 30, 2024 response, you provided the revised procedure “RC_SOP-10-003: Medical Device Reporting”, Edition No. 8, dated 30\u002F09\u002F2024. Your revised procedure continues to not meet the requirements of 21 CFR 803.17. For example:\n1. The revision does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example,\na. The procedure omits definitions of the terms ‘caused or contributed’ and ‘malfunction’ from 21 CFR Part 803.3. The exclusion of the definitions for these term from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nb. The term ‘serious injury’ is incorrectly referred to as ‘serious adverse event’, which might not allow your firm to correctly identify complaints as reportable events.\nc. The revision, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR Part 803 in a manner that will result in incomplete, inadequate, or even non‐reporting of adverse events that meet the reportability requirements under 21 CFR Part 803. For example, terms including but not necessarily limited to, ‘serious incident’ and ‘serious adverse event’, which are intended for OUS vigilance reporting, are included in the procedure within the context of the US MDR reporting requirements.\n2. The revision does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, your procedure does not include:\na. Instructions for how to obtain and complete the FDA 3500A form.\nb. A process for submitting initial and supplement or follow‐up reports to FDA in an electronic format that FDA can process, review and archive in accordance with 21 CFR 803.12(a).\nc. How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow‐up within your firm.\nAdditionally, the FDA verified that, as of October 17, 2024, your firm still does not have an active ESG production account for the electronic submission of MDR reports. Information about the ESG and creating an account can be found at: How to Enroll in eMDR Program | FDA (https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femdr-electronic-medical-device-reporting\u002Fhow-enrollemdr-program).\nPlease note that your firm’s response dated October 15, 2024 to the Form FDA 483 (FDA 483) was not reviewed because it was received too late in the review cycle after issuance of the FDA 483. Therefore, the October 15, 2024 response will be evaluated along with any other written material provided in response to the violations cited in this Warning Letter.\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #695160 when replying. If you have any questions about the contents of this letter, please contact: Ariel Ash-Shakoor at ariel.ash-shakoor@fda.hhs.gov or 240-402-4912.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nBram Zuckerman, M.D.\nDirector\nOHT 2: Office of Cardiovascular Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\n\nCC:\nJessica Osward-McLeod\nNipro Medical Corporation,\n3150 NW 107th Ave.\nMiami, Florida, 33172, USA\nTel: 786-567-6343\njessicao@nipromed.com","Rontis Hellas S.A.","rontis-hellas-sa-695160-10282024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frontis-hellas-sa-695160-10282024","2026-10-26T08:09:50.992468+00:00","Closed Out","2024-12-24","695160","2026-03-12","Ms. Efi Soultou","2026-08-19T17:06:45.675+00:00","2024-10-28",{"id":127,"raw":128,"subject":132,"body_html":133,"body_text":134,"firm_name":135,"letter_id":136,"created_at":18,"fei_number":19,"letter_url":137,"updated_at":138,"action_type":22,"case_status":23,"posted_date":139,"marcs_cms_no":140,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":141,"body_fetched_at":142,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":143,"medical_device_id":19,"response_letter_date":19},1314,[129,130,131,11,132,13,13,13],"\u003Ctime datetime=\"2024-08-15T17:00:00Z\">08\u002F15\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-08-09T04:00:00Z\">08\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faustrofood-sas-679052-08092024\">AUSTROFOOD S.A.S.\u003C\u002Fa>","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Francisco Jose Peña Cordovez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AUSTROFOOD S.A.S.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Av. General Enriquez, Tanicuchi Lote 8\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>171104\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Quito, Pichincha\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ecuador\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:francisco@wanabanafruits.com\"> francisco@wanabanafruits.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 9, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Reference #679052\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Peña:\u003C\u002Fp>\n\n\u003Cp>Beginning in October 2023, the U.S. Food and Drug Administration (FDA or we), along with the Centers for Disease Control and Prevention (CDC) and state and local partners, investigated elevated levels of lead linked to consumption of apple cinnamon fruit puree pouches manufactured at your facility. As described below, laboratory analysis of multiple lots of your apple cinnamon fruit puree pouches detected extremely high concentrations of lead. The presence of these levels of lead causes these products to be adulterated within the meaning of section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(1)] in that they bear or contain an added poisonous or deleterious substance which may render them injurious to health. The introduction or delivery for introduction into interstate commerce of adulterated food is a violation of section 301(a) of the Act [21 U.S.C. § 331(a)]. On October 29, 2023, WanaBana USA LLC recalled 39&nbsp;lots of apple cinnamon fruit puree manufactured by your firm, representing 2,998,088&nbsp;individual units distributed between November 22, 2022, and October 26, 2023.\u003C\u002Fp>\n\n\u003Cp>In response to this multistate investigation involving elevated levels of lead in apple cinnamon fruit puree pouches (intended for infants as young as six months and the general public) manufactured at your facility, FDA inspected your ready-to-eat (RTE) acidified and acid food fruit pulp and puree product manufacturing facility, located at Av. General Enriquez, Tanicuchi Lote 8, Quito, Pichincha, Ecuador, from December 4 through December 14, 2023. During the inspection of your facility, FDA investigators found serious violation of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117) and the Act. The failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, FDA issued a Form FDA 483 (FDA-483), Inspectional Observations, listing deviations found at your facility. We received your responses to the FDA-483 on January 8, 2024, and April 2, 2024, describing corrective actions taken and planned by your firm, and address your responses below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Food: Section 402(a)(1) of the Act\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In October 2023, FDA was made aware of an investigation by the North Carolina Department of Health and Human Services (NCDHHS) and the North Carolina Department of Agriculture &amp; Consumer Services (NCDA&amp;CS) regarding four children with elevated blood lead levels, indicating potential acute lead toxicity. The NCDHHS investigation identified WanaBana Apple Cinnamon Fruit Puree pouches as a potential shared source of exposure. As part of their investigation, NCDHHS analyzed multiple lots of WanaBana Apple Cinnamon Fruit Puree pouches, detecting extremely high concentrations of lead. FDA reviewed and supported NCDHHS’s analytical findings.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA and state partners also collected and analyzed additional product samples of fruit puree and applesauce pouches manufactured by your firm. FDA, the Maryland Department of Health (MDH), the NCDA&amp;CS, and the Pennsylvania Department of Agriculture (PDA) detected extremely high concentrations of lead in WanaBana Apple Cinnamon Fruit Puree pouches and Weis Cinnamon Apple Sauce pouches manufactured by your firm. FDA has reviewed and supports the MDH, NCDA&amp;CS, and PDA analytical findings. Specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>2.18 parts per million (ppm) lead was detected in FDA Sample 1234871, 6.43 ppm lead was detected in MDH Sample FC2400004901, and 2.16 - 3.19 ppm lead was detected in NCDA&amp;CS Samples FDC0222755 - FDC0222760 of WanaBana Apple Cinnamon Fruit Puree pouches collected from Dollar Tree stores; and\u003C\u002Fli>\n\t\u003Cli>1.44 ppm lead was detected in PDA Sample F2300877-1 of Weis Cinnamon Apple Sauce pouches collected from a Weis Markets store.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Further, through finished product testing and testing of cinnamon collected at your facility, FDA determined that the cinnamon ingredient was the source of elevated lead in the apple cinnamon fruit puree pouches.\u003C\u002Fp>\n\n\u003Cp>The presence of these levels of lead causes the WanaBana Apple Cinnamon Fruit Puree and Weis Cinnamon Apple Sauce pouches, which were manufactured at your facility in Ecuador, to be adulterated within the meaning of section 402(a)(1) of the Act [21 U.S.C. § 342(a)(1)] in that they bear or contain an added poisonous or deleterious substance which may render them injurious to health. Exposure to lead at the levels found in the WanaBana Apple Cinnamon Fruit Puree and Weis Cinnamon Apple Sauce pouches could result in acute lead toxicity. Lead is toxic to humans and can affect people of any age or health status; children are particularly susceptible to lead toxicity due to their low body weight. Neurological effects of lead exposure during early childhood include learning disabilities, behavior difficulties, and lowered IQ. Short term exposure to lead could result in the following symptoms: headache, abdominal pain\u002Fcolic, vomiting, and anemia. Longer term exposure could result in the following additional symptoms: irritability, lethargy, fatigue, muscle aches or muscle prickling\u002Fburning, constipation, difficulty concentrating\u002Fmuscular weakness, tremor, and weight loss.\u003C\u002Fp>\n\n\u003Cp>Your firm caused these adulterated apple cinnamon products to be imported into the United States. The products were imported into the United States in multiple shipments. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the Act [21 U.S.C. § 331(a)]. By shipping the apple cinnamon fruit puree pouches to the United States, you caused the introduction or delivery for introduction into interstate commerce of adulterated food in violation of section 301(a) of the Act.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that on October 29, 2023, WanaBana USA LLC recalled 39 lots of apple cinnamon fruit puree manufactured by your firm. Due to the serious public health concerns related to the sale of adulterated apple cinnamon fruit puree products that were manufactured by your facility with the lead-contaminated cinnamon, it is essential that this violation does not reoccur.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As stated above, FDA investigators found serious violation of the CGMP &amp; PC rule. The failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)].\u003C\u002Fp>\n\n\u003Cp>You did not appropriately conduct a hazard analysis to identify and evaluate a known or reasonably foreseeable hazard (lead) for your apple cinnamon fruit puree pouch products to determine whether that hazard (lead) required a preventive control, as required by 21 CFR 117.130(a)(1). Your hazard evaluation must consider, among other factors, the effect of raw materials and other ingredients as well as the intended and reasonably foreseeable use on the safety of the product for the intended consumer (see 21 CFR 117.130(c)(2)). You use cinnamon powder as an ingredient in your apple cinnamon fruit puree pouches, a product intended for young children, including infants as young as six months old. Lead is often found in spices, including cinnamon, and oral exposure to elevated levels of lead can pose health risks to humans, particularly children, as described above. Therefore, lead in a cinnamon ingredient is a known or reasonably foreseeable hazard for which young children are especially sensitive.\u003C\u002Fp>\n\n\u003Cp>Your hazard analysis dated November 14, 2022, identified lead as a potential hazard in your raw materials generally; your evaluation, which did not consider the cinnamon ingredient in particular, concluded lead was not a hazard requiring a preventive control, listing “Analisis de metales pesados minimo \u003Cstrong>(b)(4)\u003C\u002Fstrong>” (analysis of heavy metals minimum \u003Cstrong>(b)(4)\u003C\u002Fstrong>) as the justification for this conclusion. Your hazard analysis dated September 27, 2023, identified lead as a potential hazard in the cinnamon ingredient but your evaluation determined it did not require a preventive control, listing “Proveedor sin precedentes historicos” (supplier without historical precedents) as the justification for this conclusion. Considering the known prevalence of lead in spices such as cinnamon and the intended audience of your finished product, including the particular susceptibility of young children to the negative health effects of lead exposure, a knowledgeable person at your facility manufacturing\u002Fprocessing foods intended for young children would identify lead in this cinnamon ingredient as a hazard requiring a preventive control.\u003C\u002Fp>\n\n\u003Cp>A receiving facility that identifies raw materials and other ingredients with a hazard requiring a supply-chain-applied control, such as lead, must establish and implement a risk-based supply-chain program for those raw materials and ingredients (see 21 CFR 117.405(a)(1)). The supply-chain program must include using approved suppliers, determining appropriate supplier verification activities (including determining the frequency of conducting the activity), and conducting supplier verification activities (see 21 CFR 117.410).\u003C\u002Fp>\n\n\u003Cp>Although the two hazard analyses referenced above did not identify lead in your cinnamon ingredient as a hazard requiring a preventive control, these hazard analyses nonetheless listed purchasing from an approved supplier and receiving certificates of analysis (COAs)\u002Flab results from the supplier as controls for lead. In addition, we acknowledge that you had a written supply-chain program in place. Your supply-chain program covered Negasmart, the third-party distribution company from whom you obtained the ground cinnamon used in the recalled apple cinnamon fruit puree pouches manufactured at your facility. However, your activities involving Negasmart&nbsp;show that you did not implement the provision in your supply-chain program requiring onsite audits of suppliers located in Ecuador to be performed at least once per year. In particular, you informed our investigators that an onsite audit was not conducted of Negasmart&nbsp;(the entity which you approved as your supplier). Instead, you conducted a “desk audit” of Negasmart&nbsp;that was not consistent with your supply-chain program.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>We acknowledge correspondence from your consultant received on January 18, 2024, describing that your facility had resumed production of apple cinnamon fruit puree products using a new cinnamon supplier, and advising of plans to offer product for import into the United States under a new brand. After your recall, your revised hazard analysis dated November 15, 2023, identified presence of heavy metals in cinnamon as a hazard requiring a supply-chain control, with the rationale that there may be intentional contamination. Similarly, your revised hazard analysis dated March 5, 2024 (which you provided in your April 2, 2024, response) identifies presence of heavy metals and inclusion of prohibited substances (lead, chrome) in cinnamon as hazards requiring supply-chain controls, with the rationale that there may be intentional contamination. We note that lead in dried, ground spices (and other ingredients) may also be present due to circumstances other than economically motivated adulteration. For example, previous testing of dried, ground spices at retail have detected lead at a range of levels not suggestive of intentional adulteration. Because lead can accumulate in the body, even lower-level chronic exposure can be hazardous over time. A chemical hazard may cause immediate effects or may be associated with potential long-term effects after chronic exposure to the chemical. Your response received April 2, 2024, also includes your revised supply-chain program dated March 5, 2024, which identifies a new supplier you approved for cinnamon powder. We will assess the adequacy of your corrective actions during the next inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>In addition to the violations described above, we offer the following comments:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. After your recall, your supply-chain program for heavy metals in cinnamon powder dated March 5, 2024, describes that a representative sample of each batch received from your approved supplier will now be tested by an external laboratory to verify the levels of heavy metals reported in the supplier’s quality certificate (certificate of analysis or COA). The procedure describes that if lead is detected above permitted limits, the batch will be blocked, the supplier will be informed, and the ingredient will be returned and\u002For destroyed. Another entity may conduct the supplier verification activities; however, as the receiving facility, 21 CFR 117.415(a)(3) requires that you document your review and assessment of the entity’s applicable documentation, such as a COA. FDA recommends that a COA document that major analytical parameters for the specific food, or lots, contained in a specific shipment have been met. The laboratory conducting the testing should use scientifically valid laboratory methods and procedures that can provide reliable, accurate test results.\u003C\u002Fp>\n\n\u003Cp>After your recall, your response received April 2, 2024, includes your “Heavy Metal Monitoring Program in Finished Products” procedure dated March 8, 2024. The procedure describes plans to have an external laboratory test each batch of both the apple cinnamon puree product and the cinnamon powder for lead, and your established specification is \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppb lead for both the finished product and the cinnamon ingredient. The procedure does not describe what will constitute a representative sample, the analytical method that will be used by the external laboratory, or assurances that the analytical method will be followed. You have not provided evidence of implementation of this sampling.\u003C\u002Fp>\n\n\u003Cp>Stringent verification activities for heavy metals in cinnamon powder should be established and implemented to ensure your finished product is not adulterated, especially when considering that the intended consumer of your apple cinnamon fruit puree pouches includes a more susceptible population of infants and young children. Additional finished product testing may help assess and verify the effectiveness of your food safety plan.\u003C\u002Fp>\n\n\u003Cp>2. During the inspection, FDA collected samples of cinnamon powder that you received from Negasmart (represented by FDA Samples 1085090 and 1085091). In addition to FDA analysis revealing extremely high levels of lead, at 5,110 ppm and 2,270 ppm, FDA analysis revealed extremely high levels of chromium, at 1,201 ppm and&nbsp;531 ppm. Based on additional analyses, FDA determined that lead chromate was also present in the sampled cinnamon powder. Lead chromate in the cinnamon powder is indicative of economic adulteration.\u003C\u002Fp>\n\n\u003Cp>When conducting your hazard analysis, you must consider known or reasonably foreseeable hazards that may be intentionally introduced for purposes of economic gain (i.e., economically motivated adulteration) (see 21 CFR 117.130(b)(2)(iii)). There have now been several occurrences of lead compounds (e.g., lead chromate and lead oxide) that have appeared to be intentionally added to spices (e.g., turmeric, paprika, and cinnamon powder) that have caused illness and\u002For death, including the occurrence at your facility. Considering the pattern of economically motivated adulteration in the past, we expect that a knowledgeable person at your facility making foods intended for young children would conclude that hazards that may be intentionally introduced for economic gain (such as lead in dried ground spices) will need preventive controls (e.g., supply chain controls). We acknowledge that your updated hazard analysis, dated March 5, 2024, concludes that lead that may be intentionally introduced in cinnamon will need preventive controls. Further, when establishing verification activities for a hazard that may be intentionally introduced to a raw material or other ingredient, we expect that a knowledgeable person at your facility making foods intended for young children would consider conducting their own testing to verify levels in the raw material or other ingredient and\u002For to verify testing results provided by the supplier. We acknowledge that your “Heavy Metal Monitoring Program in Finished Products” procedure dated March 8, 2024, describes plans to have an external laboratory test each batch of both the apple cinnamon puree product and the cinnamon powder for lead; please see our comments above regarding this.\u003C\u002Fp>\n\n\u003Cp>Please respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking or have taken to correct the deviation, including an explanation of how your firm plans to prevent the violation or similar violations from occurring again. More specifically, your response should include documentation of the corrective actions your firm has taken. If you believe that your facility or your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If your firm’s planned corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed.\u003C\u002Fp>\n\n\u003Cp>You should direct your written reply to CFSANEnforcement@fda.hhs.gov, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions regarding this letter, you may contact CFSAN via email at CFSANEnforcement@fda.hhs.gov. Please reference CMS #679052 on any submissions and on the subject line of any emails to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We acknowledge that at the time you were sourcing your cinnamon ingredient from Negasmart, FDA had issued a guidance document entitled, “Temporary Policy Regarding Preventive Controls and FSVP Food Supplier Verification Onsite Audit Requirements During the COVID–19 Public Health Emergency.” The guidance communicates the Agency's intention not to enforce certain onsite audit requirements in the preventive controls regulation (as well as certain other regulations) in certain circumstances, which are not present in your case.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nFrancisco Jose Peña Cordovez\n\nRecipient Title\n\nPresident\n\nAUSTROFOOD S.A.S.\n\nAv. General Enriquez, Tanicuchi Lote 8\n\n171104\n\nQuito, Pichincha\n\nEcuador\n\nfrancisco@wanabanafruits.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nAugust 9, 2024\n\nWARNING LETTER\n\nReference #679052\n\nDear Mr. Peña:\n\nBeginning in October 2023, the U.S. Food and Drug Administration (FDA or we), along with the Centers for Disease Control and Prevention (CDC) and state and local partners, investigated elevated levels of lead linked to consumption of apple cinnamon fruit puree pouches manufactured at your facility. As described below, laboratory analysis of multiple lots of your apple cinnamon fruit puree pouches detected extremely high concentrations of lead. The presence of these levels of lead causes these products to be adulterated within the meaning of section 402(a)(1) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(1)] in that they bear or contain an added poisonous or deleterious substance which may render them injurious to health. The introduction or delivery for introduction into interstate commerce of adulterated food is a violation of section 301(a) of the Act [21 U.S.C. § 331(a)]. On October 29, 2023, WanaBana USA LLC recalled 39 lots of apple cinnamon fruit puree manufactured by your firm, representing 2,998,088 individual units distributed between November 22, 2022, and October 26, 2023.\n\nIn response to this multistate investigation involving elevated levels of lead in apple cinnamon fruit puree pouches (intended for infants as young as six months and the general public) manufactured at your facility, FDA inspected your ready-to-eat (RTE) acidified and acid food fruit pulp and puree product manufacturing facility, located at Av. General Enriquez, Tanicuchi Lote 8, Quito, Pichincha, Ecuador, from December 4 through December 14, 2023. During the inspection of your facility, FDA investigators found serious violation of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117) and the Act. The failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nAt the conclusion of the inspection, FDA issued a Form FDA 483 (FDA-483), Inspectional Observations, listing deviations found at your facility. We received your responses to the FDA-483 on January 8, 2024, and April 2, 2024, describing corrective actions taken and planned by your firm, and address your responses below.\n\nAdulterated Food: Section 402(a)(1) of the Act\n\nIn October 2023, FDA was made aware of an investigation by the North Carolina Department of Health and Human Services (NCDHHS) and the North Carolina Department of Agriculture & Consumer Services (NCDA&CS) regarding four children with elevated blood lead levels, indicating potential acute lead toxicity. The NCDHHS investigation identified WanaBana Apple Cinnamon Fruit Puree pouches as a potential shared source of exposure. As part of their investigation, NCDHHS analyzed multiple lots of WanaBana Apple Cinnamon Fruit Puree pouches, detecting extremely high concentrations of lead. FDA reviewed and supported NCDHHS’s analytical findings.\n\nIn addition, FDA and state partners also collected and analyzed additional product samples of fruit puree and applesauce pouches manufactured by your firm. FDA, the Maryland Department of Health (MDH), the NCDA&CS, and the Pennsylvania Department of Agriculture (PDA) detected extremely high concentrations of lead in WanaBana Apple Cinnamon Fruit Puree pouches and Weis Cinnamon Apple Sauce pouches manufactured by your firm. FDA has reviewed and supports the MDH, NCDA&CS, and PDA analytical findings. Specifically:\n\n2.18 parts per million (ppm) lead was detected in FDA Sample 1234871, 6.43 ppm lead was detected in MDH Sample FC2400004901, and 2.16 - 3.19 ppm lead was detected in NCDA&CS Samples FDC0222755 - FDC0222760 of WanaBana Apple Cinnamon Fruit Puree pouches collected from Dollar Tree stores; and\n\n1.44 ppm lead was detected in PDA Sample F2300877-1 of Weis Cinnamon Apple Sauce pouches collected from a Weis Markets store.\n\nFurther, through finished product testing and testing of cinnamon collected at your facility, FDA determined that the cinnamon ingredient was the source of elevated lead in the apple cinnamon fruit puree pouches.\n\nThe presence of these levels of lead causes the WanaBana Apple Cinnamon Fruit Puree and Weis Cinnamon Apple Sauce pouches, which were manufactured at your facility in Ecuador, to be adulterated within the meaning of section 402(a)(1) of the Act [21 U.S.C. § 342(a)(1)] in that they bear or contain an added poisonous or deleterious substance which may render them injurious to health. Exposure to lead at the levels found in the WanaBana Apple Cinnamon Fruit Puree and Weis Cinnamon Apple Sauce pouches could result in acute lead toxicity. Lead is toxic to humans and can affect people of any age or health status; children are particularly susceptible to lead toxicity due to their low body weight. Neurological effects of lead exposure during early childhood include learning disabilities, behavior difficulties, and lowered IQ. Short term exposure to lead could result in the following symptoms: headache, abdominal pain\u002Fcolic, vomiting, and anemia. Longer term exposure could result in the following additional symptoms: irritability, lethargy, fatigue, muscle aches or muscle prickling\u002Fburning, constipation, difficulty concentrating\u002Fmuscular weakness, tremor, and weight loss.\n\nYour firm caused these adulterated apple cinnamon products to be imported into the United States. The products were imported into the United States in multiple shipments. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the Act [21 U.S.C. § 331(a)]. By shipping the apple cinnamon fruit puree pouches to the United States, you caused the introduction or delivery for introduction into interstate commerce of adulterated food in violation of section 301(a) of the Act.\n\nWe acknowledge that on October 29, 2023, WanaBana USA LLC recalled 39 lots of apple cinnamon fruit puree manufactured by your firm. Due to the serious public health concerns related to the sale of adulterated apple cinnamon fruit puree products that were manufactured by your facility with the lead-contaminated cinnamon, it is essential that this violation does not reoccur.\n\nHazard Analysis and Risk-Based Preventive Controls (21 CFR Part 117, Subpart C)\n\nAs stated above, FDA investigators found serious violation of the CGMP & PC rule. The failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)].\n\nYou did not appropriately conduct a hazard analysis to identify and evaluate a known or reasonably foreseeable hazard (lead) for your apple cinnamon fruit puree pouch products to determine whether that hazard (lead) required a preventive control, as required by 21 CFR 117.130(a)(1). Your hazard evaluation must consider, among other factors, the effect of raw materials and other ingredients as well as the intended and reasonably foreseeable use on the safety of the product for the intended consumer (see 21 CFR 117.130(c)(2)). You use cinnamon powder as an ingredient in your apple cinnamon fruit puree pouches, a product intended for young children, including infants as young as six months old. Lead is often found in spices, including cinnamon, and oral exposure to elevated levels of lead can pose health risks to humans, particularly children, as described above. Therefore, lead in a cinnamon ingredient is a known or reasonably foreseeable hazard for which young children are especially sensitive.\n\nYour hazard analysis dated November 14, 2022, identified lead as a potential hazard in your raw materials generally; your evaluation, which did not consider the cinnamon ingredient in particular, concluded lead was not a hazard requiring a preventive control, listing “Analisis de metales pesados minimo (b)(4)” (analysis of heavy metals minimum (b)(4)) as the justification for this conclusion. Your hazard analysis dated September 27, 2023, identified lead as a potential hazard in the cinnamon ingredient but your evaluation determined it did not require a preventive control, listing “Proveedor sin precedentes historicos” (supplier without historical precedents) as the justification for this conclusion. Considering the known prevalence of lead in spices such as cinnamon and the intended audience of your finished product, including the particular susceptibility of young children to the negative health effects of lead exposure, a knowledgeable person at your facility manufacturing\u002Fprocessing foods intended for young children would identify lead in this cinnamon ingredient as a hazard requiring a preventive control.\n\nA receiving facility that identifies raw materials and other ingredients with a hazard requiring a supply-chain-applied control, such as lead, must establish and implement a risk-based supply-chain program for those raw materials and ingredients (see 21 CFR 117.405(a)(1)). The supply-chain program must include using approved suppliers, determining appropriate supplier verification activities (including determining the frequency of conducting the activity), and conducting supplier verification activities (see 21 CFR 117.410).\n\nAlthough the two hazard analyses referenced above did not identify lead in your cinnamon ingredient as a hazard requiring a preventive control, these hazard analyses nonetheless listed purchasing from an approved supplier and receiving certificates of analysis (COAs)\u002Flab results from the supplier as controls for lead. In addition, we acknowledge that you had a written supply-chain program in place. Your supply-chain program covered Negasmart, the third-party distribution company from whom you obtained the ground cinnamon used in the recalled apple cinnamon fruit puree pouches manufactured at your facility. However, your activities involving Negasmart show that you did not implement the provision in your supply-chain program requiring onsite audits of suppliers located in Ecuador to be performed at least once per year. In particular, you informed our investigators that an onsite audit was not conducted of Negasmart (the entity which you approved as your supplier). Instead, you conducted a “desk audit” of Negasmart that was not consistent with your supply-chain program.1\n\nWe acknowledge correspondence from your consultant received on January 18, 2024, describing that your facility had resumed production of apple cinnamon fruit puree products using a new cinnamon supplier, and advising of plans to offer product for import into the United States under a new brand. After your recall, your revised hazard analysis dated November 15, 2023, identified presence of heavy metals in cinnamon as a hazard requiring a supply-chain control, with the rationale that there may be intentional contamination. Similarly, your revised hazard analysis dated March 5, 2024 (which you provided in your April 2, 2024, response) identifies presence of heavy metals and inclusion of prohibited substances (lead, chrome) in cinnamon as hazards requiring supply-chain controls, with the rationale that there may be intentional contamination. We note that lead in dried, ground spices (and other ingredients) may also be present due to circumstances other than economically motivated adulteration. For example, previous testing of dried, ground spices at retail have detected lead at a range of levels not suggestive of intentional adulteration. Because lead can accumulate in the body, even lower-level chronic exposure can be hazardous over time. A chemical hazard may cause immediate effects or may be associated with potential long-term effects after chronic exposure to the chemical. Your response received April 2, 2024, also includes your revised supply-chain program dated March 5, 2024, which identifies a new supplier you approved for cinnamon powder. We will assess the adequacy of your corrective actions during the next inspection.\n\nIn addition to the violations described above, we offer the following comments:\n\n1. After your recall, your supply-chain program for heavy metals in cinnamon powder dated March 5, 2024, describes that a representative sample of each batch received from your approved supplier will now be tested by an external laboratory to verify the levels of heavy metals reported in the supplier’s quality certificate (certificate of analysis or COA). The procedure describes that if lead is detected above permitted limits, the batch will be blocked, the supplier will be informed, and the ingredient will be returned and\u002For destroyed. Another entity may conduct the supplier verification activities; however, as the receiving facility, 21 CFR 117.415(a)(3) requires that you document your review and assessment of the entity’s applicable documentation, such as a COA. FDA recommends that a COA document that major analytical parameters for the specific food, or lots, contained in a specific shipment have been met. The laboratory conducting the testing should use scientifically valid laboratory methods and procedures that can provide reliable, accurate test results.\n\nAfter your recall, your response received April 2, 2024, includes your “Heavy Metal Monitoring Program in Finished Products” procedure dated March 8, 2024. The procedure describes plans to have an external laboratory test each batch of both the apple cinnamon puree product and the cinnamon powder for lead, and your established specification is (b)(4) ppb lead for both the finished product and the cinnamon ingredient. The procedure does not describe what will constitute a representative sample, the analytical method that will be used by the external laboratory, or assurances that the analytical method will be followed. You have not provided evidence of implementation of this sampling.\n\nStringent verification activities for heavy metals in cinnamon powder should be established and implemented to ensure your finished product is not adulterated, especially when considering that the intended consumer of your apple cinnamon fruit puree pouches includes a more susceptible population of infants and young children. Additional finished product testing may help assess and verify the effectiveness of your food safety plan.\n\n2. During the inspection, FDA collected samples of cinnamon powder that you received from Negasmart (represented by FDA Samples 1085090 and 1085091). In addition to FDA analysis revealing extremely high levels of lead, at 5,110 ppm and 2,270 ppm, FDA analysis revealed extremely high levels of chromium, at 1,201 ppm and 531 ppm. Based on additional analyses, FDA determined that lead chromate was also present in the sampled cinnamon powder. Lead chromate in the cinnamon powder is indicative of economic adulteration.\n\nWhen conducting your hazard analysis, you must consider known or reasonably foreseeable hazards that may be intentionally introduced for purposes of economic gain (i.e., economically motivated adulteration) (see 21 CFR 117.130(b)(2)(iii)). There have now been several occurrences of lead compounds (e.g., lead chromate and lead oxide) that have appeared to be intentionally added to spices (e.g., turmeric, paprika, and cinnamon powder) that have caused illness and\u002For death, including the occurrence at your facility. Considering the pattern of economically motivated adulteration in the past, we expect that a knowledgeable person at your facility making foods intended for young children would conclude that hazards that may be intentionally introduced for economic gain (such as lead in dried ground spices) will need preventive controls (e.g., supply chain controls). We acknowledge that your updated hazard analysis, dated March 5, 2024, concludes that lead that may be intentionally introduced in cinnamon will need preventive controls. Further, when establishing verification activities for a hazard that may be intentionally introduced to a raw material or other ingredient, we expect that a knowledgeable person at your facility making foods intended for young children would consider conducting their own testing to verify levels in the raw material or other ingredient and\u002For to verify testing results provided by the supplier. We acknowledge that your “Heavy Metal Monitoring Program in Finished Products” procedure dated March 8, 2024, describes plans to have an external laboratory test each batch of both the apple cinnamon puree product and the cinnamon powder for lead; please see our comments above regarding this.\n\nPlease respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking or have taken to correct the deviation, including an explanation of how your firm plans to prevent the violation or similar violations from occurring again. More specifically, your response should include documentation of the corrective actions your firm has taken. If you believe that your facility or your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If your firm’s planned corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed.\n\nYou should direct your written reply to CFSANEnforcement@fda.hhs.gov, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions regarding this letter, you may contact CFSAN via email at CFSANEnforcement@fda.hhs.gov. Please reference CMS #679052 on any submissions and on the subject line of any emails to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\n___________________\n\n1 We acknowledge that at the time you were sourcing your cinnamon ingredient from Negasmart, FDA had issued a guidance document entitled, “Temporary Policy Regarding Preventive Controls and FSVP Food Supplier Verification Onsite Audit Requirements During the COVID–19 Public Health Emergency.” The guidance communicates the Agency's intention not to enforce certain onsite audit requirements in the preventive controls regulation (as well as certain other regulations) in certain circumstances, which are not present in your case.","AUSTROFOOD S.A.S.","austrofood-sas-679052-08092024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faustrofood-sas-679052-08092024","2026-10-26T08:07:59.339908+00:00","2024-08-15","679052","Francisco Jose Peña Cordovez","2026-08-19T23:53:27.364+00:00","2024-08-09",{"id":145,"raw":146,"subject":58,"body_html":151,"body_text":152,"firm_name":153,"letter_id":154,"created_at":43,"fei_number":19,"letter_url":155,"updated_at":156,"action_type":22,"case_status":119,"posted_date":157,"marcs_cms_no":158,"product_type":68,"closeout_date":159,"issuing_office":57,"recipient_name":160,"body_fetched_at":161,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":162,"medical_device_id":19,"response_letter_date":19},1672,[147,148,149,57,58,13,150,13],"\u003Ctime datetime=\"2023-12-26T14:20:00Z\">12\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-01T04:00:00Z\">11\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fterragene-sa-667432-11012023\">Terragene S.A.\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fterragene-sa-667432-04052024\">\u003Ctime datetime=\"2024-06-28T04:00:00Z\">06\u002F28\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Esteban Lombardia\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Terragene S.A.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Ruta Nacional N9\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Km 280, CP 2130, Parque Industrial Micropi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>2130\u003C\u002Fspan> \u003Cspan>Alvear\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Santa Fe\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Argentina\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\n\u003Cstrong>CMS #: 667432\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 1, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. Esteban Lombardia:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Alvear, Santa Fe, Argentina on June 06, 2023 through June 09, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and distributes Biological and Chemical Sterilization Process Indicator Systems under its own brand, and through distributors under private label manufacturers. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received a response from you dated June 30, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish adequate procedures for receiving, reviewing, and evaluating complaints by a formally designated unit (21 CFR 820.198(a)(b)).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm’s complaint handling procedure, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, does not describe complaint handling requirements that ensure your firm receives, reviews, and evaluates all complaints in a uniform and timely manner. Specifically, though your procedure identifies the timeline for closing out complaints once correspondence with complainants has been established, it fails to specify a definitive timeline to evaluate the complaint and reach out to the complainant. Additionally, the procedure does not describe the process for determining whether an investigation is necessary, and whether the complaint represents an event that is required to be reported to the FDA under 21 CFR Part 803 – Medical Device Reporting (MDR).\u003C\u002Fp>\n\n\u003Cp>Your firm received 96 U.S. market complaints from June 21, 2021 to June 09, 2023 for which your firm was not able to provide documentation to demonstrate how the complaints were reviewed or evaluated to determine whether an investigation is necessary or whether the complaint represents an event that is required to be reported to FDA under 21 CFR Part 803 – Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated June 30, 2023, and September 13, 2023, and concluded that the adequacy of your response cannot be determined. In your response, you stated that your firm is developing a new “Complaint Handling SOP,” training your personnel to the SOP, and conducting a retrospective analysis of the complaints that have been filed with your company to adjudicate the underlying issues stated in the complaints. Your response estimated a timeframe of September through November 2023 to resolve the above FDA observation. Your September 13, 2023, response only contained “certificates of attendance” for a training that some of your employees took regarding the Quality System Regulation and ISO 13485. However, you did not include documentation or evidence to support the planned corrective actions. You have not provided the new “Complaint Handling SOP” to address the concerns noted by the agency. Additionally, you did not provide the retrospective review analysis as noted on your response.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>2. Failure to develop, maintain, and implement written MDR procedures, as required by 21 CFR 803.17.\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not developed, maintained, and implemented Medical Device Reporting (MDR) procedure(s) that address the requirements of 21 CFR Part 803 - Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated June 30, 2023, and September 13, 2023, and conclude that they are not adequate. Your firm committed to develop and implement MDR reporting procedures and processes; however, your firm did not provide a draft procedure for FDA to assess its adequacy. Additionally, you did not indicate whether you plan to perform a retrospective review of events and, when applicable, report events that were not previously reported to the agency; you also did not provide a timeframe of when you plan to complete these actions.\u003C\u002Fp>\n\n\u003Cp>3. Our inspection also revealed that the Integron IT26-C (own brand), \u003Cstrong>(b)(4)\u003C\u002Fstrong> (private label brand), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> (private label brand) devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\u003Cbr>\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm obtained 510(k) clearance for the Terragene Integron IT26-C via premarket notification K191021. This device was cleared for traditional steam sterilization cycles such as:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Gravity Displacement: 121° C for 30 minutes, 132° C for 15 minutes, 132° C for 25 minutes, 135° C for 10 minutes;\u003C\u002Fli>\n\t\u003Cli>Dynamic Air Removal (Vacuum Assist): 132° C for 4 minutes, 135° C for 3 minutes; and\u003C\u002Fli>\n\t\u003Cli>Vaporized Hydrogen Peroxide (STERRAD, V-ProMax and Sterizone VP4 cycles) and Ethylene Oxide sterilization cycles.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, the instructions for use (IFU) for your firm’s own brand and private label brand devices listed above also describe the process and acceptance criteria for “extended cycles.” The IFU(s) also include a diagram showing pass\u002Ffail results and describe how to interpret the chemical indicator (CI) post-sterilization. This diagram shows in the noted table what the CI should look like after a passed or failed cycle when using the cycle specifications that were previously cleared under K191021; however, the table also includes a column for “extended cycles,” which describes the use of extended cycles and the interpretation of extended cycle results. Your device was not cleared for extended cycle use. The extended cycle description in the labeling falls outside of the parameters in the cleared IFU as it suggests that the end user can extend the cycle on their own and follow the “accept\u002Freject” diagram to interpret the results. The distribution of these devices for an extended cycle use without authorization results in improper use of the device which could result in improperly sterilized devices leading to patient infections and serious health risks.\u003C\u002Fp>\n\n\u003Cp>CIs are cleared with specific validated cycle parameters that should be clearly specified in the labeling. The addition of “extended cycle” sterilization cycles in the labeling represents a significant change or modification in the intended use of the device; therefore, a new 510(k) is required.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #: 667432 when replying. If you have any questions about the contents of this letter, please contact: Chris Dugard, Asst. Director, at Ph: 240-402-6031 or at Christopher.dugard@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nBinita S. Ashar, MD, MBA, FACS\u003Cbr>\nDirector\u003Cbr>\nOHT4 - Office of Surgery and Infection Control Devices\u003Cbr>\nOffice of Product Quality and Evaluation\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Esteban Lombardia\n\nRecipient Title\n\nCEO\n\nTerragene S.A.\n\nRuta Nacional N9\n\nKm 280, CP 2130, Parque Industrial Micropi\n\n2130 Alvear\n\nSanta Fe\n\nArgentina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nCMS #: 667432\n\nNovember 1, 2023\n\nDear Mr. Esteban Lombardia:\n\nDuring an inspection of your firm located in Alvear, Santa Fe, Argentina on June 06, 2023 through June 09, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and distributes Biological and Chemical Sterilization Process Indicator Systems under its own brand, and through distributors under private label manufacturers. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received a response from you dated June 30, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish adequate procedures for receiving, reviewing, and evaluating complaints by a formally designated unit (21 CFR 820.198(a)(b)).\n\nSpecifically, your firm’s complaint handling procedure, (b)(4), does not describe complaint handling requirements that ensure your firm receives, reviews, and evaluates all complaints in a uniform and timely manner. Specifically, though your procedure identifies the timeline for closing out complaints once correspondence with complainants has been established, it fails to specify a definitive timeline to evaluate the complaint and reach out to the complainant. Additionally, the procedure does not describe the process for determining whether an investigation is necessary, and whether the complaint represents an event that is required to be reported to the FDA under 21 CFR Part 803 – Medical Device Reporting (MDR).\n\nYour firm received 96 U.S. market complaints from June 21, 2021 to June 09, 2023 for which your firm was not able to provide documentation to demonstrate how the complaints were reviewed or evaluated to determine whether an investigation is necessary or whether the complaint represents an event that is required to be reported to FDA under 21 CFR Part 803 – Medical Device Reporting.\n\nWe reviewed your firm’s responses dated June 30, 2023, and September 13, 2023, and concluded that the adequacy of your response cannot be determined. In your response, you stated that your firm is developing a new “Complaint Handling SOP,” training your personnel to the SOP, and conducting a retrospective analysis of the complaints that have been filed with your company to adjudicate the underlying issues stated in the complaints. Your response estimated a timeframe of September through November 2023 to resolve the above FDA observation. Your September 13, 2023, response only contained “certificates of attendance” for a training that some of your employees took regarding the Quality System Regulation and ISO 13485. However, you did not include documentation or evidence to support the planned corrective actions. You have not provided the new “Complaint Handling SOP” to address the concerns noted by the agency. Additionally, you did not provide the retrospective review analysis as noted on your response.\n\nOur inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n2. Failure to develop, maintain, and implement written MDR procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not developed, maintained, and implemented Medical Device Reporting (MDR) procedure(s) that address the requirements of 21 CFR Part 803 - Medical Device Reporting.\n\nWe reviewed your firm’s responses dated June 30, 2023, and September 13, 2023, and conclude that they are not adequate. Your firm committed to develop and implement MDR reporting procedures and processes; however, your firm did not provide a draft procedure for FDA to assess its adequacy. Additionally, you did not indicate whether you plan to perform a retrospective review of events and, when applicable, report events that were not previously reported to the agency; you also did not provide a timeframe of when you plan to complete these actions.\n\n3. Our inspection also revealed that the Integron IT26-C (own brand), (b)(4) (private label brand), and (b)(4) (private label brand) devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\n\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nSpecifically, your firm obtained 510(k) clearance for the Terragene Integron IT26-C via premarket notification K191021. This device was cleared for traditional steam sterilization cycles such as:\n\nGravity Displacement: 121° C for 30 minutes, 132° C for 15 minutes, 132° C for 25 minutes, 135° C for 10 minutes;\n\nDynamic Air Removal (Vacuum Assist): 132° C for 4 minutes, 135° C for 3 minutes; and\n\nVaporized Hydrogen Peroxide (STERRAD, V-ProMax and Sterizone VP4 cycles) and Ethylene Oxide sterilization cycles.\n\nHowever, the instructions for use (IFU) for your firm’s own brand and private label brand devices listed above also describe the process and acceptance criteria for “extended cycles.” The IFU(s) also include a diagram showing pass\u002Ffail results and describe how to interpret the chemical indicator (CI) post-sterilization. This diagram shows in the noted table what the CI should look like after a passed or failed cycle when using the cycle specifications that were previously cleared under K191021; however, the table also includes a column for “extended cycles,” which describes the use of extended cycles and the interpretation of extended cycle results. Your device was not cleared for extended cycle use. The extended cycle description in the labeling falls outside of the parameters in the cleared IFU as it suggests that the end user can extend the cycle on their own and follow the “accept\u002Freject” diagram to interpret the results. The distribution of these devices for an extended cycle use without authorization results in improper use of the device which could result in improperly sterilized devices leading to patient infections and serious health risks.\n\nCIs are cleared with specific validated cycle parameters that should be clearly specified in the labeling. The addition of “extended cycle” sterilization cycles in the labeling represents a significant change or modification in the intended use of the device; therefore, a new 510(k) is required.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #: 667432 when replying. If you have any questions about the contents of this letter, please contact: Chris Dugard, Asst. Director, at Ph: 240-402-6031 or at Christopher.dugard@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBinita S. Ashar, MD, MBA, FACS\n\nDirector\n\nOHT4 - Office of Surgery and Infection Control Devices\n\nOffice of Product Quality and Evaluation\n\nCenter for Devices and Radiological Health\n\nU.S. Food and Drug Administration","Terragene S.A.","terragene-sa-667432-11012023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fterragene-sa-667432-11012023","2026-10-26T08:10:10.567012+00:00","2023-12-26","667432","2024-06-28","Mr. Esteban Lombardia","2026-08-20T00:25:23.813+00:00","2023-11-01",{"id":164,"raw":165,"subject":170,"body_html":171,"body_text":172,"firm_name":173,"letter_id":174,"created_at":175,"fei_number":19,"letter_url":176,"updated_at":177,"action_type":22,"case_status":23,"posted_date":178,"marcs_cms_no":179,"product_type":180,"closeout_date":19,"issuing_office":169,"recipient_name":181,"body_fetched_at":182,"delivery_method":183,"recipient_title":19,"reference_number":19,"action_taken_date":184,"medical_device_id":19,"response_letter_date":19},3410,[166,167,168,169,170,13,13,13],"\u003Ctime datetime=\"2021-04-13T13:20:00Z\">04\u002F13\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-09T04:00:00Z\">04\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Froque-plast-sa-de-cv-609492-04092021\">Roque Plast S.A. de C.V.\u003C\u002Fa>","Center for Drug Evaluation and Research","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Roque Cabrera\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Roque Plast S.A. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Cerrada Adolfo Manfredi 7 C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Atizapan De Zaragoza\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>52968\u003C\u002Fspan> ,\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 9, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-40\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Cabrera:\u003C\u002Fp>\n\n\u003Cp>Your firm was registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer) labeled as COMMAND BRANDS GEL ANITBAC INSTANT HAND SANITIZER. The drug product was labeled as manufactured at your facility, Roque Plast S.A. de C.V., FEI 3008251335, at Cerrada Adolfo Manfredi 7 C Atizapan De Zaragoza, Mexico. Following an attempt to import into the United States, COMMAND BRANDS GEL ANITBAC INSTANT HAND SANITIZER was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of a batch of this product detained at the border demonstrates that this drug product labeled as manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a) and is misbranded under sections 502(j), (a), (e) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e) and (ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Roque Plast Hand Sanitizer, labeled as manufactured at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that it contained an average of 38% ethanol v\u002Fv and 25% of methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\u003C\u002Fp>\n\n\u003Cp>Methanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\u003C\u002Fp>\n\n\u003Cp>On July 31, 2020, FDA held a teleconference with you and your registered U.S. Agent, Zadik, Allan dba Faz Marketing. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. FDA notified the public of the methanol contamination of your drugs at the following website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>On August 4, 2020, you issued a voluntary nationwide recall of COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER due to potential presence of undeclared methanol (Wood Alcohol), as noted on the following FDA website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Froque-plast-sa-de-cv-issues-voluntary-nationwide-recall-command-brands-gel-antibac-instant-hand\">https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Froque-plast-sa-de-cv-issues-voluntary-nationwide-recall-command-brands-gel-antibac-instant-hand\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide the following:\u003C\u002Fp>\n\n\u003Cp>• A detailed investigation into how hand sanitizer drug products manufactured at your facility, and labeled as containing ethanol, were substituted in part or in whole with methanol.\u003Cbr>\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003Cbr>\n• Copies of the complete batch records for all batches distributed to the United States.\u003C\u002Fp>\n\n\u003Cp>During the July 31st teleconference you explained that you tested your ethanol API for flammability using an in-house test method. You further stated that reviewed your supplier’s certificates of analysis and that you were unaware that the ethanol supplied was contaminated with methanol. Lastly, you stated your hand sanitizer was tested by two third-party laboratories for methanol and that both laboratories found no methanol. Considering FDA test results directly contradict your assertions and demonstrate gross substitution, FDA questions the validity of all test results generated by your facility or by others on your behalf.\u003C\u002Fp>\n\n\u003Cp>• Provide a description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity.\u003Cbr>\n• In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. Also, provide a commitment to that you will test every lot of ethanol you receive for methanol content using the USP method and conducted in a laboratory that has been previously inspected by FDA and found in compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>The substitution and contamination with methanol in a drug product labeled as manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C) because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER product label that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Drug Facts…Uses…Hand Sanitizer to help reduce bacteria on the skin * Recommended for repeated use…”\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355 is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your COMMAND BRANDS GEL\u003Cbr>\n\u003Cbr>\nANTIBAC INSTANT HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule).\u003C\u002Fp>\n\n\u003Cp>Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are permitted under the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER is not permitted under the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER purportedly contains the active ingredient ethyl alcohol (ethanol) 70%. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrated that COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER contains ethanol in a concentration that is less than the 70% stated on its product label and less than the amount of ethanol described in the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such a product is not permitted under the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analyses also demonstrated that a batch of COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER contains significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not permitted under the 1994 TFM, nor is methanol included in the formulations described in FDA’s \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, this methanol-containing drug product, COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER, is misbranded under sections 502(j), (a), (e) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e) and (ee).\u003C\u002Fp>\n\n\u003Cp>It is misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\u003C\u002Fp>\n\n\u003Cp>This hand sanitizer is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because its labeling is false and misleading. As noted above, COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER is labeled to contain ethanol 70% v\u002Fv. However, FDA laboratory analysis of a batch of this product demonstrate that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result . . .” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product label to disclose the presence of the methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>The failure of this drug product to list methyl alcohol (methanol) as an ingredient on its label also causes it to be misbranded under section 502(e)(1)(A) of the FD&amp;C Act, 21 U.S.C. 352(e)(1)(A).\u003Cbr>\n\u003Cbr>\nLastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 13, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&amp;C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3008251335and ATTN: Michael Klapal.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered US Agent\u003Cbr>\nZadik, Allan dba Faz Marketing\u003Cbr>\n13019 Debarr Dr\u003Cbr>\nAustin, TX 78729-7730\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol- Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution of hand sanitizer products declared or labeled as manufactured at your facility, a review of the formulations on the drug products’ labeling further indicates that such products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution denatured in accordance with Bureau of Alcohol, Tobacco and Firearms regulations. 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem>. Because Hand Sanitizer is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> An inactive ingredient used in OTC monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Roque Cabrera\n\nRecipient Title\n\nOwner\n\nRoque Plast S.A. de C.V.\n\nCerrada Adolfo Manfredi 7 C\n\nAtizapan De Zaragoza\n\n52968 ,\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nApril 9, 2021\n\nWarning Letter 320-21-40\n\nDear Mr. Cabrera:\n\nYour firm was registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer) labeled as COMMAND BRANDS GEL ANITBAC INSTANT HAND SANITIZER. The drug product was labeled as manufactured at your facility, Roque Plast S.A. de C.V., FEI 3008251335, at Cerrada Adolfo Manfredi 7 C Atizapan De Zaragoza, Mexico. Following an attempt to import into the United States, COMMAND BRANDS GEL ANITBAC INSTANT HAND SANITIZER was detained and refused admission at the border.\n\nThe results of the FDA laboratory testing of a batch of this product detained at the border demonstrates that this drug product labeled as manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a) and is misbranded under sections 502(j), (a), (e) and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e) and (ee). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nRoque Plast Hand Sanitizer, labeled as manufactured at your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that it contained an average of 38% ethanol v\u002Fv and 25% of methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\n\nMethanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\n\nOn July 31, 2020, FDA held a teleconference with you and your registered U.S. Agent, Zadik, Allan dba Faz Marketing. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market. FDA notified the public of the methanol contamination of your drugs at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nOn August 4, 2020, you issued a voluntary nationwide recall of COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER due to potential presence of undeclared methanol (Wood Alcohol), as noted on the following FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Froque-plast-sa-de-cv-issues-voluntary-nationwide-recall-command-brands-gel-antibac-instant-hand\n\nIn response to this letter provide the following:\n\n• A detailed investigation into how hand sanitizer drug products manufactured at your facility, and labeled as containing ethanol, were substituted in part or in whole with methanol.\n\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\n• Copies of the complete batch records for all batches distributed to the United States.\n\nDuring the July 31st teleconference you explained that you tested your ethanol API for flammability using an in-house test method. You further stated that reviewed your supplier’s certificates of analysis and that you were unaware that the ethanol supplied was contaminated with methanol. Lastly, you stated your hand sanitizer was tested by two third-party laboratories for methanol and that both laboratories found no methanol. Considering FDA test results directly contradict your assertions and demonstrate gross substitution, FDA questions the validity of all test results generated by your facility or by others on your behalf.\n\n• Provide a description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity.\n\n• In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. Also, provide a commitment to that you will test every lot of ethanol you receive for methanol content using the USP method and conducted in a laboratory that has been previously inspected by FDA and found in compliance with CGMP.\n\nThe substitution and contamination with methanol in a drug product labeled as manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.1\n\nUnapproved New Drug and Misbranding Violations\n\nCOMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C) because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic.\n\nExamples of claims observed on the COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER product label that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\nDrug Facts…Uses…Hand Sanitizer to help reduce bacteria on the skin * Recommended for repeated use…”\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your COMMAND BRANDS GEL\n\nANTIBAC INSTANT HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by the “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule).\n\nOver the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are permitted under the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER is not permitted under the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub proposed, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER purportedly contains the active ingredient ethyl alcohol (ethanol) 70%. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrated that COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER contains ethanol in a concentration that is less than the 70% stated on its product label and less than the amount of ethanol described in the 1994 TFM.2 Such a product is not permitted under the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.3\n\nFDA laboratory analyses also demonstrated that a batch of COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER contains significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not permitted under the 1994 TFM, nor is methanol included in the formulations described in FDA’s Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.4\n\nAdditionally, this methanol-containing drug product, COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER, is misbranded under sections 502(j), (a), (e) and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e) and (ee).\n\nIt is misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\n\nThis hand sanitizer is misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because its labeling is false and misleading. As noted above, COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER is labeled to contain ethanol 70% v\u002Fv. However, FDA laboratory analysis of a batch of this product demonstrate that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result . . .” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product label to disclose the presence of the methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nThe failure of this drug product to list methyl alcohol (methanol) as an ingredient on its label also causes it to be misbranded under section 502(e)(1)(A) of the FD&C Act, 21 U.S.C. 352(e)(1)(A).\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because COMMAND BRANDS GEL ANTIBAC INSTANT HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 13, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\n\nIdentify your response with FEI 3008251335and ATTN: Michael Klapal.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered US Agent\n\nZadik, Allan dba Faz Marketing\n\n13019 Debarr Dr\n\nAustin, TX 78729-7730\n\n________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol- Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution of hand sanitizer products declared or labeled as manufactured at your facility, a review of the formulations on the drug products’ labeling further indicates that such products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution denatured in accordance with Bureau of Alcohol, Tobacco and Firearms regulations. 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n3 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because Hand Sanitizer is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.\n\n4 An inactive ingredient used in OTC monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.","Roque Plast S.A. de C.V.","roque-plast-sa-de-cv-609492-04092021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Froque-plast-sa-de-cv-609492-04092021","2026-10-26T08:09:51.093766+00:00","2021-04-13","609492","Drugs","Mr. Roque Cabrera","2026-08-20T03:13:10.013+00:00","VIA UPS","2021-04-09",{"id":186,"raw":187,"subject":191,"body_html":192,"body_text":193,"firm_name":194,"letter_id":195,"created_at":43,"fei_number":19,"letter_url":196,"updated_at":197,"action_type":22,"case_status":23,"posted_date":198,"marcs_cms_no":199,"product_type":180,"closeout_date":19,"issuing_office":190,"recipient_name":200,"body_fetched_at":201,"delivery_method":183,"recipient_title":19,"reference_number":202,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1540,[188,9,189,190,191,13,13,13],"\u003Ctime datetime=\"2024-04-02T13:20:00Z\">04\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbetone-sa-de-cv-674299-03212024\">Betone S.A. de C.V.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-24-26\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Edith Parra de la Torre\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Betone S.A. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Periferico Poniente #7100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Col. Ciudad Granja\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>45010\u003C\u002Fspan> \u003Cspan>Zapopan\u003C\u002Fspan>, \u003Cspan>Jal.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-26\u003C\u002Fp>\n\n\u003Cp>March 21, 2024\u003Cbr>\n\u003Cbr>\nDear Dr. Parra de la Torre:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Betone S.A. de C.V, FEI 3016998650, at Periferico Poniente #7100, Col. Ciudad Granja, Zapopan, Jalisco 45010, from November 6 to 10, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your December 1, 2023 response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> wipe drug products. Your firm failed to adequately test your \u003Cstrong>(b)(4)\u003C\u002Fstrong> wipe drug products for the identity and strength of the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior to release and distribution.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you implemented a standard operating procedure to conduct testing for the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> in each lot of drug product. Your response is inadequate because you failed to assess drug products released without adequate testing.\u003C\u002Fp>\n\n\u003Cp>Full release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\t\u003Cli>A list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to formulate batches of your drug product with the intent to provide not less than 100% of the labeled or established amount of active ingredient (21 CFR 211.101(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to ensure that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> wipe drug products were formulated to contain the \u003Cstrong>(b)(4)\u003C\u002Fstrong> active ingredient at the labeled strength of \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Drug products must be formulated to contain the amount of active ingredient they are represented to possess.\u003C\u002Fp>\n\n\u003Cp>In your response, you confirmed that your formulation was subpotent vs the label claim, (containing \u003Cstrong>(b)(4)\u003C\u002Fstrong>% \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and that this concentration aligns with the permissible range stipulated by the FDA’s temporary guidance for \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. Your response is inadequate as FDA’s temporary guidances were not applicable to your \u003Cstrong>(b)(4)\u003C\u002Fstrong> using \u003Cstrong>(b)(4)\u003C\u002Fstrong> as the active ingredient.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, you propose changing the label and marketing the product as a \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product, but no draft labeling or timeframe for making these changes was provided.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all your drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing (including both production and packaging) operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately test your incoming components (e.g., active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and glycerin) before using the components to manufacture your \u003Cstrong>(b)(4)\u003C\u002Fstrong> wipe drug products. You also relied on your suppliers’ certificates of analysis (COA) without establishing the reliability of your suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Products Containing Glycerin\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Glycerin, along with other high-risk components, requires identification testing per the United States Pharmacopeia (USP) to ensure that it meets safety limits for diethylene glycol (DEG) or ethylene glycol (EG). Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of glycerin used in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you will send samples of components to an external laboratory for testing of DEG and EG. Your response is inadequate. You did not address testing of all other components, including identity testing, used in the manufacture of your drug products. Without appropriate testing of components, you cannot ensure the quality and safety of your drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to establish and maintain an ongoing stability testing program to support the labeled expiry on your distributed drug products. There is no assurance that your drug products will remain acceptable throughout their labeled expiry period without an ongoing stability program.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that drug product samples are sent to an external laboratory for analysis. Your response is inadequate. Your stability studies are only \u003Cstrong>(b)(4)\u003C\u002Fstrong> in duration and do not include full shelf-life studies, including testing for the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, the temperature and humidity parameters are not specifically defined for each of your proposed storage conditions.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Stability-indicating methods.\u003Cbr>\n&nbsp; &nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>\n&nbsp; &nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.&nbsp;\u003Cbr>\n&nbsp; &nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Additional Considerations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Additionally, we note that your “DODY’S Antiseptic Hand Sanitizer Wipes” drug product is marketed as “antiseptic wipes.” Antiseptic \u003Cem>wipes\u003C\u002Fem> generally refer to consumer antiseptic rub drug products that are not intended to be rinsed-off after use. However, the label for your “DODY’S Antiseptic Hand Sanitizer Wipes” also suggests that it can be used as a consumer antiseptic&nbsp;\u003Cem>wash\u003C\u002Fem>. For instance, the label states, “For hand washing to decrease bacteria on the skin.” An antiseptic wipe drug product marketed under section 505G of the FD&amp;C Act cannot also be a consumer antiseptic wash as the directions for use conflict with each other and a wipe is not an acceptable dosage form for an antiseptic wash.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Lastly, we note in your response that you are considering changing the marketing of your “DODY’S Antiseptic Hand Sanitizer Wipes” from the monograph conditions under the 1994 TFM titled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, to the monograph conditions referenced under the final Monograph “Over-the-Counter (OTC) Monograph M003: First Aid Antiseptic Drug Products for Over-the-Counter Human Use.” To help ensure that any corresponding revised labeling and product change meets the monograph conditions outlined in Section 505G of the FD&amp;C Act, it is incumbent upon your firm to retain the services of a reputable food and drug law consultant or attorney for assistance. Please note that FDA does not object to the lawful marketing of OTC products under section 505G if the product is marketed in accordance with the OTC monograph conditions AND complies with all other relevant regulations including CGMPs and general OTC drug labeling requirements. In addition, we also remind you to take a comprehensive review of your OTC drug product inventory to ensure that your OTC drug products comply with all requirements of federal laws and applicable regulations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on March 11, 2024.\u003C\u002Fp>\n\n\u003Cp>Until FDA is permitted to inspect your facility and confirms compliance with CGMP, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at Betone S.A. de C.V., Periferico Poniente #7100, Col. Ciudad Granja, Zapopan, into the United States that appear to be adulterated are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Betone S.A. de C.V., Periferico Poniente #7100, Col. Ciudad Granja, Zapopan, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3016998650 and ATTN: Joel Hustedt.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC: Registered US Agent\u003Cbr>\nMr. Carlos Jimenez\u003Cbr>\nEPort USA LLC\u003Cbr>\n4490 Via Aciando\u003Cbr>\nCamarillo, CA 93012 - 4044\u003C\u002Fp>\n\n\u003Cp>__________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including dosage form, and comply with all other applicable requirements. The permitted dosage forms for consumer antiseptic washes are set forth here: “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Proposed Rule, 78 FR 76444 (December 17, 2013) and “OTC Safety and Effectiveness of Topical Antimicrobial Drug Products for Over-the Counter Human Use,” Final Rule, 81 FR 61106 (September 6, 2016).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-24-26\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDr. Edith Parra de la Torre\n\nRecipient Title\n\nCEO\n\nBetone S.A. de C.V.\n\nPeriferico Poniente #7100\n\nCol. Ciudad Granja\n\n45010 Zapopan, Jal.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-24-26\n\nMarch 21, 2024\n\nDear Dr. Parra de la Torre:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Betone S.A. de C.V, FEI 3016998650, at Periferico Poniente #7100, Col. Ciudad Granja, Zapopan, Jalisco 45010, from November 6 to 10, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your December 1, 2023 response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYour firm manufactures over-the-counter (OTC) (b)(4) wipe drug products. Your firm failed to adequately test your (b)(4) wipe drug products for the identity and strength of the active ingredient (b)(4) prior to release and distribution.\n\nIn your response, you state that you implemented a standard operating procedure to conduct testing for the active ingredient (b)(4) in each lot of drug product. Your response is inadequate because you failed to assess drug products released without adequate testing.\n\nFull release testing, including strength and identity testing of the active ingredient, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that your drug products conform to appropriate specifications before release.\n\nIn response to this letter, provide:\n\nA comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nA list of chemical and microbial test methods and specifications used to analyze each lot of your drug product before making a lot disposition decision, and the associated written procedures.\n\n2. Your firm failed to formulate batches of your drug product with the intent to provide not less than 100% of the labeled or established amount of active ingredient (21 CFR 211.101(a)).\n\nYour firm failed to ensure that your (b)(4) wipe drug products were formulated to contain the (b)(4) active ingredient at the labeled strength of (b)(4)%. Drug products must be formulated to contain the amount of active ingredient they are represented to possess.\n\nIn your response, you confirmed that your formulation was subpotent vs the label claim, (containing (b)(4)% (b)(4)) and that this concentration aligns with the permissible range stipulated by the FDA’s temporary guidance for (b)(4) drug products. Your response is inadequate as FDA’s temporary guidances were not applicable to your (b)(4) using (b)(4) as the active ingredient.1 In addition, you propose changing the label and marketing the product as a (b)(4) drug product, but no draft labeling or timeframe for making these changes was provided.\n\nIn response to this letter, provide a remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all your drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing (including both production and packaging) operations meet appropriate parameters and quality standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\n\n3. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYou failed to adequately test your incoming components (e.g., active ingredient (b)(4), and glycerin) before using the components to manufacture your (b)(4) wipe drug products. You also relied on your suppliers’ certificates of analysis (COA) without establishing the reliability of your suppliers’ test analyses at appropriate intervals.\n\nProducts Containing Glycerin\n\nGlycerin, along with other high-risk components, requires identification testing per the United States Pharmacopeia (USP) to ensure that it meets safety limits for diethylene glycol (DEG) or ethylene glycol (EG). Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of glycerin used in the manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn your response, you state that you will send samples of components to an external laboratory for testing of DEG and EG. Your response is inadequate. You did not address testing of all other components, including identity testing, used in the manufacture of your drug products. Without appropriate testing of components, you cannot ensure the quality and safety of your drug products.\n\nIn response to this letter, provide:\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of your drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your suppliers’ results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n4. Your firm failed to assure that the drug product bore an expiration date that was supported by appropriate stability testing (21 CFR 211.137(a)).\n\nYou failed to establish and maintain an ongoing stability testing program to support the labeled expiry on your distributed drug products. There is no assurance that your drug products will remain acceptable throughout their labeled expiry period without an ongoing stability program.\n\nIn your response, you state that drug product samples are sent to an external laboratory for analysis. Your response is inadequate. Your stability studies are only (b)(4) in duration and do not include full shelf-life studies, including testing for the active ingredient (b)(4). In addition, the temperature and humidity parameters are not specifically defined for each of your proposed storage conditions.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability-indicating methods.\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\n\no Detailed definition of the specific attributes to be tested at each station (timepoint).\n\nAll procedures that describe these and other elements of your remediated stability program.\n\nAdditional Considerations\n\nAdditionally, we note that your “DODY’S Antiseptic Hand Sanitizer Wipes” drug product is marketed as “antiseptic wipes.” Antiseptic wipes generally refer to consumer antiseptic rub drug products that are not intended to be rinsed-off after use. However, the label for your “DODY’S Antiseptic Hand Sanitizer Wipes” also suggests that it can be used as a consumer antiseptic wash. For instance, the label states, “For hand washing to decrease bacteria on the skin.” An antiseptic wipe drug product marketed under section 505G of the FD&C Act cannot also be a consumer antiseptic wash as the directions for use conflict with each other and a wipe is not an acceptable dosage form for an antiseptic wash.2\n\nLastly, we note in your response that you are considering changing the marketing of your “DODY’S Antiseptic Hand Sanitizer Wipes” from the monograph conditions under the 1994 TFM titled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, to the monograph conditions referenced under the final Monograph “Over-the-Counter (OTC) Monograph M003: First Aid Antiseptic Drug Products for Over-the-Counter Human Use.” To help ensure that any corresponding revised labeling and product change meets the monograph conditions outlined in Section 505G of the FD&C Act, it is incumbent upon your firm to retain the services of a reputable food and drug law consultant or attorney for assistance. Please note that FDA does not object to the lawful marketing of OTC products under section 505G if the product is marketed in accordance with the OTC monograph conditions AND complies with all other relevant regulations including CGMPs and general OTC drug labeling requirements. In addition, we also remind you to take a comprehensive review of your OTC drug product inventory to ensure that your OTC drug products comply with all requirements of federal laws and applicable regulations.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on March 11, 2024.\n\nUntil FDA is permitted to inspect your facility and confirms compliance with CGMP, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at Betone S.A. de C.V., Periferico Poniente #7100, Col. Ciudad Granja, Zapopan, into the United States that appear to be adulterated are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Betone S.A. de C.V., Periferico Poniente #7100, Col. Ciudad Granja, Zapopan, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3016998650 and ATTN: Joel Hustedt.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC: Registered US Agent\n\nMr. Carlos Jimenez\n\nEPort USA LLC\n\n4490 Via Aciando\n\nCamarillo, CA 93012 - 4044\n\n__________________\n\n1 (b)(4)\n\n2 Section 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including dosage form, and comply with all other applicable requirements. The permitted dosage forms for consumer antiseptic washes are set forth here: “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use,” Proposed Rule, 78 FR 76444 (December 17, 2013) and “OTC Safety and Effectiveness of Topical Antimicrobial Drug Products for Over-the Counter Human Use,” Final Rule, 81 FR 61106 (September 6, 2016).","Betone S.A. de C.V.","betone-sa-de-cv-674299-03212024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbetone-sa-de-cv-674299-03212024","2026-10-26T08:08:03.845758+00:00","2024-04-02","674299","Dr. Edith Parra de la Torre","2026-08-20T00:12:19.066+00:00","320-24-26",{"id":204,"raw":205,"subject":191,"body_html":209,"body_text":210,"firm_name":211,"letter_id":212,"created_at":213,"fei_number":19,"letter_url":214,"updated_at":215,"action_type":22,"case_status":23,"posted_date":216,"marcs_cms_no":217,"product_type":180,"closeout_date":19,"issuing_office":190,"recipient_name":218,"body_fetched_at":219,"delivery_method":220,"recipient_title":19,"reference_number":19,"action_taken_date":221,"medical_device_id":19,"response_letter_date":19},2122,[206,207,208,190,191,13,13,13],"\u003Ctime datetime=\"2023-04-25T13:20:00Z\">04\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-04-13T04:00:00Z\">04\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmaplast-sae-648883-04132023\">Pharmaplast S.A.E.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Wassim Attia\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President of Quality\u002FRegulatory\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Pharmaplast S.A.E.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Amria Free Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>30 Beside Lord International Factory Building\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alexandria Governorate\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>21599\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Egypt\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:wasim.gad@pharmaplast-online.com\"> wasim.gad@pharmaplast-online.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-23-14\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 13, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Attia:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Pharmaplast S.A.E., FEI 3003767891, at Amria Free Zone, 30 Beside Lord International Factory Building, Alexandria from November 6 to November 10, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your December 11, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to perform adequate identity testing for each component lot used in the production of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products, including ethanol, your active pharmaceutical ingredient (API). Additionally, your API, ethanol, is not tested for methanol content, and your procedures did not ensure that you test glycerin for presence of diethylene glycol (DEG) or ethylene glycol (EG). For example, you failed to test your incoming components for identity prior to manufacturing \u003Cstrong>(b)(4)\u003C\u002Fstrong> Gel, batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n\u003Cbr>\nComponent testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your incoming components conform to appropriate specifications before use in the manufacture of drug products.\u003C\u002Fp>\n\n\u003Cp>In your response, you provide a corrective action and preventive action (CAPA) that states samples of your raw materials in your warehouse will be tested for conformance to the supplier’s certificate of analysis (COA). You also state that glycerin will be tested for DEG and EG.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because it fails to include a detailed plan for how raw materials will be tested such as test method and review of compendial requirements. Your proposed action plan does not include a strategy to implement corrective actions. Also, you do not provide a detailed plan to ensure that previously distributed drug products were manufactured with incoming components that meet the identity and impurity testing requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Products Contain Glycerin\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture drugs that contain glycerin. The use of glycerin contaminated with diethylene glycol (DEG) has resulted in various lethal poisoning incidents in humans worldwide.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Testing of Glycerin for Diethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing glycerin at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-diethylene-glycol\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-diethylene-glycol\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Products Contain Ethanol\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19)\u003C\u002Fem> at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>Results of tests for DEG and EG in retain samples of all glycerin lots used to manufacture your drug products.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that contain glycerin and are within expiry in the U.S. market. Take prompt corrective actions and preventive actions and detail your future actions to ensure appropriate selection of your suppliers, ongoing scrutiny of their supply chain, and appropriate incoming lot controls.\u003C\u002Fli>\n\t\u003Cli>Limit test of methanol and test results for all \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches released and distributed.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to include all pieces of product-contact equipment used for manufacturing your drug and device products in your cleaning validation protocols and procedures. Your cleaning validation protocols and procedures did not include the transfer carriage vessels that are used for moving drug and chemical device component during manufacturing, creating a risk of cross contamination.\u003C\u002Fp>\n\n\u003Cp>In your response, you provide a CAPA and cleaning validation for the transfer carriage vessel. Your CAPA contains a list of products evaluated for use of the transfer carriage vessel.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because the list of products provided in the CAPA contained products without “orders” and therefore lacks a complete evaluation of all possible uses of the transfer carriage vessel. You state that \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished products are the worst-case product to clean. Your response, however, does not provide information on products listed in your CAPA without “orders,” whether those products use the transfer carriage vessel, and what impact those products had on your worst-case product selection.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003Cbr>\n\u003Cbr>\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on April 4, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Pharmaplast S.A.E., Amria Free Zone, 30 Beside Lord International Factory Building, Alexandria into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003767891 and ATTN: Sarah Rhoades, Compliance Officer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Wassim Attia\n\nRecipient Title\n\nVice President of Quality\u002FRegulatory\n\nPharmaplast S.A.E.\n\nAmria Free Zone\n\n30 Beside Lord International Factory Building\n\nAlexandria Governorate\n\n21599\n\nEgypt\n\nwasim.gad@pharmaplast-online.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-14\n\nApril 13, 2023\n\nDear Mr. Attia:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Pharmaplast S.A.E., FEI 3003767891, at Amria Free Zone, 30 Beside Lord International Factory Building, Alexandria from November 6 to November 10, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your December 11, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and (2)).\n\nYou failed to perform adequate identity testing for each component lot used in the production of your (b)(4) drug products, including ethanol, your active pharmaceutical ingredient (API). Additionally, your API, ethanol, is not tested for methanol content, and your procedures did not ensure that you test glycerin for presence of diethylene glycol (DEG) or ethylene glycol (EG). For example, you failed to test your incoming components for identity prior to manufacturing (b)(4) Gel, batch (b)(4).\n\nComponent testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your incoming components conform to appropriate specifications before use in the manufacture of drug products.\n\nIn your response, you provide a corrective action and preventive action (CAPA) that states samples of your raw materials in your warehouse will be tested for conformance to the supplier’s certificate of analysis (COA). You also state that glycerin will be tested for DEG and EG.\n\nYour response is inadequate because it fails to include a detailed plan for how raw materials will be tested such as test method and review of compendial requirements. Your proposed action plan does not include a strategy to implement corrective actions. Also, you do not provide a detailed plan to ensure that previously distributed drug products were manufactured with incoming components that meet the identity and impurity testing requirements.\n\nProducts Contain Glycerin\n\nYou manufacture drugs that contain glycerin. The use of glycerin contaminated with diethylene glycol (DEG) has resulted in various lethal poisoning incidents in humans worldwide.\n\nSee FDA’s guidance document Testing of Glycerin for Diethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing glycerin at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Ftesting-glycerin-diethylene-glycol.\n\nProducts Contain Ethanol\n\nYou manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide.\n\nSee FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19) at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F145262\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nResults of tests for DEG and EG in retain samples of all glycerin lots used to manufacture your drug products.\n\nA full risk assessment for drug products that contain glycerin and are within expiry in the U.S. market. Take prompt corrective actions and preventive actions and detail your future actions to ensure appropriate selection of your suppliers, ongoing scrutiny of their supply chain, and appropriate incoming lot controls.\n\nLimit test of methanol and test results for all (b)(4) batches released and distributed.\n\n2. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nYou failed to include all pieces of product-contact equipment used for manufacturing your drug and device products in your cleaning validation protocols and procedures. Your cleaning validation protocols and procedures did not include the transfer carriage vessels that are used for moving drug and chemical device component during manufacturing, creating a risk of cross contamination.\n\nIn your response, you provide a CAPA and cleaning validation for the transfer carriage vessel. Your CAPA contains a list of products evaluated for use of the transfer carriage vessel.\n\nYour response is inadequate because the list of products provided in the CAPA contained products without “orders” and therefore lacks a complete evaluation of all possible uses of the transfer carriage vessel. You state that (b)(4) and (b)(4) finished products are the worst-case product to clean. Your response, however, does not provide information on products listed in your CAPA without “orders,” whether those products use the transfer carriage vessel, and what impact those products had on your worst-case product selection.\n\nIn response to this letter, provide:\n\nA detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\nA summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on April 4, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Pharmaplast S.A.E., Amria Free Zone, 30 Beside Lord International Factory Building, Alexandria into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3003767891 and ATTN: Sarah Rhoades, Compliance Officer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","Pharmaplast S.A.E.","pharmaplast-sae-648883-04132023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpharmaplast-sae-648883-04132023","2026-10-26T08:09:41.440758+00:00","2023-04-25","648883","Mr. Wassim Attia","2026-08-20T01:08:39.944+00:00","VIA Electronic Mail","2023-04-13",{"id":223,"raw":224,"subject":12,"body_html":228,"body_text":229,"firm_name":230,"letter_id":231,"created_at":63,"fei_number":19,"letter_url":232,"updated_at":233,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":234,"product_type":26,"closeout_date":19,"issuing_office":227,"recipient_name":235,"body_fetched_at":236,"delivery_method":237,"recipient_title":19,"reference_number":19,"action_taken_date":238,"medical_device_id":19,"response_letter_date":19},876,[54,225,226,227,12,13,13,13],"\u003Ctime datetime=\"2024-12-23T05:00:00Z\">12\u002F23\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frey-de-los-camarones-s-695816-12232024\">Rey de los Camarones S. A.\u003C\u002Fa>","Human Foods Program","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jianwei Rong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u002FOwner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Rey de los Camarones S. A.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Kilometer 9 Of The New Road to Leon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>In Front of the New York Motel, Barrio Xavier Gruta\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ciudad Sandino\u003C\u002Fspan>, \u003Cspan>Managua\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nicaragua\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 23, 2024\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: # 695816\u003C\u002Fp>\u003Cp>Dear Mr. Jianwei Rong:\u003C\u002Fp>\u003Cp>On August 26, 2024 through August 30, 2024, the United States Food and Drug Administration (FDA) conducted a Foreign Remote Regulatory Assessment (FRRA) inspection of your seafood processing facility, located at Kilometer 9 Of The New Road to Leon, In Front of the New York Motel, Barrio Xavier Gruta Ciudad Sandino, Managua, Nicaragua. During our assessment of your facility, the FDA investigators found serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123. To date, we have not received a response to the observations provided to you at the close of the assessment.\u003C\u002Fp>\u003Cp>In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your dried and salted sea cucumber products, are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the 4th Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>Your significant violations were as follows:\u003C\u002Fp>\u003Cp>1. You must conduct a hazard analysis to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the critical control points, to comply with 21 CFR 123.6(a) and (c)(2). A critical control point is defined in 21 CFR 123.3 (b) as a “point, step, or procedure in a food process at which control can be applied and a food safety hazard can as a result be prevented, eliminated, or reduced to acceptable levels.” However, your HACCP plan for dried sea cucumber does not list one or more critical control points (CCP) that are necessary for each of the identified food safety hazards. Specifically, your HACCP plan for dried sea cucumber does include a CCP for drying of sea cucumber.\u003C\u002Fp>\u003Cp>Your hazard analysis for dried sea cucumber states that the hazard of biological pathogen growth at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> step requires a CCP to control this hazard. However, your HACCP plan does not identify a CCP for drying. Your firm dries sea cucumbers at either: a) \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C (\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F - \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F) for \u003Cstrong>(b)(4)\u003C\u002Fstrong> days in a drying room; or b) on plastic screens in the sun for \u003Cstrong>(b)(4)\u003C\u002Fstrong> days on the roof of the facility during the summer. Your firm relies on sensory examinations of the sea cucumber after drying to determine when they are adequately dried, and you do not perform any water activity level testing of the finished product. Your firm did not have any studies performed or supporting documentation showing that these drying procedures are adequate to control relevant biological pathogens. You distribute your finished dried sea cucumber product at ambient temperatures to the U.S. with a shelf-life of \u003Cstrong>(b)(4)\u003C\u002Fstrong> months. Your HACCP plan should include a CCP at the Drying step to control the hazard of pathogenic bacteria growth and toxin formation, including Staphylococcus aureus.\u003C\u002Fp>\u003Cp>Drying the product sufficiently to reduce the water activity to \u003Cstrong>(b)(4)\u003C\u002Fstrong> or below is critical to obtaining a safe final product. This value is based on the minimum water activity for toxin formation of \u003Cem>Staphylococcus aureus\u003C\u002Fem>. Achieving the above-mentioned water activity will also inhibit the growth of other microbiological hazards. Your firm should establish the drying parameters utilizing a scientific validation study to ensure that the final product will consistently achieve a water activity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or below. Once all the parameters are validated, the critical factors for achieving the established water activity of less than 0.85 should be included as Critical Limits in the HACCP plan.\u003C\u002Fp>\u003Cp>In addition to achieving a safe water activity in your finished product, you must implement time and temperature controls to prevent \u003Cem>Staphylococcus aureuss\u003C\u002Fem> growth and toxin formation prior to achieving a water activity of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. FDA recommends that processing temperatures be maintained below 10°C (50°F) during processing and stored under refrigeration, either surrounded by ice or maintained below 4.4°C (40°F). In the absence of refrigeration, exposure to uncontrolled temperatures should be limited to 3 hours cumulatively if ambient temperatures exceed 21°C (70°F) at any point. When temperatures remain between 10°C (50°F) and 21°C (70°F) safe exposure times can be extended to 12 hours cumulatively.\u003C\u002Fp>\u003Cp>2. You must implement the monitoring procedures and frequency that you have listed in your HACCP plan, to comply with 21 CFR 123.6(b) and (c)(4). However, your firm did not follow the monitoring procedures of monitoring the location and status of the fishing areas for each batch of sea cucumbers that you receive by asking the fisherman about the fishing areas and checking with state and local authorities about the status of the areas at the Raw Material CCP to control environmental chemicals and pesticides listed in your HACCP plan for dried sea cucumber that you export to the U.S. The HACCP plan states that these monitoring procedures will be documented on the Reception Record. The HACCP plan also states that the firm will receive an INPESCA Letter that informs the firm that there is no pollution of marine waters where the sea cucumbers were obtained. A review of your firm’s Registro de Recepcion de Pepino de Mar (Registro de monitoreo de PCC) for sea cucumber that were received at your firm on 6\u002F2\u002F24 and 6\u002F7\u002F24, and later dried and exported to the U.S., indicated that you were only documenting an organoleptic exam of incoming sea cucumber and no information about the monitoring of the status of the fishing areas with the fisherman or state and local authorities was performed or documented. This document is the only record used to monitor the performance of this CCP. During the assessment, you were not able to provide copies of any of these INPESCA letters showing that the sea cucumbers were obtained from safe marine waters.\u003C\u002Fp>\u003Cp>You should respond in writing within (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these violations. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you do not believe that your products are in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your dried and salted sea cucumber products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. Imports alerts can be found on FDA’s web site www.FDA.gov.\u003C\u002Fp>\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the CGMP &amp; PC rule (21 CFR Part 117) and Seafood HACCP regulation (21 CFR Part 123). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Rosemary Sexton, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Rosemary Sexton via email at: Rosemary.Sexton@fda.hhs.gov. Please include reference # 695816 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, J.D., M.B.A\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Jianwei Rong\n\nRecipient Title\n\nGeneral Manager\u002FOwner\n\nRey de los Camarones S. A.\n\nKilometer 9 Of The New Road to Leon\n\nIn Front of the New York Motel, Barrio Xavier Gruta\n\nCiudad Sandino, Managua\n\nNicaragua\n\n(b)(6)\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nDecember 23, 2024\nWARNING LETTER\nRe: # 695816\nDear Mr. Jianwei Rong:\nOn August 26, 2024 through August 30, 2024, the United States Food and Drug Administration (FDA) conducted a Foreign Remote Regulatory Assessment (FRRA) inspection of your seafood processing facility, located at Kilometer 9 Of The New Road to Leon, In Front of the New York Motel, Barrio Xavier Gruta Ciudad Sandino, Managua, Nicaragua. During our assessment of your facility, the FDA investigators found serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 123. To date, we have not received a response to the observations provided to you at the close of the assessment.\nIn accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your dried and salted sea cucumber products, are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the 4th Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\nYour significant violations were as follows:\n1. You must conduct a hazard analysis to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at a minimum, lists the critical control points, to comply with 21 CFR 123.6(a) and (c)(2). A critical control point is defined in 21 CFR 123.3 (b) as a “point, step, or procedure in a food process at which control can be applied and a food safety hazard can as a result be prevented, eliminated, or reduced to acceptable levels.” However, your HACCP plan for dried sea cucumber does not list one or more critical control points (CCP) that are necessary for each of the identified food safety hazards. Specifically, your HACCP plan for dried sea cucumber does include a CCP for drying of sea cucumber.\nYour hazard analysis for dried sea cucumber states that the hazard of biological pathogen growth at the (b)(4) step requires a CCP to control this hazard. However, your HACCP plan does not identify a CCP for drying. Your firm dries sea cucumbers at either: a) (b)(4)°C ((b)(4)°F - (b)(4)°F) for (b)(4) days in a drying room; or b) on plastic screens in the sun for (b)(4) days on the roof of the facility during the summer. Your firm relies on sensory examinations of the sea cucumber after drying to determine when they are adequately dried, and you do not perform any water activity level testing of the finished product. Your firm did not have any studies performed or supporting documentation showing that these drying procedures are adequate to control relevant biological pathogens. You distribute your finished dried sea cucumber product at ambient temperatures to the U.S. with a shelf-life of (b)(4) months. Your HACCP plan should include a CCP at the Drying step to control the hazard of pathogenic bacteria growth and toxin formation, including Staphylococcus aureus.\nDrying the product sufficiently to reduce the water activity to (b)(4) or below is critical to obtaining a safe final product. This value is based on the minimum water activity for toxin formation of Staphylococcus aureus. Achieving the above-mentioned water activity will also inhibit the growth of other microbiological hazards. Your firm should establish the drying parameters utilizing a scientific validation study to ensure that the final product will consistently achieve a water activity of (b)(4) or below. Once all the parameters are validated, the critical factors for achieving the established water activity of less than 0.85 should be included as Critical Limits in the HACCP plan.\nIn addition to achieving a safe water activity in your finished product, you must implement time and temperature controls to prevent Staphylococcus aureuss growth and toxin formation prior to achieving a water activity of (b)(4). FDA recommends that processing temperatures be maintained below 10°C (50°F) during processing and stored under refrigeration, either surrounded by ice or maintained below 4.4°C (40°F). In the absence of refrigeration, exposure to uncontrolled temperatures should be limited to 3 hours cumulatively if ambient temperatures exceed 21°C (70°F) at any point. When temperatures remain between 10°C (50°F) and 21°C (70°F) safe exposure times can be extended to 12 hours cumulatively.\n2. You must implement the monitoring procedures and frequency that you have listed in your HACCP plan, to comply with 21 CFR 123.6(b) and (c)(4). However, your firm did not follow the monitoring procedures of monitoring the location and status of the fishing areas for each batch of sea cucumbers that you receive by asking the fisherman about the fishing areas and checking with state and local authorities about the status of the areas at the Raw Material CCP to control environmental chemicals and pesticides listed in your HACCP plan for dried sea cucumber that you export to the U.S. The HACCP plan states that these monitoring procedures will be documented on the Reception Record. The HACCP plan also states that the firm will receive an INPESCA Letter that informs the firm that there is no pollution of marine waters where the sea cucumbers were obtained. A review of your firm’s Registro de Recepcion de Pepino de Mar (Registro de monitoreo de PCC) for sea cucumber that were received at your firm on 6\u002F2\u002F24 and 6\u002F7\u002F24, and later dried and exported to the U.S., indicated that you were only documenting an organoleptic exam of incoming sea cucumber and no information about the monitoring of the status of the fishing areas with the fisherman or state and local authorities was performed or documented. This document is the only record used to monitor the performance of this CCP. During the assessment, you were not able to provide copies of any of these INPESCA letters showing that the sea cucumbers were obtained from safe marine waters.\nYou should respond in writing within (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these violations. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you do not believe that your products are in violation of the Act, include your reasoning and any supporting information for our consideration.\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your dried and salted sea cucumber products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. Imports alerts can be found on FDA’s web site www.FDA.gov.\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the CGMP & PC rule (21 CFR Part 117) and Seafood HACCP regulation (21 CFR Part 123). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\nPlease send your reply to the Food and Drug Administration, Attention: Rosemary Sexton, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Rosemary Sexton via email at: Rosemary.Sexton@fda.hhs.gov. Please include reference # 695816 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, J.D., M.B.A\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Rey de los Camarones S. A.","rey-de-los-camarones-s-695816-12232024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frey-de-los-camarones-s-695816-12232024","2026-10-26T08:09:49.37689+00:00","695816","Mr. Jianwei Rong","2026-08-19T16:44:37.027+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2024-12-23",{"id":240,"raw":241,"subject":245,"body_html":247,"body_text":248,"firm_name":249,"letter_id":250,"created_at":251,"fei_number":19,"letter_url":252,"updated_at":253,"action_type":22,"case_status":119,"posted_date":254,"marcs_cms_no":255,"product_type":180,"closeout_date":256,"issuing_office":190,"recipient_name":257,"body_fetched_at":258,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":259,"medical_device_id":19,"response_letter_date":19},2636,[242,243,244,190,245,13,246,13],"\u003Ctime datetime=\"2022-05-31T13:20:00Z\">05\u002F31\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-23T04:00:00Z\">05\u002F23\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgrimann-sa-de-cv-632272-05232022\">Grimann S.A. de C.V. \u003C\u002Fa>","Failure to Comply with Drug Registration and Listing Requirements","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgrimann-sa-de-cv-632272-06032022\">\u003Ctime datetime=\"2022-06-24T04:00:00Z\">06\u002F24\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Esther Gonzalez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Grimann S.A. de C.V. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Circuito Nemesio Diez Riega No. 11\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lerma (P. Industrial El Cerrillo II)\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>52250\u003C\u002Fspan> \u003Cspan>Lerma\u003C\u002Fspan>, \u003Cspan>Méx.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>May 23, 2022\u003C\u002Fp>\n\n\u003Cp>RE: WL 2257\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Gonzalez:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has reviewed your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug product, Derofen Miel, NDC 81660-435. Our review determined that your firm has submitted contradictory information between the labeling and the electronic listing file. As such, your firm is in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) as explained below.\u003C\u002Fp>\n\n\u003Cp>We refer you to FDA’s drug listing deficiency letter notification dated October 18, 2021, describing several observed listing deficiencies in the information you submitted. We also refer you to FDA’s data removal email notification sent on December 2, 2021, informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s Online NDC Directory.\u003C\u002Fp>\n\n\u003Cp>Section 510(j) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and 21 CFR Part 207 outline the requirements for registration and listing of drug products. In the case of, Derofen Miel NDC 81660-435, the listing includes several deficiencies as outlined below:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The listing file for Derofen Miel, NDC 81660-435, must include the name and quantity of each active pharmaceutical ingredient as required under section 510 j(1)(C) and 21 CFR 207.49(a)(4). In the listing file submitted for Derofen Miel, NDC 81660-435, the active ingredients included in the labeling do not match the active ingredient included in the electronic listing file (SPL). Specifically, the active ingredients described on the carton label are dextromethorphan and guaifenesin, while the active ingredient included in the electronic listing file is propylene glycol.\u003C\u002Fli>\n\t\u003Cli>Section 510(j)(1)(B)(i) and the listing requirements under 21 CFR 207.49 (a)(15)(ii) also state that all current labeling except that only one representative container or carton label need to be submitted where differences exist only in the quantity of contents statement or the bar code. Therefore, the submitted labeling for the listed product needs to appropriately represent the current product. The review of the listing for Derofen Miel, NDC 81660-435, also revealed that the image uploaded into the FDA’s electronic Drug Registration and Listing System (eDRLS) does not appear to be an image of your product’s label. Specifically, the carton label refers to a syrup containing dextromethorphan and guaifenesin, but the Drug Facts section of the labeling includes loratadine tablets indicated for allergic rhinitis, while the listing SPL refers to propylene glycol as active ingredient.\u003C\u002Fli>\n\t\u003Cli>Additionally, under section 510(j) of the FD&amp;C Act, and the drug listing requirements under 207.49 (a)(2), the package type and volume information should correspond to the package code segment of the NDC. For your product Derofen Miel, NDC 81660-435, the package description found in the labeling does not match the description found in the packaging section of the electronic listing file, specifically, the carton label image includes the size as 118 ml, while the electronic listing file includes the size as 1 U in 1 bottle.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&amp;C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). In addition, failure to properly list a drug with FDA also renders it misbranded under section 502(o) of the FD&amp;C Act, and in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 352(o) and 331(a).\u003C\u002Fp>\n\n\u003Cp>Complete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\n\n\u003Cp>We note that this warning letter only addresses registration and listing issues associated with your product. It is not intended to be an all-inclusive statement of violations that may exist in connection with your product. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the product into compliance.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number, “2257” on all correspondence.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCarolyn E. Becker J.D.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nEsther Gonzalez\n\nGrimann S.A. de C.V.\n\nCircuito Nemesio Diez Riega No. 11\n\nLerma (P. Industrial El Cerrillo II)\n\n52250 Lerma, Méx.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nMay 23, 2022\n\nRE: WL 2257\n\nDear Ms. Gonzalez:\n\nThe United States Food and Drug Administration (FDA) has reviewed your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug product, Derofen Miel, NDC 81660-435. Our review determined that your firm has submitted contradictory information between the labeling and the electronic listing file. As such, your firm is in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as explained below.\n\nWe refer you to FDA’s drug listing deficiency letter notification dated October 18, 2021, describing several observed listing deficiencies in the information you submitted. We also refer you to FDA’s data removal email notification sent on December 2, 2021, informing you of a data removal action. As stated in this email, the continued deficiencies resulted in your product’s data removal from FDA’s Online NDC Directory.\n\nSection 510(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and 21 CFR Part 207 outline the requirements for registration and listing of drug products. In the case of, Derofen Miel NDC 81660-435, the listing includes several deficiencies as outlined below:\n\nThe listing file for Derofen Miel, NDC 81660-435, must include the name and quantity of each active pharmaceutical ingredient as required under section 510 j(1)(C) and 21 CFR 207.49(a)(4). In the listing file submitted for Derofen Miel, NDC 81660-435, the active ingredients included in the labeling do not match the active ingredient included in the electronic listing file (SPL). Specifically, the active ingredients described on the carton label are dextromethorphan and guaifenesin, while the active ingredient included in the electronic listing file is propylene glycol.\n\nSection 510(j)(1)(B)(i) and the listing requirements under 21 CFR 207.49 (a)(15)(ii) also state that all current labeling except that only one representative container or carton label need to be submitted where differences exist only in the quantity of contents statement or the bar code. Therefore, the submitted labeling for the listed product needs to appropriately represent the current product. The review of the listing for Derofen Miel, NDC 81660-435, also revealed that the image uploaded into the FDA’s electronic Drug Registration and Listing System (eDRLS) does not appear to be an image of your product’s label. Specifically, the carton label refers to a syrup containing dextromethorphan and guaifenesin, but the Drug Facts section of the labeling includes loratadine tablets indicated for allergic rhinitis, while the listing SPL refers to propylene glycol as active ingredient.\n\nAdditionally, under section 510(j) of the FD&C Act, and the drug listing requirements under 207.49 (a)(2), the package type and volume information should correspond to the package code segment of the NDC. For your product Derofen Miel, NDC 81660-435, the package description found in the labeling does not match the description found in the packaging section of the electronic listing file, specifically, the carton label image includes the size as 118 ml, while the electronic listing file includes the size as 1 U in 1 bottle.\n\nTherefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). In addition, failure to properly list a drug with FDA also renders it misbranded under section 502(o) of the FD&C Act, and in violation of section 301(a) of the FD&C Act, 21 U.S.C. 352(o) and 331(a).\n\nComplete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply chain security, and post-market surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\n\nWe note that this warning letter only addresses registration and listing issues associated with your product. It is not intended to be an all-inclusive statement of violations that may exist in connection with your product. Your firm should investigate and determine the causes of any violations and take prompt actions to correct the violations and bring the product into compliance.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. In absence of a corrective action, the deficient listing data will not be available for certification under 21 CFR 207.57(b)(2) requirements and will be ultimately inactivated by FDA. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to eDRLS@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at eDRLS@fda.hhs.gov. for further assistance. Include the case identification number, “2257” on all correspondence.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker J.D.","Grimann S.A. de C.V.","grimann-sa-de-cv-632272-05232022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgrimann-sa-de-cv-632272-05232022","2026-10-26T08:08:50.550288+00:00","2022-05-31","632272","2022-06-24","Esther Gonzalez","2026-08-20T01:51:32.537+00:00","2022-05-23",{"id":261,"raw":262,"subject":79,"body_html":266,"body_text":267,"firm_name":268,"letter_id":269,"created_at":251,"fei_number":19,"letter_url":270,"updated_at":271,"action_type":22,"case_status":23,"posted_date":272,"marcs_cms_no":273,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":274,"body_fetched_at":275,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":276,"medical_device_id":19,"response_letter_date":19},2614,[263,264,265,11,79,13,13,13],"\u003Ctime datetime=\"2022-06-28T13:20:00Z\">06\u002F28\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-06-17T04:00:00Z\">06\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fconservas-ortiz-sa-634440-06172022\">Conservas Ortiz S.A.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Santiago Ortiz de Zarate\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Conservas Ortiz S.A.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Poligono Industrial La Estacion\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Basusta Bidea, 15\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>20750\u003C\u002Fspan> \u003Cspan>Zumaia\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Spain\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:murdangarin@ortiz.es\"> murdangarin@ortiz.es\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 17, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Reference # 634440\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Santiago Ortiz de Zarate:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your seafood\u002Flowacid canned food (LACF) processing facility, located at Inaki Deuna, 15, Ondarroa, Bizkaia, 48700 Spain, on February 14 through 16, 2022. During the inspection, we found that you had serious violations of the Seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). That inspection resulted in FDA’s issuance of an FDA‐483, Inspectional Observations, listing the deviations found at your firm at the conclusion of the inspection. On March 8, 2022 and April 11, 2022, you responded to the observations issued to your facility on February 16, 2022. Your responses included an updated HACCP plan, HACCP monitoring and verification records, and LACF records which were reviewed and addressed below.\u003C\u002Fp>\n\n\u003Cp>In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your canned tuna products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the 4th Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Your significant deviation is as follows:\u003Cbr>\n1. You must conduct a Hazard Analysis to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at minimum, lists the critical control points, to comply with 21 CFR 123.6(c)(2). A critical control point is defined in 21 CFR 123.3(b) as a “point, step, or procedure in a food process at which control can be applied and a food safety hazard can as a result be prevented, eliminated, or reduced to acceptable levels”. However, your firm’s HACCP plan for “CANNED TUNA PRODUCTS” does not list critical control points for the following processing steps:\u003C\u002Fp>\n\n\u003Cp>a. At the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step after the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step to control the food safety hazard of scombrotoxin (histamine) formation. During processing of scombrotoxin‐forming fish or fishery products that have been (1) previously frozen or (2) heat processed sufficiently to destroy scombrotoxin‐forming bacteria, FDA recommends:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. That the fish are not exposed to ambient temperatures above 40°F (4.4°C) for more than 12 hours, cumulatively, if any portion of that time is at temperatures above 70°F (21.1°C).\u003Cbr>\nOR\u003Cbr>\n&nbsp; ii. That the fish are not exposed to ambient temperatures above 40°F (4.4°C) for more than 24 hours, cumulatively, so long as no portion of that time is at temperatures above 70°F (21.1°C).\u003C\u002Fp>\n\n\u003Cp>We acknowledge that your firm has established a critical limit of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>°C” at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step. However, per the cited reference “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” this temperature is only sufficient to “pause subsequent histamine formation for 12 to 18 h,” not to eliminate histamine formation.\u003C\u002Fp>\n\n\u003Cp>b. At the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” steps up until the retort comes up temperatures to control the food safety hazard of&nbsp;\u003Cem>Staphylococcus aureus\u003C\u002Fem> growth and toxin formation. For product handling after cooking, FDA recommends the following:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. If at any time the product is held at internal temperatures above 80°F (26.7°C), exposure time should be limited to 3 hours.\u003Cbr>\nOR\u003Cbr>\n&nbsp; ii. If at any time the product is held at internal temperatures above 70°F (21.1°C) but never above 80°F (26.7°C), exposure time should be limited to 3 hours.\u003Cbr>\nOR\u003Cbr>\n&nbsp; iii. If at any time the product is held at internal temperatures above 50°F (10°C) but never above 70°F (21.1°C), exposure time should be limited to 5 hours.\u003C\u002Fp>\n\n\u003Cp>2. You must have a HACCP Plan that, that at minimum, lists the critical limits that must be met, to comply with 21 CFR 123.6(c)(3). A critical limit is defined in 21 CFR 123.3(c) as “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard.” However, your firm’s HACCP plan for “CANNED TUNA PRODUCTS” does not list a critical limit at the “Fresh Fish and Frozen Fish reception CCP1 and CCP3” critical control point to control the food safety hazard of scombrotoxin (histamine) formation.\u003C\u002Fp>\n\n\u003Cp>Specifically, your HACCP plan does not list a critical limit for measuring internal fish temperatures at the time the fish are offloaded from the harvest vessel. We acknowledge your HACCP plan does include the critical limit of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>°C refrigerated fish \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C (\u003Cstrong>(b)(4)\u003C\u002Fstrong>°C in case of brine frozen whole round fish).” However, this critical limit appears to apply to the fish temperatures at the time they are received at the processing facility. For primary processors offloading at the dock and then transporting fish to the processing facility, it may be necessary to select more than one control strategy in order to fully control the hazard. In addition to your listed critical limits for sensory exams, histamine analyses, and temperature measurements when the fish arrive at the processing facility, FDA also recommends the following critical limits for fish internal temperatures at the time fish are offloaded from the harvest vessel:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. For fish held iced or refrigerated (not frozen) onboard the vessel 24 or more hours after death, the internal temperatures should be 40°F (4.4°C) or below.\u003Cbr>\nOR\u003Cbr>\n&nbsp; ii. For fish held iced or refrigerated (not frozen) onboard the vessel from 15 to less than 24 hours after death, the internal temperature should be 50°F (10°C) or below.\u003Cbr>\nOR\u003Cbr>\n&nbsp; iii. For fish held iced or refrigerated (not frozen) onboard the vessel from 12 to less than 15 hours after death, the internal temperature should be 60°F (15.6°C) or below.\u003Cbr>\nOR\u003Cbr>\n&nbsp; iv. For fish held iced or refrigerated (not frozen) onboard the vessel less than 12 hours after death, the internal temperature should be sufficiently below water and air temperatures to indicate that appropriate chilling methods were implemented onboard the harvest vessel.\u003Cbr>\nOR\u003Cbr>\n&nbsp; v. For fish held iced or refrigerated (not frozen) onboard the vessel, elapsed time from death and internal temperatures at the time of off‐loading from the vessel by the processor should be consistent with cooling curves that will prevent development of an unsafe level of histamine in the specific species, as established through a scientific study.\u003C\u002Fp>\n\n\u003Cp>We note, during the inspection, you stated you operate as a primary processor of fresh tuna and as a secondary processor of frozen tuna and you perform histamine testing using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> assay on a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples” on fresh tuna. Although your firm is a primary processor of fresh fish and a secondary processor of frozen fish, you combine receipt of both fresh and frozen fish at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” critical control point with primary processor critical limits for histamine testing and sensory examinations. A firm’s HACCP plan may group kinds of fish and fishery products together, or group kinds of production methods together, if the food safety hazards, critical control points, critical limits, and procedures required to be identified and performed are identical for all fish and fishery products so grouped or for all production methods so grouped. Based on the current receiving critical limits listed in your HACCP plan for canned tuna, your firm is expected to perform histamine testing and sensory testing when receiving both fresh and frozen fish.\u003C\u002Fp>\n\n\u003Cp>3. You must have a HACCP plan that, at minimum, lists the critical limits that must be met, to comply with 21 CFR 123.6(c)(3). A critical limit is defined in 21 CFR 123.3(c) as “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard”. However, your firm’s HACCP plan for “CANNED TUNA PRODUCTS” lists the following critical limits that are not adequate:\u003C\u002Fp>\n\n\u003Cp>&nbsp; a. Your firm’s HACCP plan lists a critical limit of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” critical control point that is not adequate to control scombrotoxin (histamine) formation. FDA recommends, sensory examination of a representative sample of scombrotoxin‐forming fish shows decomposition (persistent and readily perceptible) in&nbsp;\u003Cstrong>less than 2.5%\u003C\u002Fstrong> (&lt;2.5%) of the fish in the sample. For example, no more than 2 fish in a sample of 118 fish may show signs of decomposition. Note that the FFD&amp;C Act prohibits interstate commerce of any decomposed fish whether or not the HACCP critical limit has been exceeded.\u003C\u002Fp>\n\n\u003Cp>&nbsp; b. Your firm’s HACCP plan lists critical limits of “\u003Cstrong>(b)(4)\u003C\u002Fstrong> and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” critical control point that that are not adequate to control scombrotoxin (histamine) formation. Specifically, this critical control point appears to combine refrigerated storage and refrigerated processing steps with unrefrigerated processing steps. A firm’s HACCP plan may group kinds of fish and fishery products together, or group kinds of production methods together, if the food safety hazards, critical control points, critical limits, and procedures required to be identified and performed are identical for all fish and fishery products so grouped or for all production methods so grouped. However, the critical limits recommended by FDA to control scombrotoxin (histamine) formation during refrigerated storage and refrigerated processing are not identical to the critical limits to control scombrotoxin (histamine) formation during unrefrigerated processing.\u003C\u002Fp>\n\n\u003Cp>For unrefrigerated processing of fresh fish (not frozen) at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” steps performed before the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), FDA recommends:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. The fish are not exposed to ambient temperatures above 40°F (4.4°C) for more than 4 hours, cumulatively, if any portion of that time is at temperatures above 70°F (21.1°C).\u003Cbr>\nOR\u003Cbr>\n&nbsp; ii. The fish are not exposed to ambient temperatures above 40°F (4.4°C) for more than 8 hours, cumulatively, as long as no portion of that time is at temperatures above 70°F (21.1°C). \u003Cstrong>Note:\u003C\u002Fstrong> only one of the two limits above should be selected. They should not be added for a total exposure of 12 hours.\u003C\u002Fp>\n\n\u003Cp>For unrefrigerated processing of frozen fish at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” steps performed before the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), FDA recommends:\u003Cbr>\n\u003Cbr>\n&nbsp; i. The fish are not exposed to ambient temperatures above 40°F (4.4°C) for more than 12 hours, cumulatively, if any portion of that time is at temperatures above 70°F (21.1°C).\u003Cbr>\nOR\u003Cbr>\n&nbsp; ii. The fish are not exposed to ambient temperatures above 40°F (4.4°C) for more than 24 hours, cumulatively, as long as no portion of that time is at temperatures above 70°F (21.1°C).\u003C\u002Fp>\n\n\u003Cp>For refrigerated (not frozen) storage of fish at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” steps, or for the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” step, FDA recommends:\u003Cbr>\n&nbsp; i. The product is held at a cooler temperature of 40°F (4.4°C) or below throughout storage or throughout the thawing process.\u003C\u002Fp>\n\n\u003Cp>4. You must have a HACCP plan that, at minimum, lists monitoring procedures and their frequency for each critical control point, to comply with 21 CFR 123.6(c)(4). However, your firm’s HACCP plan for “CANNED TUNA PRODUCTS” lists a monitoring frequency at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” critical control point that is not adequate to control the hazard of undeclared allergens. Specifically, your monitoring procedures state you will perform a visual confirmation of the labels with the frequency “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” This frequency does not provide specific information about the how you will identify the “middle” of the labeling step or process. FDA recommends you monitor the labeling critical limit with the following frequency:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. At the start of the production lot\u003Cbr>\nAND\u003Cbr>\n&nbsp; ii. At least every 2 hours\u003Cbr>\nOR\u003Cbr>\n&nbsp; iii. When new containers of labels are opened or rolls of labels are changed.\u003C\u002Fp>\n\n\u003Cp>5. Because you chose to include a corrective action plan in your HACCP plan, your described corrective actions must be appropriate, to comply with 21 CFR 123.7(b). However, your HACCP plan for “CANNED TUNA PRODUCTS” at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” critical control point lists corrective actions that are not appropriate to control scombrotoxin (histamine) formation. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. Your listed corrective action of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” does not ensure unsafe product does not reach the consumer. When the histamine critical limit has not been met, FDA recommends you reject the lot or divert the lot to a non‐food use. Conducting additional histamine testing is not appropriate.\u003Cbr>\nb. Your listed corrective action of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” does not ensure unsafe product does not reach the consumer. When the sensory critical limit has not been met, and if histamine did not exceed 35 ppm (mg\u002Fkg) in the initial testing, FDA recommends the following:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. Chill and hold the affected lot until histamine analysis is performed on a minimum of 60 fish representatively collected from throughout the lot, including all fish in the lot that show evidence of decomposition. Reject the lot if any fish are found with histamine greater than or equal to 35 ppm.\u003Cbr>\nAND\u003Cbr>\n&nbsp; ii. If any fish in the lot are to proceed into commerce for food use, perform a sensory examination on all fish in the lot to ensure that no decomposed fish proceed.\u003Cbr>\nAND\u003Cbr>\n&nbsp; iii. Any individual fish found to be decomposed should be destroyed or diverted to a non‐food use.\u003Cbr>\nOR\u003Cbr>\n&nbsp; iv. Reject the lot.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan or plans, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16‐120. You may view this alert at: \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>You should direct your written reply to Rosemary Sexton, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS‐608), Division of Enforcement, College Park, Maryland 20740‐3835. If you have any questions regarding this letter, you may contact Rosemary Sexton via email at Rosemary.Sexton@fda.hhs.gov. Please reference CMS #634440 on any submissions and on the subject line of any emails to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Santiago Ortiz de Zarate\n\nRecipient Title\n\nGeneral Manager\u002FOwner\n\nConservas Ortiz S.A.\n\nPoligono Industrial La Estacion\n\nBasusta Bidea, 15\n\n20750 Zumaia\n\nSpain\n\nmurdangarin@ortiz.es\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nJune 17, 2022\n\nWARNING LETTER\n\nReference # 634440\n\nDear Mr. Santiago Ortiz de Zarate:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your seafood\u002Flowacid canned food (LACF) processing facility, located at Inaki Deuna, 15, Ondarroa, Bizkaia, 48700 Spain, on February 14 through 16, 2022. During the inspection, we found that you had serious violations of the Seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). That inspection resulted in FDA’s issuance of an FDA‐483, Inspectional Observations, listing the deviations found at your firm at the conclusion of the inspection. On March 8, 2022 and April 11, 2022, you responded to the observations issued to your facility on February 16, 2022. Your responses included an updated HACCP plan, HACCP monitoring and verification records, and LACF records which were reviewed and addressed below.\n\nIn accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your canned tuna products are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the 4th Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\n\nYour significant deviation is as follows:\n\n1. You must conduct a Hazard Analysis to determine whether there are food safety hazards that are reasonably likely to occur and have a HACCP plan that, at minimum, lists the critical control points, to comply with 21 CFR 123.6(c)(2). A critical control point is defined in 21 CFR 123.3(b) as a “point, step, or procedure in a food process at which control can be applied and a food safety hazard can as a result be prevented, eliminated, or reduced to acceptable levels”. However, your firm’s HACCP plan for “CANNED TUNA PRODUCTS” does not list critical control points for the following processing steps:\n\na. At the “(b)(4)” step after the “(b)(4)” step to control the food safety hazard of scombrotoxin (histamine) formation. During processing of scombrotoxin‐forming fish or fishery products that have been (1) previously frozen or (2) heat processed sufficiently to destroy scombrotoxin‐forming bacteria, FDA recommends:\n\ni. That the fish are not exposed to ambient temperatures above 40°F (4.4°C) for more than 12 hours, cumulatively, if any portion of that time is at temperatures above 70°F (21.1°C).\n\nOR\n\nii. That the fish are not exposed to ambient temperatures above 40°F (4.4°C) for more than 24 hours, cumulatively, so long as no portion of that time is at temperatures above 70°F (21.1°C).\n\nWe acknowledge that your firm has established a critical limit of “(b)(4)°C” at the “(b)(4)” step. However, per the cited reference “(b)(4),” this temperature is only sufficient to “pause subsequent histamine formation for 12 to 18 h,” not to eliminate histamine formation.\n\nb. At the “(b)(4)”, “(b)(4)”, “(b)(4)”, “(b)(4)”, “(b)(4)”, “(b)(4)” and “(b)(4)” steps up until the retort comes up temperatures to control the food safety hazard of Staphylococcus aureus growth and toxin formation. For product handling after cooking, FDA recommends the following:\n\ni. If at any time the product is held at internal temperatures above 80°F (26.7°C), exposure time should be limited to 3 hours.\n\nOR\n\nii. If at any time the product is held at internal temperatures above 70°F (21.1°C) but never above 80°F (26.7°C), exposure time should be limited to 3 hours.\n\nOR\n\niii. If at any time the product is held at internal temperatures above 50°F (10°C) but never above 70°F (21.1°C), exposure time should be limited to 5 hours.\n\n2. You must have a HACCP Plan that, that at minimum, lists the critical limits that must be met, to comply with 21 CFR 123.6(c)(3). A critical limit is defined in 21 CFR 123.3(c) as “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard.” However, your firm’s HACCP plan for “CANNED TUNA PRODUCTS” does not list a critical limit at the “Fresh Fish and Frozen Fish reception CCP1 and CCP3” critical control point to control the food safety hazard of scombrotoxin (histamine) formation.\n\nSpecifically, your HACCP plan does not list a critical limit for measuring internal fish temperatures at the time the fish are offloaded from the harvest vessel. We acknowledge your HACCP plan does include the critical limit of “(b)(4)°C refrigerated fish (b)(4)°C ((b)(4)°C in case of brine frozen whole round fish).” However, this critical limit appears to apply to the fish temperatures at the time they are received at the processing facility. For primary processors offloading at the dock and then transporting fish to the processing facility, it may be necessary to select more than one control strategy in order to fully control the hazard. In addition to your listed critical limits for sensory exams, histamine analyses, and temperature measurements when the fish arrive at the processing facility, FDA also recommends the following critical limits for fish internal temperatures at the time fish are offloaded from the harvest vessel:\n\ni. For fish held iced or refrigerated (not frozen) onboard the vessel 24 or more hours after death, the internal temperatures should be 40°F (4.4°C) or below.\n\nOR\n\nii. For fish held iced or refrigerated (not frozen) onboard the vessel from 15 to less than 24 hours after death, the internal temperature should be 50°F (10°C) or below.\n\nOR\n\niii. For fish held iced or refrigerated (not frozen) onboard the vessel from 12 to less than 15 hours after death, the internal temperature should be 60°F (15.6°C) or below.\n\nOR\n\niv. For fish held iced or refrigerated (not frozen) onboard the vessel less than 12 hours after death, the internal temperature should be sufficiently below water and air temperatures to indicate that appropriate chilling methods were implemented onboard the harvest vessel.\n\nOR\n\nv. For fish held iced or refrigerated (not frozen) onboard the vessel, elapsed time from death and internal temperatures at the time of off‐loading from the vessel by the processor should be consistent with cooling curves that will prevent development of an unsafe level of histamine in the specific species, as established through a scientific study.\n\nWe note, during the inspection, you stated you operate as a primary processor of fresh tuna and as a secondary processor of frozen tuna and you perform histamine testing using the (b)(4) assay on a minimum of (b)(4) samples” on fresh tuna. Although your firm is a primary processor of fresh fish and a secondary processor of frozen fish, you combine receipt of both fresh and frozen fish at the “(b)(4)” critical control point with primary processor critical limits for histamine testing and sensory examinations. A firm’s HACCP plan may group kinds of fish and fishery products together, or group kinds of production methods together, if the food safety hazards, critical control points, critical limits, and procedures required to be identified and performed are identical for all fish and fishery products so grouped or for all production methods so grouped. Based on the current receiving critical limits listed in your HACCP plan for canned tuna, your firm is expected to perform histamine testing and sensory testing when receiving both fresh and frozen fish.\n\n3. You must have a HACCP plan that, at minimum, lists the critical limits that must be met, to comply with 21 CFR 123.6(c)(3). A critical limit is defined in 21 CFR 123.3(c) as “the maximum or minimum value to which a physical, biological, or chemical parameter must be controlled at a critical control point to prevent, eliminate, or reduce to an acceptable level the occurrence of the identified food safety hazard”. However, your firm’s HACCP plan for “CANNED TUNA PRODUCTS” lists the following critical limits that are not adequate:\n\na. Your firm’s HACCP plan lists a critical limit of “(b)(4)” at the “(b)(4)” critical control point that is not adequate to control scombrotoxin (histamine) formation. FDA recommends, sensory examination of a representative sample of scombrotoxin‐forming fish shows decomposition (persistent and readily perceptible) in less than 2.5% (\u003C2.5%) of the fish in the sample. For example, no more than 2 fish in a sample of 118 fish may show signs of decomposition. Note that the FFD&C Act prohibits interstate commerce of any decomposed fish whether or not the HACCP critical limit has been exceeded.\n\nb. Your firm’s HACCP plan lists critical limits of “(b)(4) and “(b)(4)” at the “(b)(4)” critical control point that that are not adequate to control scombrotoxin (histamine) formation. Specifically, this critical control point appears to combine refrigerated storage and refrigerated processing steps with unrefrigerated processing steps. A firm’s HACCP plan may group kinds of fish and fishery products together, or group kinds of production methods together, if the food safety hazards, critical control points, critical limits, and procedures required to be identified and performed are identical for all fish and fishery products so grouped or for all production methods so grouped. However, the critical limits recommended by FDA to control scombrotoxin (histamine) formation during refrigerated storage and refrigerated processing are not identical to the critical limits to control scombrotoxin (histamine) formation during unrefrigerated processing.\n\nFor unrefrigerated processing of fresh fish (not frozen) at the “(b)(4)” and “(b)(4)” steps performed before the “(b)(4)” step ((b)(4)), FDA recommends:\n\ni. The fish are not exposed to ambient temperatures above 40°F (4.4°C) for more than 4 hours, cumulatively, if any portion of that time is at temperatures above 70°F (21.1°C).\n\nOR\n\nii. The fish are not exposed to ambient temperatures above 40°F (4.4°C) for more than 8 hours, cumulatively, as long as no portion of that time is at temperatures above 70°F (21.1°C). Note: only one of the two limits above should be selected. They should not be added for a total exposure of 12 hours.\n\nFor unrefrigerated processing of frozen fish at the “(b)(4)”, “(b)(4)” and “(b)(4)” steps performed before the “(b)(4)” step ((b)(4)), FDA recommends:\n\ni. The fish are not exposed to ambient temperatures above 40°F (4.4°C) for more than 12 hours, cumulatively, if any portion of that time is at temperatures above 70°F (21.1°C).\n\nOR\n\nii. The fish are not exposed to ambient temperatures above 40°F (4.4°C) for more than 24 hours, cumulatively, as long as no portion of that time is at temperatures above 70°F (21.1°C).\n\nFor refrigerated (not frozen) storage of fish at the “(b)(4),” “(b)(4) and “(b)(4)” steps, or for the “(b)(4)” step, FDA recommends:\n\ni. The product is held at a cooler temperature of 40°F (4.4°C) or below throughout storage or throughout the thawing process.\n\n4. You must have a HACCP plan that, at minimum, lists monitoring procedures and their frequency for each critical control point, to comply with 21 CFR 123.6(c)(4). However, your firm’s HACCP plan for “CANNED TUNA PRODUCTS” lists a monitoring frequency at the “(b)(4)” critical control point that is not adequate to control the hazard of undeclared allergens. Specifically, your monitoring procedures state you will perform a visual confirmation of the labels with the frequency “(b)(4).” This frequency does not provide specific information about the how you will identify the “middle” of the labeling step or process. FDA recommends you monitor the labeling critical limit with the following frequency:\n\ni. At the start of the production lot\n\nAND\n\nii. At least every 2 hours\n\nOR\n\niii. When new containers of labels are opened or rolls of labels are changed.\n\n5. Because you chose to include a corrective action plan in your HACCP plan, your described corrective actions must be appropriate, to comply with 21 CFR 123.7(b). However, your HACCP plan for “CANNED TUNA PRODUCTS” at the “(b)(4)” critical control point lists corrective actions that are not appropriate to control scombrotoxin (histamine) formation. Specifically:\n\na. Your listed corrective action of “(b)(4)” does not ensure unsafe product does not reach the consumer. When the histamine critical limit has not been met, FDA recommends you reject the lot or divert the lot to a non‐food use. Conducting additional histamine testing is not appropriate.\n\nb. Your listed corrective action of “(b)(4)” does not ensure unsafe product does not reach the consumer. When the sensory critical limit has not been met, and if histamine did not exceed 35 ppm (mg\u002Fkg) in the initial testing, FDA recommends the following:\n\ni. Chill and hold the affected lot until histamine analysis is performed on a minimum of 60 fish representatively collected from throughout the lot, including all fish in the lot that show evidence of decomposition. Reject the lot if any fish are found with histamine greater than or equal to 35 ppm.\n\nAND\n\nii. If any fish in the lot are to proceed into commerce for food use, perform a sensory examination on all fish in the lot to ensure that no decomposed fish proceed.\n\nAND\n\niii. Any individual fish found to be decomposed should be destroyed or diverted to a non‐food use.\n\nOR\n\niv. Reject the lot.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan or plans, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16‐120. You may view this alert at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\n\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\n\nYou should direct your written reply to Rosemary Sexton, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS‐608), Division of Enforcement, College Park, Maryland 20740‐3835. If you have any questions regarding this letter, you may contact Rosemary Sexton via email at Rosemary.Sexton@fda.hhs.gov. Please reference CMS #634440 on any submissions and on the subject line of any emails to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition","Conservas Ortiz S.A.","conservas-ortiz-sa-634440-06172022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fconservas-ortiz-sa-634440-06172022","2026-10-26T08:08:17.53091+00:00","2022-06-28","634440","Mr. Santiago Ortiz de Zarate","2026-08-20T01:48:20.415+00:00","2022-06-17",{"id":278,"raw":279,"subject":283,"body_html":284,"body_text":285,"firm_name":286,"letter_id":287,"created_at":175,"fei_number":19,"letter_url":288,"updated_at":289,"action_type":22,"case_status":23,"posted_date":290,"marcs_cms_no":291,"product_type":180,"closeout_date":19,"issuing_office":190,"recipient_name":292,"body_fetched_at":293,"delivery_method":183,"recipient_title":19,"reference_number":19,"action_taken_date":294,"medical_device_id":19,"response_letter_date":19},3089,[280,281,282,190,283,13,13,13],"\u003Ctime datetime=\"2021-10-12T13:20:00Z\">10\u002F12\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-07T04:00:00Z\">10\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnotarika-sa-de-cv-609174-10072021\">Notarika, S.A. de C.V.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Susana Elizabeth Garcia Ballesteros\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Notarika, S.A. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Eléctrica de México No. 41 Vista Hermosa\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>54080\u003C\u002Fspan> \u003Cspan>Tlalnepantla de Baz\u003C\u002Fspan>, \u003Cspan>Méx.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-22-01\u003C\u002Fp>\n\n\u003Cp>October 7, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Garcia:\u003C\u002Fp>\n\n\u003Cp>Your firm was recently registered as a human drug manufacturer. The United States Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub (also referred to as a consumer hand sanitizer) labeled as Greenfrog HAND SANITIZER. This drug product was labeled as manufactured at your facility, Notarika, S.A. de C.V., FEI 3017177797 at Prolongación 5 de Mayo 35, Col. Parque Industrial, 55370 Naucalpan, Exo de Mexico. Following an attempted import into the United States, Greenfrog HAND SANITIZER was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of FDA laboratory testing of batches of Greenfrog HAND SANITIZER drug products detained at the border demonstrate that this drug product labeled as manufactured by your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, Greenfrog HAND SANITIZER drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), (c), (f)(2), (i), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), a), (e), (c), (f)(2), (i), and (ee). Introduction or delivery for introduction for such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Greenfrog HAND SANITIZER, a drug product labeled as manufactured by your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that your Greenfrog HAND SANITIZER contained an average of 0% ethanol and 54% of methanol v\u002Fv. Therefore, your hand sanitizer drug products are adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient, ethanol was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\u003C\u002Fp>\n\n\u003Cp>Methanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products and adolescents and adults who drink these products as an alcohol (ethyl alcohol) substitute are most at risk for methanol poisoning.\u003C\u002Fp>\n\n\u003Cp>While the contaminated drug product described above was shipped to the United States, information available to FDA suggests that all of your consumer antiseptic drug products were detained and refused admission at the border and did not enter the United States. Therefore, FDA did not recommend that you remove this product from the market. On August 3, 2020, FDA notified the public of the methanol contamination in your consumer antiseptic drug product at the following website:\u003Cbr>\n\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A detailed investigation into how hand sanitizer drug products manufactured at your facility, and labeled as containing ethanol, were substituted in part or in whole with methanol.\u003Cbr>\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003Cbr>\n• Copies of the complete batch records for all batches distributed to the United States.\u003Cbr>\n• You communicated to FDA that Notarika S.A. de C.V. has not shipped your Greenfrog HAND SANITIZER drug product to the United States. However, FDA is concerned that other entities may be purchasing your drug products and distributing them to the United States. Provide a list of all hand sanitizer lots that you have manufactured and distributed regardless of the destination country.\u003C\u002Fp>\n\n\u003Cp>The substitution and methanol contamination in hand sanitizer drug products manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accord with CGMP requirements under section 501(a)(2)(B) of the Act.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Greenfrog HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the product label that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“HAND SANITIZER . . . Put enough product on hands to cover all surfaces. Rub hands together, until hands feel dry.”\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this hand sanitizer product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your Greenfrog HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) )(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, Greenfrog HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, Greenfrog HAND SANITIZER purportedly contains the active ingredient ethyl alcohol 70%. However, as previously discussed, FDA laboratory analysis of a batch of this product detained at the border demonstrated that Greenfrog HAND SANITIZER contains 0% ethyl alcohol, which is less than the 70% stated on its product label and less than the amount of ethanol described in the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analyses also demonstrated that a batch of Greenfrog HAND SANITIZER contained a significant concentration of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the TFM, nor is methanol included in the formulations described in FDA’s \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, this methanol-containing drug product, Greenfrog HAND SANITIZER, is misbranded under sections 502(j), (a), (e), (c), (f)(2), (i), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), (c), (f)(2), (i), and (ee).\u003C\u002Fp>\n\n\u003Cp>It is misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\u003C\u002Fp>\n\n\u003Cp>This hand sanitizer is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, Greenfrog HAND SANITIZER is labeled to contain alcohol 70%. However, FDA laboratory analysis of batches of this product demonstrate that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result. . ..” Thus, the misleading representation of the active ingredient ethyl alcohol (ethanol) and the failure to disclose the presence of the ingredients methyl alcohol (methanol) in the product causes this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>The failure of this product to list methyl alcohol (methanol) as an ingredient on its label also causes it to be misbranded under section 502(e)(1)(A) of the FD&amp;C Act, 21 U.S.C. 352(e)(1)(A).\u003C\u002Fp>\n\n\u003Cp>Greenfrog HAND SANITIZER is not labeled in accordance with the “Drug Facts” labeling requirements described in 21 CFR 201.66. Specifically, the product label fails to include a Drug Facts panel. Further, the label fails to separately list the active ingredients and the inactive ingredients, as required by 201.66(c). Therefore, this product is misbranded under section 502(c) of the FD&amp;C Act, 21 U.S.C. 352(c), because the information that is required to appear on the labeling is not prominently placed thereon with such conspicuousness and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.\u003C\u002Fp>\n\n\u003Cp>Greenfrog HAND SANITIZER is misbranded under section 502(f)(2) of the FD&amp;C Act, 21 U.S.C. 352(f)(2), because the product label does not include all of the applicable warnings as required under 21 CFR 330.1(g). Specifically, the label does not include the warning statement required for drugs used topically that reads “If swallowed, get medical help or contact a Poison Control Center right away.”\u003C\u002Fp>\n\n\u003Cp>In addition, Greenfrog HAND SANITIZER is packaged in a clear plastic container that resembles a drinking water bottle customarily purchased and used by U.S. consumers. Section 502(i)(1) of the FD&amp;C Act, 21 U.S.C. 352(i)(1), provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading . . .” As such, your clear, colorless hand sanitizer that fills a 33.8 fluid ounce container resembling plastic bottles ordinarily used to package drinking water is misbranded under section 502(i)(1) of the FD&amp;C Act, 21 U.S.C. 352(i)(1).\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because Greenfrog HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 11, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of the violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003Cbr>\n\u003Cbr>\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3016931302 and ATTN: William Yang.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered U.S. Agent\u003Cbr>\nDavid Lennarz\u003Cbr>\nRegistrar Corp\u003Cbr>\n144 Research Drive\u003Cbr>\nHampton, VA 23666\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol- Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act&nbsp;if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative testing results detailed above that demonstrate the substitution of the hand sanitizer products declared as manufactured at your facility, a review of the purported formulations on your drug product’s labeling further indicate that such products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution. 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem>. Because Greenfrog HAND SANITIZER is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> An inactive ingredient used in OTC monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Susana Elizabeth Garcia Ballesteros\n\nRecipient Title\n\nDirector\n\nNotarika, S.A. de C.V.\n\nEléctrica de México No. 41 Vista Hermosa\n\n54080 Tlalnepantla de Baz, Méx.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-22-01\n\nOctober 7, 2021\n\nDear Ms. Garcia:\n\nYour firm was recently registered as a human drug manufacturer. The United States Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub (also referred to as a consumer hand sanitizer) labeled as Greenfrog HAND SANITIZER. This drug product was labeled as manufactured at your facility, Notarika, S.A. de C.V., FEI 3017177797 at Prolongación 5 de Mayo 35, Col. Parque Industrial, 55370 Naucalpan, Exo de Mexico. Following an attempted import into the United States, Greenfrog HAND SANITIZER was detained and refused admission at the border.\n\nThe results of FDA laboratory testing of batches of Greenfrog HAND SANITIZER drug products detained at the border demonstrate that this drug product labeled as manufactured by your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, Greenfrog HAND SANITIZER drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), (c), (f)(2), (i), and (ee) of the FD&C Act, 21 U.S.C. 352(j), a), (e), (c), (f)(2), (i), and (ee). Introduction or delivery for introduction for such a product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nGreenfrog HAND SANITIZER, a drug product labeled as manufactured by your facility, is labeled to contain 70% volume\u002Fvolume (v\u002Fv) of the active ingredient alcohol ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that your Greenfrog HAND SANITIZER contained an average of 0% ethanol and 54% of methanol v\u002Fv. Therefore, your hand sanitizer drug products are adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient, ethanol was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\n\nMethanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products and adolescents and adults who drink these products as an alcohol (ethyl alcohol) substitute are most at risk for methanol poisoning.\n\nWhile the contaminated drug product described above was shipped to the United States, information available to FDA suggests that all of your consumer antiseptic drug products were detained and refused admission at the border and did not enter the United States. Therefore, FDA did not recommend that you remove this product from the market. On August 3, 2020, FDA notified the public of the methanol contamination in your consumer antiseptic drug product at the following website:\n\nhttps:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nIn response to this letter, provide the following:\n\n• A detailed investigation into how hand sanitizer drug products manufactured at your facility, and labeled as containing ethanol, were substituted in part or in whole with methanol.\n\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\n• Copies of the complete batch records for all batches distributed to the United States.\n\n• You communicated to FDA that Notarika S.A. de C.V. has not shipped your Greenfrog HAND SANITIZER drug product to the United States. However, FDA is concerned that other entities may be purchasing your drug products and distributing them to the United States. Provide a list of all hand sanitizer lots that you have manufactured and distributed regardless of the destination country.\n\nThe substitution and methanol contamination in hand sanitizer drug products manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accord with CGMP requirements under section 501(a)(2)(B) of the Act.1\n\nUnapproved New Drug and Misbranding Violations\n\nGreenfrog HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic.\n\nExamples of claims observed on the product label that provide evidence of the intended use (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“HAND SANITIZER . . . Put enough product on hands to cover all surfaces. Rub hands together, until hands feel dry.”\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this hand sanitizer product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your Greenfrog HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) )(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, Greenfrog HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rub Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, Greenfrog HAND SANITIZER purportedly contains the active ingredient ethyl alcohol 70%. However, as previously discussed, FDA laboratory analysis of a batch of this product detained at the border demonstrated that Greenfrog HAND SANITIZER contains 0% ethyl alcohol, which is less than the 70% stated on its product label and less than the amount of ethanol described in the 1994 TFM.2 Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.3\n\nFDA laboratory analyses also demonstrated that a batch of Greenfrog HAND SANITIZER contained a significant concentration of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the TFM, nor is methanol included in the formulations described in FDA’s Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.4\n\nAdditionally, this methanol-containing drug product, Greenfrog HAND SANITIZER, is misbranded under sections 502(j), (a), (e), (c), (f)(2), (i), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), (c), (f)(2), (i), and (ee).\n\nIt is misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\n\nThis hand sanitizer is misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, Greenfrog HAND SANITIZER is labeled to contain alcohol 70%. However, FDA laboratory analysis of batches of this product demonstrate that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result. . ..” Thus, the misleading representation of the active ingredient ethyl alcohol (ethanol) and the failure to disclose the presence of the ingredients methyl alcohol (methanol) in the product causes this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nThe failure of this product to list methyl alcohol (methanol) as an ingredient on its label also causes it to be misbranded under section 502(e)(1)(A) of the FD&C Act, 21 U.S.C. 352(e)(1)(A).\n\nGreenfrog HAND SANITIZER is not labeled in accordance with the “Drug Facts” labeling requirements described in 21 CFR 201.66. Specifically, the product label fails to include a Drug Facts panel. Further, the label fails to separately list the active ingredients and the inactive ingredients, as required by 201.66(c). Therefore, this product is misbranded under section 502(c) of the FD&C Act, 21 U.S.C. 352(c), because the information that is required to appear on the labeling is not prominently placed thereon with such conspicuousness and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use.\n\nGreenfrog HAND SANITIZER is misbranded under section 502(f)(2) of the FD&C Act, 21 U.S.C. 352(f)(2), because the product label does not include all of the applicable warnings as required under 21 CFR 330.1(g). Specifically, the label does not include the warning statement required for drugs used topically that reads “If swallowed, get medical help or contact a Poison Control Center right away.”\n\nIn addition, Greenfrog HAND SANITIZER is packaged in a clear plastic container that resembles a drinking water bottle customarily purchased and used by U.S. consumers. Section 502(i)(1) of the FD&C Act, 21 U.S.C. 352(i)(1), provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading . . .” As such, your clear, colorless hand sanitizer that fills a 33.8 fluid ounce container resembling plastic bottles ordinarily used to package drinking water is misbranded under section 502(i)(1) of the FD&C Act, 21 U.S.C. 352(i)(1).\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because Greenfrog HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified, as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on August 11, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of the violation have been resolved, and the Agency has confidence that future entries will be in compliance with the Act. This may include an inspection prior to the agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nIdentify your response with FEI 3016931302 and ATTN: William Yang.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered U.S. Agent\n\nDavid Lennarz\n\nRegistrar Corp\n\n144 Research Drive\n\nHampton, VA 23666\n\n_____________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol- Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative testing results detailed above that demonstrate the substitution of the hand sanitizer products declared as manufactured at your facility, a review of the purported formulations on your drug product’s labeling further indicate that such products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic hand washes and healthcare personnel hand washes an alcohol concentration of 60 to 95% by volume in an aqueous solution. 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n3 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because Greenfrog HAND SANITIZER is not consistent with the formulations described in these guidances, it does not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.\n\n4 An inactive ingredient used in OTC monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.","Notarika, S.A. de C.V.","notarika-sa-de-cv-609174-10072021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnotarika-sa-de-cv-609174-10072021","2026-10-26T08:09:35.066052+00:00","2021-10-12","609174","Ms. Susana Elizabeth Garcia Ballesteros","2026-08-20T02:32:00.615+00:00","2021-10-07",{"id":296,"raw":297,"subject":170,"body_html":301,"body_text":302,"firm_name":303,"letter_id":304,"created_at":175,"fei_number":19,"letter_url":305,"updated_at":306,"action_type":22,"case_status":23,"posted_date":307,"marcs_cms_no":308,"product_type":180,"closeout_date":19,"issuing_office":169,"recipient_name":309,"body_fetched_at":310,"delivery_method":183,"recipient_title":19,"reference_number":19,"action_taken_date":311,"medical_device_id":19,"response_letter_date":19},3312,[298,299,300,169,170,13,13,13],"\u003Ctime datetime=\"2021-06-08T13:20:00Z\">06\u002F08\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-03T04:00:00Z\">06\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdmm-vission-sa-de-cv-609797-06032021\">DMM Vission, S.A. de C.V.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ma. de la Luz Escorza\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DMM Vission, S.A. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Calle Lago Guija 234\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Col. Agua Azul\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>57500\u003C\u002Fspan> \u003Cspan>Ciudad Nezahualcoyotl\u003C\u002Fspan>, \u003Cspan>Méx.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-21-48\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 03, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Escorza:\u003C\u002Fp>\n\n\u003Cp>Your firm was registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers) labeled as SYP HEALTH HAND SANITIZER ALCOHOL GEL and Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel. SYP HEALTH HAND SANITIZER ALCOHOL GEL was labeled as manufactured at your facility, and Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel was declared to be manufactured at your facility, DMM Vission, S.A. de C.V., FEI 3016833130, at Calle Lago Guija 234, Col. Agua Azul, Cuidad Nezahualcoyotl, Mexico. Following an attempt to import DMM Hand Sanitizer drug products into the United States, these products were detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of FDA laboratory testing of batches of these drug products detained at the border demonstrate that these drug products, labeled or declared to be manufactured at your facility, are adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, these products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, your Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL drug products are unapproved new drugs in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and are misbranded under sections 502(j), (a), (e), (f)(2), (x) and (ee) of the FD&amp;C Act, 21 U.S.C. 352 (j), (a), (e), (f)(2), (x) and (ee). Lastly, SYP HEALTH HAND SANITIZER is also misbranded under 502 (i) of the FD&amp;C Act, 21 U.S.C 352(i).\u003C\u002Fp>\n\n\u003Cp>Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>SYP HEALTH HAND SANITIZER ALCOHOL GEL, labeled as manufactured at your facility, is labeled to contain 70% of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of SYP HEALTH HAND SANITIZER ALCOHOL GEL product detained at the border found that the product contained an average of 31% ethanol and an average of 2.3% methanol volume\u002Fvolume (v\u002Fv).\u003C\u002Fp>\n\n\u003Cp>Additionally, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel, declared to be manufactured at your facility, is labeled to contain 70% v\u002Fv of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel product detained at the border found that the product contained an average of 22% ethanol and an average of 10% methanol v\u002Fv.\u003C\u002Fp>\n\n\u003Cp>Therefore, these hand sanitizer drug products are adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient of ethanol was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\u003C\u002Fp>\n\n\u003Cp>Methanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products and adolescents and adults who drink these products as an alcohol (ethanol) substitute are most at risk for methanol poisoning.\u003C\u002Fp>\n\n\u003Cp>On August 21, 2020, FDA held a teleconference with you and Registrar Corp, your registered U.S. agent. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution from the U.S. market. On August 21, 2020, FDA notified the public of methanol contamination of your hand sanitizer at the following website: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>On September 8, 2020, you announced a voluntary nationwide recall for five lots of Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel 500ml and 1200ml bottles due to potential presence of undeclared methanol (Wood Alcohol), as noted on the following FDA webpage: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fdmm-vission-sa-de-cv-issues-voluntary-nationwide-recall-cleaner-hand-sanitizer-500-ml-and-1200-ml?utm_medium=email&amp;utm_source=govdelivery\">https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fdmm-vission-sa-de-cv-issues-voluntary-nationwide-recall-cleaner-hand-sanitizer-500-ml-and-1200-ml?utm_medium=email&amp;utm_source=govdelivery\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Additionally, the FDA contacted your firm’s consignees to recall. On September 24, 2020, one of your firm’s consignees, AA Products Inc., recalled one lot of SYP HEALTH HAND SANITIZER ALCOHOL GEL 500ml bottles.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003Cbr>\n• A detailed investigation into how the drug products described above, which were declared or labeled as manufactured at your facility, and which were labeled as containing ethanol, were substituted in part or in whole with methanol.\u003Cbr>\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003Cbr>\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003Cbr>\n• Copies of the complete batch records for all batches distributed to the U.S.\u003C\u002Fp>\n\n\u003Cp>The substitution and methanol contamination in a drug product declared or labeled as manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL are intended for use as consumer topical antiseptics.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel:\u003Cbr>\n“\u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . \u003Cstrong>Purpose\u003C\u002Fstrong> . . . Antimicrobial \u003Cstrong>Use\u003C\u002Fstrong>: To help reduce bacteria on the skin. . . Directions: Wet hands thoroughly with product, gently rub into skin and allow to dry without wiping.\u003Cbr>\n\u003Cbr>\nSYP HEALTH HAND SANITIZER ALCOHOL GEL:\u003Cbr>\n\u003Cstrong>DRUG FACTS:\u003C\u002Fstrong> . . . USES: hand sanitizer to help decrease bacteria on the skin. . . DIRECTIONS: pump as needed into your palms thoroughly spread on both hands, rub into skin until dry.\u003C\u002Fp>\n\n\u003Cp>These topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the Act (which is not the case for these products, as further described below) or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL drug products are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified in Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rue, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product labels, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL purportedly contain the active ingredient ethyl alcohol (ethanol) 70%. However, as previously discussed, FDA laboratory analyses of batches of these products detained at the border demonstrated that Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL contain ethyl alcohol (ethanol) in a concentration that is less than the 70% stated on its product labels and less than the amount of ethyl alcohol (ethanol) described in the 1994 TFM.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Such products do not conform with the TFM or applicable requirements nor are they consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analyses also demonstrated that batches of Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL contain significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994 TFM, nor is methanol included in the formulations described in FDA’s \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that its inactive ingredients be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Additionally, these methanol-containing drug products, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL, are misbranded under sections 502(j), (a), (e), (f)(2), (x) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), (x) and (ee). SYP HEALTH HAND SANITIZER ALCOHOL GEL is also misbranded under section 502(i) of the FD&amp;C Act, 21 U.S.C 352(i).\u003C\u002Fp>\n\n\u003Cp>These products are misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because they are dangerous to health when used according to their labeling as hand sanitizers. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death. These hand sanitizers are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because their labeling is false or misleading. As noted above, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL are labeled to contain ethyl alcohol (ethanol) 70%. However, FDA laboratory analyses of batches of these products demonstrate that the products contain a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product labels and contain a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product labels. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result. . ..” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product labels to disclose the presence of methyl alcohol (methanol) in the products, causes these products to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>The failure of these products to list methyl alcohol (methanol) as an ingredient on their labels causes them to be misbranded under section 502(e)(1)(A) of the FD&amp;C Act, 21 U.S.C. 352(e)(1)(A).\u003C\u002Fp>\n\n\u003Cp>Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER GEL are also misbranded under section 502(f)(2) of the FD&amp;C Act, 21 U.S.C. 352(f)(2) because the product labels do not include all of the applicable warnings as required under 21 CFR 330.1(g). Specifically, the labels do not include the warning statement that reads, “If swallowed, get medical help or contact a Poison Control Center right away.”\u003C\u002Fp>\n\n\u003Cp>Furthermore, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL are misbranded under section 502(x) of the FD&amp;C Act, 21 U.S.C. 352(x) because the product labels fail to disclose a complete domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\u003C\u002Fp>\n\n\u003Cp>In addition, SYP HEALTH HAND SANITIZER ALCOHOL GEL is packaged in a container that resembles a drinking water bottle customarily purchased by U.S. consumers. Section 502(i)(1) of the FD&amp;C Act, 21 U.S.C. 352(i)(1), provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading …”As such, your clear, colorless hand sanitizer that fills a 33.8 fl oz container resembling a plastic water bottle ordinarily used to package drinking water is misbranded under section 502(i)(1) of the FD&amp;C Act, 21 U.S.C. 352(i)(1).\u003C\u002Fp>\n\n\u003Cp>Lastly, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on September 02, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of the violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&amp;C Act. This may include an inspection prior to the agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3016833130 and ATTN: Towanda Terrell.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nRegistered US Agent:\u003Cbr>\nRegistrar Corp David Lennarz\u003Cbr>\n144 Research Drive\u003Cbr>\nHampton, VA 23666\u003C\u002Fp>\n\n\u003Cp>Firm’s External Attorney:\u003Cbr>\nTeresa Arellano\u003Cbr>\nTere_Arellano8@hotmail.com\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rubs) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution of hand sanitizer products declared or labeled as manufactured at your facility, a review of the purported formulations on the drug products’ labeling further indicates that these products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic handwashes and healthcare personnel handwashes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem>. Because Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMa. de la Luz Escorza\n\nRecipient Title\n\nCEO\n\nDMM Vission, S.A. de C.V.\n\nCalle Lago Guija 234\n\nCol. Agua Azul\n\n57500 Ciudad Nezahualcoyotl, Méx.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nWarning Letter 320-21-48\n\nJune 03, 2021\n\nDear Ms. Escorza:\n\nYour firm was registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of consumer antiseptic hand rub drug products (also referred to as consumer hand sanitizers) labeled as SYP HEALTH HAND SANITIZER ALCOHOL GEL and Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel. SYP HEALTH HAND SANITIZER ALCOHOL GEL was labeled as manufactured at your facility, and Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel was declared to be manufactured at your facility, DMM Vission, S.A. de C.V., FEI 3016833130, at Calle Lago Guija 234, Col. Agua Azul, Cuidad Nezahualcoyotl, Mexico. Following an attempt to import DMM Hand Sanitizer drug products into the United States, these products were detained and refused admission at the border.\n\nThe results of FDA laboratory testing of batches of these drug products detained at the border demonstrate that these drug products, labeled or declared to be manufactured at your facility, are adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, these products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, your Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL drug products are unapproved new drugs in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and are misbranded under sections 502(j), (a), (e), (f)(2), (x) and (ee) of the FD&C Act, 21 U.S.C. 352 (j), (a), (e), (f)(2), (x) and (ee). Lastly, SYP HEALTH HAND SANITIZER is also misbranded under 502 (i) of the FD&C Act, 21 U.S.C 352(i).\n\nIntroduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a).\n\nAdulteration Violations\n\nSYP HEALTH HAND SANITIZER ALCOHOL GEL, labeled as manufactured at your facility, is labeled to contain 70% of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of SYP HEALTH HAND SANITIZER ALCOHOL GEL product detained at the border found that the product contained an average of 31% ethanol and an average of 2.3% methanol volume\u002Fvolume (v\u002Fv).\n\nAdditionally, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel, declared to be manufactured at your facility, is labeled to contain 70% v\u002Fv of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel product detained at the border found that the product contained an average of 22% ethanol and an average of 10% methanol v\u002Fv.\n\nTherefore, these hand sanitizer drug products are adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient of ethanol was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\n\nMethanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products and adolescents and adults who drink these products as an alcohol (ethanol) substitute are most at risk for methanol poisoning.\n\nOn August 21, 2020, FDA held a teleconference with you and Registrar Corp, your registered U.S. agent. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution from the U.S. market. On August 21, 2020, FDA notified the public of methanol contamination of your hand sanitizer at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\n\nOn September 8, 2020, you announced a voluntary nationwide recall for five lots of Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel 500ml and 1200ml bottles due to potential presence of undeclared methanol (Wood Alcohol), as noted on the following FDA webpage: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Fdmm-vission-sa-de-cv-issues-voluntary-nationwide-recall-cleaner-hand-sanitizer-500-ml-and-1200-ml?utm_medium=email&utm_source=govdelivery.\n\nAdditionally, the FDA contacted your firm’s consignees to recall. On September 24, 2020, one of your firm’s consignees, AA Products Inc., recalled one lot of SYP HEALTH HAND SANITIZER ALCOHOL GEL 500ml bottles.\n\nIn response to this letter, provide the following:\n\n• A detailed investigation into how the drug products described above, which were declared or labeled as manufactured at your facility, and which were labeled as containing ethanol, were substituted in part or in whole with methanol.\n\n• A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\n• A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\n• Copies of the complete batch records for all batches distributed to the U.S.\n\nThe substitution and methanol contamination in a drug product declared or labeled as manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).1\n\nUnapproved New Drug and Misbranding Violations\n\nCleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL are intended for use as consumer topical antiseptics.\n\nExamples of claims observed on the Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL labeling that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\nCleaner BY CRYSTALWARE HAND SANITIZER alcohol gel:\n\n“Drug Facts . . . Purpose . . . Antimicrobial Use: To help reduce bacteria on the skin. . . Directions: Wet hands thoroughly with product, gently rub into skin and allow to dry without wiping.\n\nSYP HEALTH HAND SANITIZER ALCOHOL GEL:\n\nDRUG FACTS: . . . USES: hand sanitizer to help decrease bacteria on the skin. . . DIRECTIONS: pump as needed into your palms thoroughly spread on both hands, rub into skin until dry.\n\nThese topical antiseptic products are “new drugs” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the Act (which is not the case for these products, as further described below) or under other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these drug products, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL drug products are GRASE for use under the conditions suggested, recommended, or prescribed in their labeling. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under FDA’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016) (Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified in Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL do not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rue, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product labels, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL purportedly contain the active ingredient ethyl alcohol (ethanol) 70%. However, as previously discussed, FDA laboratory analyses of batches of these products detained at the border demonstrated that Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL contain ethyl alcohol (ethanol) in a concentration that is less than the 70% stated on its product labels and less than the amount of ethyl alcohol (ethanol) described in the 1994 TFM.2 Such products do not conform with the TFM or applicable requirements nor are they consistent with the formulations described in the guidances setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.3\n\nFDA laboratory analyses also demonstrated that batches of Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL contain significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994 TFM, nor is methanol included in the formulations described in FDA’s Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that its inactive ingredients be safe and suitable.4\n\nAdditionally, these methanol-containing drug products, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL, are misbranded under sections 502(j), (a), (e), (f)(2), (x) and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), (x) and (ee). SYP HEALTH HAND SANITIZER ALCOHOL GEL is also misbranded under section 502(i) of the FD&C Act, 21 U.S.C 352(i).\n\nThese products are misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because they are dangerous to health when used according to their labeling as hand sanitizers. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death. These hand sanitizers are misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because their labeling is false or misleading. As noted above, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL are labeled to contain ethyl alcohol (ethanol) 70%. However, FDA laboratory analyses of batches of these products demonstrate that the products contain a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product labels and contain a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product labels. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result. . ..” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product labels to disclose the presence of methyl alcohol (methanol) in the products, causes these products to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nThe failure of these products to list methyl alcohol (methanol) as an ingredient on their labels causes them to be misbranded under section 502(e)(1)(A) of the FD&C Act, 21 U.S.C. 352(e)(1)(A).\n\nCleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER GEL are also misbranded under section 502(f)(2) of the FD&C Act, 21 U.S.C. 352(f)(2) because the product labels do not include all of the applicable warnings as required under 21 CFR 330.1(g). Specifically, the labels do not include the warning statement that reads, “If swallowed, get medical help or contact a Poison Control Center right away.”\n\nFurthermore, Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL are misbranded under section 502(x) of the FD&C Act, 21 U.S.C. 352(x) because the product labels fail to disclose a complete domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\n\nIn addition, SYP HEALTH HAND SANITIZER ALCOHOL GEL is packaged in a container that resembles a drinking water bottle customarily purchased by U.S. consumers. Section 502(i)(1) of the FD&C Act, 21 U.S.C. 352(i)(1), provides that a drug is misbranded if “its container is so made, formed, or filled as to be misleading …”As such, your clear, colorless hand sanitizer that fills a 33.8 fl oz container resembling a plastic water bottle ordinarily used to package drinking water is misbranded under section 502(i)(1) of the FD&C Act, 21 U.S.C. 352(i)(1).\n\nLastly, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on September 02, 2020, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated or misbranded may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert, until there is evidence establishing that the conditions that gave rise to the appearance of the violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&C Act. This may include an inspection prior to the agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov\n\nIdentify your response with FEI 3016833130 and ATTN: Towanda Terrell.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered US Agent:\n\nRegistrar Corp David Lennarz\n\n144 Research Drive\n\nHampton, VA 23666\n\nFirm’s External Attorney:\n\nTeresa Arellano\n\nTere_Arellano8@hotmail.com\n\n________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as health care personnel hand rubs) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution of hand sanitizer products declared or labeled as manufactured at your facility, a review of the purported formulations on the drug products’ labeling further indicates that these products are not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, these products do not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 The 1994 TFM, which does not distinguish between antiseptic hand washes and rubs, proposed for antiseptic handwashes and healthcare personnel handwashes an alcohol concentration of 60 to 95% by volume in an aqueous solution: 59 FR at 31442. Later amendments to the 1994 TFM distinguished between antiseptic hand washes and rubs, and between consumer and healthcare personnel antiseptics, but did not change the alcohol concentration originally proposed in 1994.\n\n3 See, e.g., Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19). Because Cleaner BY CRYSTALWARE HAND SANITIZER alcohol gel and SYP HEALTH HAND SANITIZER ALCOHOL GEL are not consistent with the formulations described in these guidances, they do not fall within any temporary Agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 505 of the FD&C Act.\n\n4 An inactive ingredient used in over-the-counter (OTC) monograph drugs must meet the requirements of 21 CFR 330.1(e), which requires, among other things, that inactive ingredients must be safe in the amount administered.","DMM Vission, S.A. de C.V.","dmm-vission-sa-de-cv-609797-06032021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdmm-vission-sa-de-cv-609797-06032021","2026-10-26T08:08:25.848245+00:00","2021-06-08","609797","Ma. de la Luz Escorza","2026-08-20T03:04:48.035+00:00","2021-06-03",{"id":313,"raw":314,"subject":320,"body_html":321,"body_text":322,"firm_name":323,"letter_id":324,"created_at":18,"fei_number":19,"letter_url":325,"updated_at":326,"action_type":22,"case_status":23,"posted_date":327,"marcs_cms_no":328,"product_type":180,"closeout_date":19,"issuing_office":318,"recipient_name":329,"body_fetched_at":330,"delivery_method":183,"recipient_title":19,"reference_number":331,"action_taken_date":332,"medical_device_id":19,"response_letter_date":19},1252,[315,316,317,318,319,13,13,13],"\u003Ctime datetime=\"2024-09-17T13:20:00Z\">09\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-10T04:00:00Z\">09\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faromas-para-el-alma-sa-672728-09102024\">Aromas Para El Alma S.A.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-24-61\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Andrea Becerra\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aromas Para El Alma S.A.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Calle Lindora, Commercial Park Warehouse 23\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Santa Ana\u003C\u002Fspan>, \u003Cspan>San Jose\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>10903\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Costa Rica\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-61\u003C\u002Fp>\n\n\u003Cp>September 10, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Becerra:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Aromas Para El Alma S.A., FEI 3018061317, at Oficentro Ultima Park 2, Bodega No. 74, Calle Mango, Guachipelín, San Rafael, Escazu, San Jose 10203, Costa Rica, from October 16 to 19, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, EREWHON ANTIBACTERIAL SPRAY is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d). The product is also misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). In addition, your EREWHON HAND SANITIZER and EREWHON ANTIBACTERIAL SPRAY are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your November 8, 2023 response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish adequate written production and control procedures for the charge-in of components designed to assure that the drug products produced have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.101).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to formulate your drug products with the intent to provide no less than 100% of the declared active ingredient. For example, your EREWHON drug products, EREWHON ANTIBACTERIAL SPRAY and EREWHON HAND SANITIZER, manufactured by your firm, are labeled to contain 60% and 70% of the active ingredient ethyl alcohol (ethanol), respectively. You originally formulated your drug products using \u003Cstrong>(b)(4)\u003C\u002Fstrong>% ethanol (active ingredient). Your firm failed to revise your manufacturing formulation after replacing the \u003Cstrong>(b)(4)\u003C\u002Fstrong>% ethanol with a lower strength ethanol. Your firm made this formulation change without assessing the impact of the change on the quality of your finished drug products, including failing to conduct validation studies. As a result, multiple batches were formulated to contain ethanol concentrations lower than what was declared on the labeling, with some concentration values calculated as low as approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. These batches were ultimately released for distribution.\u003C\u002Fp>\n\n\u003Cp>CDC recommends\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph (1994 TFM) for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by the “Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 80 FR 25166 (May 1, 2015) (2015 Health Care Personnel Hand Rub Proposed Rule).\u003C\u002Fp>\n\n\u003Cp>On October 18, 2023, FDA inquired whether you had conducted a voluntary recall for any batches of drug products currently in distribution from the U.S. market that were potentially subpotent due to inadequate formulation. On October 19, 2023, you provided a written statement of your intent to voluntarily recall affected drug product batches. FDA has made multiple attempts to follow-up with you and your registered U.S. Agent. As of the date of this letter, you have not initiated a voluntary recall, nor contacted the Agency after multiple requests to do so.\u003C\u002Fp>\n\n\u003Cp>On March 13, 2024, FDA notified the public that your drug products are subpotent at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\u003C\u002Fp>\n\n\u003Cp>Your response includes actions that will be taken to evaluate your drug product formulations. Your response is inadequate because you did not provide supportive documentation, did not consider a retrospective evaluation of potential impact to your products currently on the market, and your interim production plans are unclear.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A list of all batches of any drug product distributed in the United States by your firm, including lot numbers and expiry dates, and a full reconciliation of all material you distributed, including a list of customers and location for where the product was distributed.\u003Cbr>\n• An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed in the United States within expiry. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003Cbr>\n• An action plan for updating the formulation for your drug products including process validation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm also failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your batch production records for your drug products do not include adequate production instructions, including but not limited to, identification of critical steps in your manufacturing processes such as critical parameters (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> times) or the weight or volume of each formulation component.\u003C\u002Fp>\n\n\u003Cp>Your response includes actions that will be taken to improve your batch production records. Your response is inadequate because you did not provide supportive documentation, did not consider a retrospective evaluation of potential impact to your products currently on the market, and your interim production plans are unclear.\u003C\u002Fp>\n\n\u003Cp>Complete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and reproducible. Incomplete manufacturing records deprive you of the ability to ensure the batches are formulated to provide not less than 100% of the labeled or established amount of active ingredient.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• Your master production and control records for your drug products, to demonstrate that they fully document each significant and validated manufacturing step.\u003Cbr>\n• Procedures you have implemented to ensure production records are completed as\u003Cbr>\nrequired and reviewed by your quality unit (QU) before release of products for distribution.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to conduct an adequate identity test on each shipment of each lot of components (including the ethanol active ingredient), used in the production of your drug products. You also failed to determine whether each component conformed with all appropriate written specifications for purity, strength, and quality before use.\u003C\u002Fp>\n\n\u003Cp>In addition, your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a component in your drug products. Your firm has not shown that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> that you use for component \u003Cstrong>(b)(4)\u003C\u002Fstrong> is suitable for \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosage form drug product manufacturing and, at a minimum, meets the USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph and appropriate microbial limits.\u003C\u002Fp>\n\n\u003Cp>Your response includes actions that will be taken to improve your component controls. Your response is inadequate because you did not provide supportive documentation, did not consider a retrospective evaluation of potential impact to your products currently on the market, and your interim production plans are unclear.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003Cbr>\n• The chemical and microbiological quality control specifications you use to test and release each incoming batch of components for use in manufacturing.\u003Cbr>\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ certificates of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003Cbr>\n• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\u003Cbr>\n• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003Cbr>\n• A description of how you will consistently produce or acquire \u003Cstrong>(b)(4)\u003C\u002Fstrong> adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, USP monograph specifications and appropriate microbial limits.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your QU did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cp>• Adequate chemical and microbial testing and appropriate specifications for your finished drug products (21 CFR 211.165(a) and 21 CFR 211.165(b)).\u003Cbr>\n• Establishment of an adequate stability program (21 CFR 211.137(a)).\u003Cbr>\n• Establishment of adequate procedures describing the QU’s responsibilities 21 CFR 211.22(d)).\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you will revise your QU procedures. However, your response is inadequate because you did not provide any further detail or supportive documentation.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive assessment and remediation plan to ensure that your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fp>\n\n\u003Cp>• A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n• Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n• A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n• Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Based on its labeled intended uses, EREWHON HAND SANITIZER and EREWHON ANTIBACTERIAL SPRAY products are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, EREWHON HAND SANITIZER and EREWHON ANTIBACTERIAL SPRAY products are intended for use as topical consumer antiseptic rubs.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from the products’ label that provide evidence of the intended use (as defined by 21 CFR 201.128) of these products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>EREWHON HAND SANITIZER\u003Cbr>\n&nbsp; &nbsp; “Hand Sanitizer” ; “Antiseptic” ; “For hand cleansing to decrease bacteria on the skin.” [from product label]\u003C\u002Fp>\n\n\u003Cp>EREWHON ANTIBACTERIAL SPRAY\u003Cbr>\n&nbsp; &nbsp; “Antibacterial Spray” ; “Antiseptic” ; “For hand cleansing to decrease bacteria on the skin.” [from product label]\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic, EREWHON ANTIBACTERIAL SPRAY, is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exceptions not applicate here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your EREWHON ANTIBACTERIAL SPRAY drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>Over-the-counter (OTC) topical antiseptic products had been the subject of rulemakings under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G(a)(3) of the FD&amp;C Act governs nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for a drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they meet the relevant conditions outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, your EREWHON ANTIBACTERIAL SPRAY does not conform to the 1994 TFM, as amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>For example, your EREWHON ANTIBACTERIAL SPRAY states the use is “For hand cleansing to decrease bacteria on the skin.” However, it includes in the directions the statement, “Spray hands or body with product as many times as needed.” The monograph conditions of use for OTC antiseptic rub products as set forth in the rulemakings described above limit the use of the product to the hands and do not include application to the whole body, therefore, your product does not conform to the TFM or the applicable requirements and goes beyond describing the intended use of topical antiseptics as set forth in the 1994 TFM and amended by the 2016 Consumer Antiseptic Rubs Proposed Rule.\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>This intended use claim is inconsistent with the applicable TFMs or any other TFM or proposed rule, and accordingly does not meet the conditions under sections 505G(a)(1) or 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Misbranding Drug Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>In addition, both your EREWHON HAND SANITIZER and EREWHON ANTIBACTERIAL SPRAY are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), because the labeling for these products is false and misleading. Under 21 CFR 201.10(c)(4), “[t]he labeling of a drug may be misleading by reason … [of] [t]he featuring in the labeling of inert or inactive ingredients in a manner that creates an impression of value greater than their true functional role in the formulation.” The labeling for EREWHON HAND SANITIZER prominently features eucalyptus oil on the principal display panel, and the labeling for EREWHON ANTIBACTERIAL SPRAY prominently features lemon oil, rosemary oil, eucalyptus oil, clove bud oil, and cinnamon oil on the principal display panel. Featuring these inactive ingredients prominently on the principal display panel creates an impression of value greater than their true functional role in the formulation and thus causes the products to be misbranded under 502(a) of the FD&amp;C Act, 21 U.SC 352(a).\u003C\u002Fp>\n\n\u003Cp>Lastly, your EREWHON ANTIBACTERIAL SPRAY is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because it is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section, and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>Introduction or delivery for introduction of misbranded drug products into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Additionally, we note that under 21 CFR 201.61(a), “[t]he principal display panel of an over-the-counter drug in package form shall bear as one of its principal features a statement of identity of the commodity.” The 1994 TFM states that the statement of identity for health-care antiseptic drug products, a category that includes consumer antiseptic rub drug products, contains “the established name of the drug, if any” (59 FR 31442). Currently, there is no established name for consumer antiseptic rub drug products that have the active ingredient ethyl alcohol and are formulated as a gel or spray. However, we recommend that you include the name “alcohol gel” and “alcohol spray” as part of the statement of identity that appears on the principal display panels of the labels for EREWHON HAND SANITIZER and EREWHON ANTIBACTERIAL SPRAY respectively. Additionally, the statement of identity in the principal display panel should include the pharmacological category of the product, which in this case is represented by “Hand Sanitizer.”\u003C\u002Fp>\n\n\u003Cp>The above general comments are not all-inclusive of the labeling issues that may be presented by your products. Should you have further questions concerning the labeling of drug products, we recommend that you retain a consultant with expertise in applicable requirements for non-prescription drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Products Contain Ethanol (Methanol Risk)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Products Contain (b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture drugs that contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. \u003Cstrong>(b)(4)\u003C\u002Fstrong> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on February 29, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Aromas Para El Alma S.A., at Oficentro Ultima Park 2, Bodega No. 74, Calle Mango, Guachipelín, San Rafael, Escazu San Jose 10203 into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3018061317 and ATTN: Rory Geyer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>U.S. Agent\u003Cbr>\nMs. Melissa Sayers, M.S.\u003Cbr>\nTeam Lead, Medical Device &amp; Drugs Department\u003Cbr>\nRegistrar Corp.\u003Cbr>\n144 Research Drive\u003Cbr>\nHampton, VA 23666\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The 1994 TFM covers health care antiseptics that are indicated for use to help reduce bacteria that potentially can cause disease and health care and consumer antiseptics that are indicated for use to decrease bacteria on the skin. 59 FR at 31443.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-24-61\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Andrea Becerra\n\nRecipient Title\n\nCEO\n\nAromas Para El Alma S.A.\n\nCalle Lindora, Commercial Park Warehouse 23\n\nSanta Ana, San Jose\n\n10903\n\nCosta Rica\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-24-61\n\nSeptember 10, 2024\n\nDear Ms. Becerra:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Aromas Para El Alma S.A., FEI 3018061317, at Oficentro Ultima Park 2, Bodega No. 74, Calle Mango, Guachipelín, San Rafael, Escazu, San Jose 10203, Costa Rica, from October 16 to 19, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, EREWHON ANTIBACTERIAL SPRAY is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such a product into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d). The product is also misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). In addition, your EREWHON HAND SANITIZER and EREWHON ANTIBACTERIAL SPRAY are misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\n\nWe reviewed your November 8, 2023 response to our Form FDA 483 in detail.\n\nCGMP Violations\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish adequate written production and control procedures for the charge-in of components designed to assure that the drug products produced have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.101).\n\nYou failed to formulate your drug products with the intent to provide no less than 100% of the declared active ingredient. For example, your EREWHON drug products, EREWHON ANTIBACTERIAL SPRAY and EREWHON HAND SANITIZER, manufactured by your firm, are labeled to contain 60% and 70% of the active ingredient ethyl alcohol (ethanol), respectively. You originally formulated your drug products using (b)(4)% ethanol (active ingredient). Your firm failed to revise your manufacturing formulation after replacing the (b)(4)% ethanol with a lower strength ethanol. Your firm made this formulation change without assessing the impact of the change on the quality of your finished drug products, including failing to conduct validation studies. As a result, multiple batches were formulated to contain ethanol concentrations lower than what was declared on the labeling, with some concentration values calculated as low as approximately (b)(4)%. These batches were ultimately released for distribution.\n\nCDC recommends1 that, if soap and water are not readily available, consumers use an alcohol-based hand sanitizer that contains not less than 60% alcohol (ethanol). This is the minimum active ingredient concentration of ethanol specified in the 1994 Tentative Final Monograph (1994 TFM) for Health-Care Antiseptic Drug Products (59 FR 31402), as further amended by the “Safety and Effectiveness of Health Care Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 80 FR 25166 (May 1, 2015) (2015 Health Care Personnel Hand Rub Proposed Rule).\n\nOn October 18, 2023, FDA inquired whether you had conducted a voluntary recall for any batches of drug products currently in distribution from the U.S. market that were potentially subpotent due to inadequate formulation. On October 19, 2023, you provided a written statement of your intent to voluntarily recall affected drug product batches. FDA has made multiple attempts to follow-up with you and your registered U.S. Agent. As of the date of this letter, you have not initiated a voluntary recall, nor contacted the Agency after multiple requests to do so.\n\nOn March 13, 2024, FDA notified the public that your drug products are subpotent at the following website: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\n\nYour response includes actions that will be taken to evaluate your drug product formulations. Your response is inadequate because you did not provide supportive documentation, did not consider a retrospective evaluation of potential impact to your products currently on the market, and your interim production plans are unclear.\n\nIn response to this letter, provide:\n\n• A list of all batches of any drug product distributed in the United States by your firm, including lot numbers and expiry dates, and a full reconciliation of all material you distributed, including a list of customers and location for where the product was distributed.\n\n• An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed in the United States within expiry. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n• An action plan for updating the formulation for your drug products including process validation.\n\n2. Your firm also failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\n\nYour batch production records for your drug products do not include adequate production instructions, including but not limited to, identification of critical steps in your manufacturing processes such as critical parameters (e.g., (b)(4) and (b)(4) times) or the weight or volume of each formulation component.\n\nYour response includes actions that will be taken to improve your batch production records. Your response is inadequate because you did not provide supportive documentation, did not consider a retrospective evaluation of potential impact to your products currently on the market, and your interim production plans are unclear.\n\nComplete and accurate batch production and control records are necessary to ensure that manufacturing processes are consistently followed and reproducible. Incomplete manufacturing records deprive you of the ability to ensure the batches are formulated to provide not less than 100% of the labeled or established amount of active ingredient.\n\nIn response to this letter, provide:\n\n• Your master production and control records for your drug products, to demonstrate that they fully document each significant and validated manufacturing step.\n\n• Procedures you have implemented to ensure production records are completed as\n\nrequired and reviewed by your quality unit (QU) before release of products for distribution.\n\n3. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYou failed to conduct an adequate identity test on each shipment of each lot of components (including the ethanol active ingredient), used in the production of your drug products. You also failed to determine whether each component conformed with all appropriate written specifications for purity, strength, and quality before use.\n\nIn addition, your firm uses (b)(4) as a component in your drug products. Your firm has not shown that the (b)(4) that you use for component (b)(4) is suitable for (b)(4) dosage form drug product manufacturing and, at a minimum, meets the USP (b)(4) monograph and appropriate microbial limits.\n\nYour response includes actions that will be taken to improve your component controls. Your response is inadequate because you did not provide supportive documentation, did not consider a retrospective evaluation of potential impact to your products currently on the market, and your interim production plans are unclear.\n\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n• The chemical and microbiological quality control specifications you use to test and release each incoming batch of components for use in manufacturing.\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ certificates of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\n• A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure that describes this COA validation program.\n\n• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\n• A description of how you will consistently produce or acquire (b)(4) adhering to (b)(4), USP monograph specifications and appropriate microbial limits.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour QU did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\n• Adequate chemical and microbial testing and appropriate specifications for your finished drug products (21 CFR 211.165(a) and 21 CFR 211.165(b)).\n\n• Establishment of an adequate stability program (21 CFR 211.137(a)).\n\n• Establishment of adequate procedures describing the QU’s responsibilities 21 CFR 211.22(d)).\n\nIn your response, you state that you will revise your QU procedures. However, your response is inadequate because you did not provide any further detail or supportive documentation.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide a comprehensive assessment and remediation plan to ensure that your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\n• A determination of whether procedures used by your firm are robust and appropriate.\n\n• Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\n• A complete and final review of each batch and its related information before the QU disposition decision.\n\n• Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all drug products.\n\nUnapproved New Drug and Misbranding Violations\n\nBased on its labeled intended uses, EREWHON HAND SANITIZER and EREWHON ANTIBACTERIAL SPRAY products are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, EREWHON HAND SANITIZER and EREWHON ANTIBACTERIAL SPRAY products are intended for use as topical consumer antiseptic rubs.\n\nExamples of claims from the products’ label that provide evidence of the intended use (as defined by 21 CFR 201.128) of these products include, but may not be limited to, the following:\n\nEREWHON HAND SANITIZER\n\n“Hand Sanitizer” ; “Antiseptic” ; “For hand cleansing to decrease bacteria on the skin.” [from product label]\n\nEREWHON ANTIBACTERIAL SPRAY\n\n“Antibacterial Spray” ; “Antiseptic” ; “For hand cleansing to decrease bacteria on the skin.” [from product label]\n\nUnapproved New Drug Violations\n\nThis topical antiseptic, EREWHON ANTIBACTERIAL SPRAY, is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exceptions not applicate here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your EREWHON ANTIBACTERIAL SPRAY drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nOver-the-counter (OTC) topical antiseptic products had been the subject of rulemakings under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G(a)(3) of the FD&C Act governs nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety or effectiveness in a TFM that is the most recently applicable proposal or determination for a drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they meet the relevant conditions outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, your EREWHON ANTIBACTERIAL SPRAY does not conform to the 1994 TFM, as amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and does not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nFor example, your EREWHON ANTIBACTERIAL SPRAY states the use is “For hand cleansing to decrease bacteria on the skin.” However, it includes in the directions the statement, “Spray hands or body with product as many times as needed.” The monograph conditions of use for OTC antiseptic rub products as set forth in the rulemakings described above limit the use of the product to the hands and do not include application to the whole body, therefore, your product does not conform to the TFM or the applicable requirements and goes beyond describing the intended use of topical antiseptics as set forth in the 1994 TFM and amended by the 2016 Consumer Antiseptic Rubs Proposed Rule.2\n\nThis intended use claim is inconsistent with the applicable TFMs or any other TFM or proposed rule, and accordingly does not meet the conditions under sections 505G(a)(1) or 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nMisbranding Drug Violations\n\nIn addition, both your EREWHON HAND SANITIZER and EREWHON ANTIBACTERIAL SPRAY are misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because the labeling for these products is false and misleading. Under 21 CFR 201.10(c)(4), “[t]he labeling of a drug may be misleading by reason … [of] [t]he featuring in the labeling of inert or inactive ingredients in a manner that creates an impression of value greater than their true functional role in the formulation.” The labeling for EREWHON HAND SANITIZER prominently features eucalyptus oil on the principal display panel, and the labeling for EREWHON ANTIBACTERIAL SPRAY prominently features lemon oil, rosemary oil, eucalyptus oil, clove bud oil, and cinnamon oil on the principal display panel. Featuring these inactive ingredients prominently on the principal display panel creates an impression of value greater than their true functional role in the formulation and thus causes the products to be misbranded under 502(a) of the FD&C Act, 21 U.SC 352(a).\n\nLastly, your EREWHON ANTIBACTERIAL SPRAY is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because it is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section, and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nIntroduction or delivery for introduction of misbranded drug products into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nAdditionally, we note that under 21 CFR 201.61(a), “[t]he principal display panel of an over-the-counter drug in package form shall bear as one of its principal features a statement of identity of the commodity.” The 1994 TFM states that the statement of identity for health-care antiseptic drug products, a category that includes consumer antiseptic rub drug products, contains “the established name of the drug, if any” (59 FR 31442). Currently, there is no established name for consumer antiseptic rub drug products that have the active ingredient ethyl alcohol and are formulated as a gel or spray. However, we recommend that you include the name “alcohol gel” and “alcohol spray” as part of the statement of identity that appears on the principal display panels of the labels for EREWHON HAND SANITIZER and EREWHON ANTIBACTERIAL SPRAY respectively. Additionally, the statement of identity in the principal display panel should include the pharmacological category of the product, which in this case is represented by “Hand Sanitizer.”\n\nThe above general comments are not all-inclusive of the labeling issues that may be presented by your products. Should you have further questions concerning the labeling of drug products, we recommend that you retain a consultant with expertise in applicable requirements for non-prescription drug products.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nProducts Contain Ethanol (Methanol Risk)\n\nYou manufacture drugs that contain ethanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\n\nProducts Contain (b)(4)\n\nYou manufacture drugs that contain (b)(4). The use of (b)(4) contaminated with (b)(4) or (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. (b)(4) to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for (b)(4) or (b)(4) contamination (b)(4).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on February 29, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Aromas Para El Alma S.A., at Oficentro Ultima Park 2, Bodega No. 74, Calle Mango, Guachipelín, San Rafael, Escazu San Jose 10203 into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3018061317 and ATTN: Rory Geyer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCc:\n\nU.S. Agent\n\nMs. Melissa Sayers, M.S.\n\nTeam Lead, Medical Device & Drugs Department\n\nRegistrar Corp.\n\n144 Research Drive\n\nHampton, VA 23666\n\n________________________\n\n1 https:\u002F\u002Fwww.cdc.gov\u002Fhandwashing\u002Fhand-sanitizer-use.html\n\n2 The 1994 TFM covers health care antiseptics that are indicated for use to help reduce bacteria that potentially can cause disease and health care and consumer antiseptics that are indicated for use to decrease bacteria on the skin. 59 FR at 31443.","Aromas Para El Alma S.A.","aromas-para-el-alma-sa-672728-09102024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faromas-para-el-alma-sa-672728-09102024","2026-10-26T08:07:57.646815+00:00","2024-09-17","672728","Ms. Andrea Becerra","2026-08-19T23:47:38.129+00:00","320-24-61","2024-09-10",{"id":334,"raw":335,"subject":191,"body_html":339,"body_text":340,"firm_name":341,"letter_id":342,"created_at":43,"fei_number":19,"letter_url":343,"updated_at":344,"action_type":22,"case_status":23,"posted_date":345,"marcs_cms_no":346,"product_type":180,"closeout_date":19,"issuing_office":190,"recipient_name":347,"body_fetched_at":348,"delivery_method":183,"recipient_title":19,"reference_number":19,"action_taken_date":349,"medical_device_id":19,"response_letter_date":19},1933,[336,337,338,190,191,13,13,13],"\u003Ctime datetime=\"2023-08-15T13:20:00Z\">08\u002F15\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-07T04:00:00Z\">08\u002F07\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flaavo-clean-sa-de-cv-646574-08072023\">Laavo Clean, S.A. de C.V.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Diego Velázquez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Laavo Clean, S.A. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Elías Flores Sur. No. 300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Apodaca Centro\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>66600\u003C\u002Fspan> \u003Cspan>Ciudad Apodaca\u003C\u002Fspan>, \u003Cspan>N.L.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-33\u003C\u002Fp>\n\n\u003Cp>August 7, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Velázquez:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer), labeled as Instant Hand Sanitizer LaavoClean without Alcohol and Instant Hand Sanitizer LaavoClean KIDS without Alcohol. These drug products were labeled as being manufactured at your facility, Laavo Clean, S.A. de C.V., FEI 3017301021, at Elias Flores Sur. No. 300, Apodaca Centro, Ciudad Apodaca, Nuevo Leon 66600, Mexico. Following an attempt to import Instant Hand Santizer LaavoClean without Alcohol and Instant Hand Sanitizer LaavoClean KIDS without Alcohol into the United States, they were detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of batches of these products detained at the border demonstrate that these drug products, labeled as being manufactured at your facility, are adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or Act), 21 U.S.C. 351(c), in that their strength differs from, or their purity or quality falls below, that which they purport or are represented to possess.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Instant Hand Sanitizer LaavoClean KIDS without Alcohol, labeled as being manufactured at your facility, is labeled to contain 0.13% of the active ingredient benzalkonium chloride (BZK). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average of 0.15% w\u002Fv BZK, or 115% of the label claim (United States Pharmacopeia (USP) Limits: NLT 93.0% and NMT 107.0%). Additionally, Instant Hand Sanitizer LaavoClean without Alcohol, labeled as being manufactured at your facility, is labeled to contain 0.13% of the active ingredient BZK. However, FDA laboratory testing of two batches of this product detained at the border found that the drug products contained an average of 0.15% and 0.12% w\u002Fv BZK, or 92.7% of the label claim, respectively (USP Limits: NLT 93.0% and NMT 107.0%).\u003C\u002Fp>\n\n\u003Cp>These hand sanitizer drug products are adulterated under section 501(c) of the FD&amp;C Act in that the active ingredient of BZK is present at levels that differ than that which is declared on their labeling.\u003C\u002Fp>\n\n\u003Cp>While the drug products detailed above were shipped to the United States, information available to FDA demonstrated that all of your hand sanitizers were detained and refused admission at the border and did not enter the United States. Therefore, FDA did not recommend that you remove these products from the market.\u003C\u002Fp>\n\n\u003Cp>On May 17, 2023, FDA notified the public of the subpotency and superpotency of your hand sanitizer drug products at the following webpage: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed investigation into how the hand sanitizer drug products described above, labeled as containing 0.13% BZK, in fact contained an average of 0.15% BZK and 0.12% BZK, respectively.\u003C\u002Fli>\n\t\u003Cli>A list of all raw materials used to manufacture your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003C\u002Fli>\n\t\u003Cli>A list of any batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003C\u002Fli>\n\t\u003Cli>Copies of the complete batch records for any batches distributed to the United States.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on May 9, 2023, and accordingly drugs and drug products that appear to be adulterated may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&amp;C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 3017301021 and ATTN: Philip Kreiter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Diego Velázquez\n\nRecipient Title\n\nManager\n\nLaavo Clean, S.A. de C.V.\n\nElías Flores Sur. No. 300\n\nApodaca Centro\n\n66600 Ciudad Apodaca, N.L.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-33\n\nAugust 7, 2023\n\nDear Mr. Velázquez:\n\nYour firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer), labeled as Instant Hand Sanitizer LaavoClean without Alcohol and Instant Hand Sanitizer LaavoClean KIDS without Alcohol. These drug products were labeled as being manufactured at your facility, Laavo Clean, S.A. de C.V., FEI 3017301021, at Elias Flores Sur. No. 300, Apodaca Centro, Ciudad Apodaca, Nuevo Leon 66600, Mexico. Following an attempt to import Instant Hand Santizer LaavoClean without Alcohol and Instant Hand Sanitizer LaavoClean KIDS without Alcohol into the United States, they were detained and refused admission at the border.\n\nThe results of the FDA laboratory testing of batches of these products detained at the border demonstrate that these drug products, labeled as being manufactured at your facility, are adulterated within the meaning of section 501(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or Act), 21 U.S.C. 351(c), in that their strength differs from, or their purity or quality falls below, that which they purport or are represented to possess.\n\nAdulteration Violations\n\nInstant Hand Sanitizer LaavoClean KIDS without Alcohol, labeled as being manufactured at your facility, is labeled to contain 0.13% of the active ingredient benzalkonium chloride (BZK). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average of 0.15% w\u002Fv BZK, or 115% of the label claim (United States Pharmacopeia (USP) Limits: NLT 93.0% and NMT 107.0%). Additionally, Instant Hand Sanitizer LaavoClean without Alcohol, labeled as being manufactured at your facility, is labeled to contain 0.13% of the active ingredient BZK. However, FDA laboratory testing of two batches of this product detained at the border found that the drug products contained an average of 0.15% and 0.12% w\u002Fv BZK, or 92.7% of the label claim, respectively (USP Limits: NLT 93.0% and NMT 107.0%).\n\nThese hand sanitizer drug products are adulterated under section 501(c) of the FD&C Act in that the active ingredient of BZK is present at levels that differ than that which is declared on their labeling.\n\nWhile the drug products detailed above were shipped to the United States, information available to FDA demonstrated that all of your hand sanitizers were detained and refused admission at the border and did not enter the United States. Therefore, FDA did not recommend that you remove these products from the market.\n\nOn May 17, 2023, FDA notified the public of the subpotency and superpotency of your hand sanitizer drug products at the following webpage: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nIn response to this letter, provide the following:\n\nA detailed investigation into how the hand sanitizer drug products described above, labeled as containing 0.13% BZK, in fact contained an average of 0.15% BZK and 0.12% BZK, respectively.\n\nA list of all raw materials used to manufacture your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\nA list of any batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\nCopies of the complete batch records for any batches distributed to the United States.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nNote that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on May 9, 2023, and accordingly drugs and drug products that appear to be adulterated may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of a violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nPlease identify your response with FEI 3017301021 and ATTN: Philip Kreiter.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","Laavo Clean, S.A. de C.V.","laavo-clean-sa-de-cv-646574-08072023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flaavo-clean-sa-de-cv-646574-08072023","2026-10-26T08:09:11.77834+00:00","2023-08-15","646574","Mr. Diego Velázquez","2026-08-20T00:47:47.65+00:00","2023-08-07",{"id":351,"raw":352,"subject":79,"body_html":356,"body_text":357,"firm_name":358,"letter_id":359,"created_at":43,"fei_number":19,"letter_url":360,"updated_at":361,"action_type":22,"case_status":23,"posted_date":362,"marcs_cms_no":363,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":364,"body_fetched_at":365,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":366,"medical_device_id":19,"response_letter_date":19},1978,[353,354,355,11,79,13,13,13],"\u003Ctime datetime=\"2023-07-25T13:20:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-30T04:00:00Z\">06\u002F30\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaits-and-sea-foods-sa-661622-06302023\">Baits and Sea Foods, S.A.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Ramiro J. Saborio\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director of Operations\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Baits and Sea Foods, S.A.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>KM 25 Tipitapa-Masaya Highway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Parque Industrial Astro, Nave 24C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tipitapa\u003C\u002Fspan>, \u003Cspan>Managua\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nicaragua\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 30, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nReference # 661622\u003C\u002Fp>\n\n\u003Cp>Dear Ramiro J. Saborio:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted Foreign Remote Regulatory Assessment (FRRA) of your seafood processing facility, located at KM 25 Tipitapa-Masaya Highway, Parque Industrial, Astro, Nave 24C, Tipitapa, Mangua, Nicaragua, on May 8 through 11, 2023. During the remote assessment, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). At the conclusion of the assessment, the FDA investigator discussed items of concern. Your firm has not responded to the discussion items identified during the FFRA.\u003C\u002Fp>\n\n\u003Cp>In accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your fresh and frozen histamine forming seafood products, including but not limited to mahi-mahi, are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the 4th Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Your significant deviation is as follows:\u003C\u002Fp>\n\n\u003Cp>1. The HACCP plan does not list the food safety hazards that are reasonably likely to occur. Specifically, the HACCP plan for histamine forming species including frozen, raw, individually vacuum-packaged, wild caught, mahi-mahi portions and fillets does not list the food safety hazard of \u003Cem>Clostridium botulinum\u003C\u002Fem> growth and toxin formation, and undeclared allergens as required by 21 CFR 123.6(c)(1).\u003C\u002Fp>\n\n\u003Cp>2. The HACCP plan does not list one or more critical control points that are necessary for each of the identified food safety hazards. Specifically, the HACCP plan for histamine forming species including frozen, raw, individually vacuum-packaged, wild caught, mahi-mahi portions and fillets does not list as required by 21 CFR 123.6(c)(2):\u003Cbr>\n&nbsp; a. A critical control point (CCP) at the receiving of fresh whole gutted mahi mahi that is necessary to control the hazards of histamine formation during transit from the local ports to the processing plant.\u003Cbr>\n&nbsp; b. A critical control point at the fish storage between layers of ice that is necessary to control the histamine formation hazard. The fresh whole, gutted mahi mahi fish can be stored up to 48 hours between layers of ice.\u003C\u002Fp>\n\n\u003Cp>3. Your HACCP plan lists a critical limit that does not ensure control of one or more hazards. Specifically, your HACCP plan for histamine forming species including frozen, raw, individually vacuum-packaged, wild caught, mahi-mahi portions and fillets does not list the sensory examination critical limit to control the histamine formation hazard at the receiving critical control point as required by 21 CFR 123.6(c)(3).\u003C\u002Fp>\n\n\u003Cp>4. Your HACCP plan lists monitoring procedures that do not ensure compliance with the critical limit. Specifically, the HACCP plan for histamine forming species including frozen, raw, individually vacuum-packaged, wild caught, mahi-mahi portions and fillets as required by 21 CFR 123.6(c)(4):\u003Cbr>\n&nbsp; a. Lists the incomplete monitoring procedure of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. This procedure does not ensure compliance with the critical limit at the receiving CCP. The monitoring procedure does not list the number of fish to be analyzed for histamine.\u003Cbr>\n&nbsp; b. Lists incomplete monitoring procedures to monitor the internal temperature of the fish at the receiving CCP. The monitoring procedure does not list the minimum number of fish to be temperature checked.\u003C\u002Fp>\n\n\u003Cp>5. Your HACCP plan includes a corrective action plan that is not in accordance with 21 CFR 123.7 to ensure affected product is not entered into commerce and the cause of the deviation was corrected. Specifically, the HACCP plan for histamine forming species lists an inadequate corrective action procedure at the receiving CCP when the temperature measurement is above the critical limits.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan or plans, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. You may view this alert at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\n\n\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>You should direct your written reply to Rosemary Sexton, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions regarding this letter, you may contact Rosemary Sexton via email at Rosemary.Sexton@fda.hhs.gov. Please reference CMS #661622 on any submissions and on the subject line of any emails to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Ramiro J. Saborio\n\nRecipient Title\n\nDirector of Operations\n\nBaits and Sea Foods, S.A.\n\nKM 25 Tipitapa-Masaya Highway\n\nParque Industrial Astro, Nave 24C\n\nTipitapa, Managua\n\nNicaragua\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nJune 30, 2023\n\nWARNING LETTER\n\nReference # 661622\n\nDear Ramiro J. Saborio:\n\nThe United States Food and Drug Administration (FDA) conducted Foreign Remote Regulatory Assessment (FRRA) of your seafood processing facility, located at KM 25 Tipitapa-Masaya Highway, Parque Industrial, Astro, Nave 24C, Tipitapa, Mangua, Nicaragua, on May 8 through 11, 2023. During the remote assessment, we found that you had serious violations of the seafood Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations (21 CFR Part 123). At the conclusion of the assessment, the FDA investigator discussed items of concern. Your firm has not responded to the discussion items identified during the FFRA.\n\nIn accordance with 21 CFR 123.6(g), failure of a processor of fish or fishery products to have and implement a HACCP plan that complies with this section or otherwise operate in accordance with the requirements of Part 123, renders the fish or fishery products adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug and Cosmetic Act (the Act), 21 U.S.C. § 342(a)(4). Accordingly, your fresh and frozen histamine forming seafood products, including but not limited to mahi-mahi, are adulterated, in that they have been prepared, packed, or held under conditions whereby they may have been rendered injurious to health. You may find the Act, the seafood HACCP regulation and the 4th Edition of the Fish and Fisheries Products Hazards and Controls Guidance (the Hazards Guide) through links in FDA's home page at www.fda.gov.\n\nYour significant deviation is as follows:\n\n1. The HACCP plan does not list the food safety hazards that are reasonably likely to occur. Specifically, the HACCP plan for histamine forming species including frozen, raw, individually vacuum-packaged, wild caught, mahi-mahi portions and fillets does not list the food safety hazard of Clostridium botulinum growth and toxin formation, and undeclared allergens as required by 21 CFR 123.6(c)(1).\n\n2. The HACCP plan does not list one or more critical control points that are necessary for each of the identified food safety hazards. Specifically, the HACCP plan for histamine forming species including frozen, raw, individually vacuum-packaged, wild caught, mahi-mahi portions and fillets does not list as required by 21 CFR 123.6(c)(2):\n\na. A critical control point (CCP) at the receiving of fresh whole gutted mahi mahi that is necessary to control the hazards of histamine formation during transit from the local ports to the processing plant.\n\nb. A critical control point at the fish storage between layers of ice that is necessary to control the histamine formation hazard. The fresh whole, gutted mahi mahi fish can be stored up to 48 hours between layers of ice.\n\n3. Your HACCP plan lists a critical limit that does not ensure control of one or more hazards. Specifically, your HACCP plan for histamine forming species including frozen, raw, individually vacuum-packaged, wild caught, mahi-mahi portions and fillets does not list the sensory examination critical limit to control the histamine formation hazard at the receiving critical control point as required by 21 CFR 123.6(c)(3).\n\n4. Your HACCP plan lists monitoring procedures that do not ensure compliance with the critical limit. Specifically, the HACCP plan for histamine forming species including frozen, raw, individually vacuum-packaged, wild caught, mahi-mahi portions and fillets as required by 21 CFR 123.6(c)(4):\n\na. Lists the incomplete monitoring procedure of “(b)(4)”. This procedure does not ensure compliance with the critical limit at the receiving CCP. The monitoring procedure does not list the number of fish to be analyzed for histamine.\n\nb. Lists incomplete monitoring procedures to monitor the internal temperature of the fish at the receiving CCP. The monitoring procedure does not list the minimum number of fish to be temperature checked.\n\n5. Your HACCP plan includes a corrective action plan that is not in accordance with 21 CFR 123.7 to ensure affected product is not entered into commerce and the cause of the deviation was corrected. Specifically, the HACCP plan for histamine forming species lists an inadequate corrective action procedure at the receiving CCP when the temperature measurement is above the critical limits.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific steps you are taking to correct these deviations. More specifically, your response should include documentation reflecting the changes you made, such as a copy of your revised HACCP plan or plans, five (5) consecutive days of completed monitoring records (i.e., complete sets of monitoring records for the production of 5 production date codes of products) to demonstrate implementation of the plan, and any additional information that you wish to supply that provides assurance of your intent to fully comply now and in the future with the seafood HACCP regulation. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you do not respond or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported fish or fishery products under Section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with the seafood HACCP regulation is Import Alert #16-120. You may view this alert at: http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\n\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the seafood HACCP regulation and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\n\nYou should direct your written reply to Rosemary Sexton, Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835. If you have any questions regarding this letter, you may contact Rosemary Sexton via email at Rosemary.Sexton@fda.hhs.gov. Please reference CMS #661622 on any submissions and on the subject line of any emails to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition","Baits and Sea Foods, S.A.","baits-and-sea-foods-sa-661622-06302023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbaits-and-sea-foods-sa-661622-06302023","2026-10-26T08:08:00.70277+00:00","2023-07-25","661622","Mr. Ramiro J. Saborio","2026-08-20T00:51:11.075+00:00","2023-06-30",{"id":368,"raw":369,"subject":191,"body_html":374,"body_text":375,"firm_name":376,"letter_id":377,"created_at":213,"fei_number":19,"letter_url":378,"updated_at":379,"action_type":22,"case_status":23,"posted_date":380,"marcs_cms_no":381,"product_type":180,"closeout_date":19,"issuing_office":190,"recipient_name":382,"body_fetched_at":383,"delivery_method":183,"recipient_title":19,"reference_number":19,"action_taken_date":384,"medical_device_id":19,"response_letter_date":19},2404,[370,371,372,190,373,13,13,13],"\u003Ctime datetime=\"2022-10-11T13:20:00Z\">10\u002F11\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-05T04:00:00Z\">10\u002F05\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feksa-mills-sa-de-cv-634706-10052022\">Eksa Mills S.A. de C.V.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Esteban Sabugo Rivero\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Director\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Eksa Mills S.A. de C.V.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>E. Parque Industrial Carretera Federal Mexico Veracruz 1056\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Heroica Puebla De Zaragoza\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>72225\u003C\u002Fspan> , \u003Cspan>Pue.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mexico\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-02\u003C\u002Fp>\n\n\u003Cp>October 5, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Rivero:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Eksa Mills S.A. de C.V., FEI 3016927597, at E. Parque Industrial Carretera Federal Mexico Veracruz 1056, Heroica Puebla De Zaragoza, Puebla, from April 18 to April 19, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 24, 2022, response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) drug products such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You also manufacture commercial chemical \u003Cstrong>(b)(4)\u003C\u002Fstrong> solution products for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> industry on the same manufacturing equipment as your OTC drug products. Inadequate removal of residues from manufacturing equipment during cleaning can lead to contamination of drug products subsequently manufactured on the non-dedicated equipment. Further, your firm did not maintain written cleaning procedures or equipment use logs for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> tanks used to manufacture drug products.\u003C\u002Fp>\n\n\u003Cp>It is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture commercial \u003Cstrong>(b)(4)\u003C\u002Fstrong> solutions or other non-pharmaceutical products due to the risk of cross-contamination.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, discontinue manufacturing drugs on shared equipment with non-pharmaceuticals in your facility. If you intend to resume manufacture both pharmaceutical and non-pharmaceutical products at your facility, provide a plan to show how you will separate the areas in which you will maintain dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>In addition, conduct a risk assessment for all drugs you have previously manufactured on equipment shared with non-pharmaceutical products. For each product, assess the risk of potential contamination due to shared equipment and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cp>• Adequate procedures describing roles and responsibilities of the QU, including the handling of vendor qualification, batch release, reserve samples, investigations, complaints, and CGMP training (21 CFR 211.22(a) and (d)).\u003Cbr>\n• Adequate testing of your incoming components for identity, purity, strength, and other appropriate quality attributes (21 CFR 211.84(d)(1) and (2)).\u003Cbr>\n• Adherence to a stability program (21 CFR 211.166(a)).\u003Cbr>\n• Adequate maintenance of batch records (21 CFR 211.188).\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of drugs at this facility and that you deregistered your facility as a drug manufacturer. If you plan to resume manufacturing drugs for the U.S. market, notify this office before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on August 12, 2022.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Eksa Mills S.A. de C.V., E. Parque Industrial Carretera Federal Mexico Veracruz 1056, Heroica Puebla De Zaragoza, Puebla into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3016927597 and ATTN: Tamara Rosbury.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research, FDA\u003C\u002Fp>\n\n\u003Cp>_________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Esteban Sabugo Rivero\n\nRecipient Title\n\nDirector\u002FCEO\n\nEksa Mills S.A. de C.V.\n\nE. Parque Industrial Carretera Federal Mexico Veracruz 1056\n\nHeroica Puebla De Zaragoza\n\n72225 , Pue.\n\nMexico\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-02\n\nOctober 5, 2022\n\nDear Mr. Rivero:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Eksa Mills S.A. de C.V., FEI 3016927597, at E. Parque Industrial Carretera Federal Mexico Veracruz 1056, Heroica Puebla De Zaragoza, Puebla, from April 18 to April 19, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your April 24, 2022, response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n\nYour firm manufactures over-the-counter (OTC) drug products such as (b)(4) and (b)(4).1 You also manufacture commercial chemical (b)(4) solution products for the (b)(4) industry on the same manufacturing equipment as your OTC drug products. Inadequate removal of residues from manufacturing equipment during cleaning can lead to contamination of drug products subsequently manufactured on the non-dedicated equipment. Further, your firm did not maintain written cleaning procedures or equipment use logs for the (b)(4) tanks used to manufacture drug products.\n\nIt is unacceptable as a matter of CGMP to continue manufacturing drugs using the same equipment that you use to manufacture commercial (b)(4) solutions or other non-pharmaceutical products due to the risk of cross-contamination.\n\nIn response to this letter, discontinue manufacturing drugs on shared equipment with non-pharmaceuticals in your facility. If you intend to resume manufacture both pharmaceutical and non-pharmaceutical products at your facility, provide a plan to show how you will separate the areas in which you will maintain dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\n\nIn addition, conduct a risk assessment for all drugs you have previously manufactured on equipment shared with non-pharmaceutical products. For each product, assess the risk of potential contamination due to shared equipment and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\n\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\n• Adequate procedures describing roles and responsibilities of the QU, including the handling of vendor qualification, batch release, reserve samples, investigations, complaints, and CGMP training (21 CFR 211.22(a) and (d)).\n\n• Adequate testing of your incoming components for identity, purity, strength, and other appropriate quality attributes (21 CFR 211.84(d)(1) and (2)).\n\n• Adherence to a stability program (21 CFR 211.166(a)).\n\n• Adequate maintenance of batch records (21 CFR 211.188).\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nDrug Production Ceased\n\nWe acknowledge your commitment to cease production of drugs at this facility and that you deregistered your facility as a drug manufacturer. If you plan to resume manufacturing drugs for the U.S. market, notify this office before resuming your operations.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on August 12, 2022.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Eksa Mills S.A. de C.V., E. Parque Industrial Carretera Federal Mexico Veracruz 1056, Heroica Puebla De Zaragoza, Puebla into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3016927597 and ATTN: Tamara Rosbury.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research, FDA\n\n_________________________________\n\n1 (b)(4)","Eksa Mills S.A. de C.V.","eksa-mills-sa-de-cv-634706-10052022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feksa-mills-sa-de-cv-634706-10052022","2026-10-26T08:08:32.035182+00:00","2022-10-11","634706","Mr. Esteban Sabugo Rivero","2026-08-20T01:30:56.653+00:00","2022-10-05",54,{"510k":387,"classification":388,"enforcement":389,"event":390,"event_backfill":391,"pma":392,"warning_letter":393},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]